<!DOCTYPE html>
<html lang="en">
  
<!-- Mirrored from www.allindianpatents.com/patents/264416-pharmaceutical-compositions-for-the-prevention-and-treatment-of-complex-diseases-and-their-delivery-by-insertable-medical-devices by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 01:17:06 GMT -->
<!-- Added by HTTrack --><meta http-equiv="content-type" content="text/html;charset=utf-8" /><!-- /Added by HTTrack -->
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=Edge,chrome=1">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Indian Patents. 264416:PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF COMPLEX DISEASES AND THEIR DELIVERY BY INSERTABLE MEDICAL DEVICES</title>
    <meta content="authenticity_token" name="csrf-param" />
<meta content="cYcP52B8zyTWKbLwby2YPh9z/gvY/RLjWOwY4YXkiXg=" name="csrf-token" />

    <!-- Le HTML5 shim, for IE6-8 support of HTML elements -->
    <!--[if lt IE 9]>
      <script src="//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.6.1/html5shiv.js" type="text/javascript"></script>
    <![endif]-->

    <link href="../assets/application-e80cf34975c5b1730c80b2f7170e7d26.css" media="all" rel="stylesheet" type="text/css" />

  </head>
  <body>

    <div class="navbar navbar-fluid-top">
      <div class="navbar-inner">
        <div class="container-fluid">
          <a class="btn btn-navbar" data-target=".nav-collapse" data-toggle="collapse">
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
          </a>
          <a class="brand" href="../index.html">Indian Patents</a>
          <div class="container-fluid nav-collapse">
            <ul class="nav">
              <li><a href="../recently-granted.html">Recently Granted Patents</a></li>
              <li><a href="../recently-published.html">Recently Published Patents</a></li>
            </ul>
            <form id="gform" class="navbar-search pull-right" action="https://www.google.com/search" method="get" target="_blank" onsubmit="document.getElementById('gform').q.value='site:http://www.allindianpatents.com '+document.getElementById('gform').q.value">
                <input type="text" name="q" id="q" class="search-query" placeholder="Search" onclick="this.value=''" autocomplete="off">
            </form>
          </div><!--/.nav-collapse -->
        </div>
      </div>
    </div>

    <div class="container-fluid">
      <div class="row-fluid">
        <div class="span12">

          <style>
          .allindianpatents-top { width: 320px; height: 50px; }
          @media(min-width: 500px) { .allindianpatents-top { width: 468px; height: 60px; } }
          @media(min-width: 800px) { .allindianpatents-top { width: 728px; height: 90px; } }
          </style>
          <center>
          </center>
          
          <div class="row-fluid">
	<div class="span8">

		<table class="table">
			<tr>
				<th>Title of Invention</th>
				<td><h1 style="font-size:large;">PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF COMPLEX DISEASES AND THEIR DELIVERY BY INSERTABLE MEDICAL DEVICES</h1></td>
			</tr>
			<tr>
				<th>Abstract</th>
				<td>The present invention relates to polyphenol-like compounds that are useful for inhibiting VCAM-1 expression, MCP-1 expression and/or SMC proliferation in a mammal. The disclosed compounds are useful for regulating markers of inflammatory conditions, including vascular inflammation, and for treatment and prevention of inflammatory and cardiovascular diseases and related disease states.</td>
			</tr>
		</table>

					<style>
					.allindianpatents-post-abstract { width: 320px; height: 50px; }
					@media(min-width: 880px) { .allindianpatents-post-abstract { width: 468px; height: 60px; } }
					@media(min-width: 1267px) { .allindianpatents-post-abstract { width: 728px; height: 90px; } }
					</style>
					<center>
					<script async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script>
					<!-- AllIndianPatents-post-abstract -->
					<ins class="adsbygoogle allindianpatents-post-abstract"
					     style="display:inline-block"
					     data-ad-client="ca-pub-7914358224572760"
					     data-ad-slot="9152759240"></ins>
					<script>
					(adsbygoogle = window.adsbygoogle || []).push({});
					</script>					
					</center>

		<table class="table">
			<tr>
				<th>Full Text</th>
				<td>PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND<br>
TREATMENT OF COMPLEX DISEASES AND THEIR DELIVERY BY<br>
INSERTABLE MEDICAL DEVICES<br>
CROSS-REFERENCE TO RELATED APPLICATIONS<br>
This application claims the benefit of U.S. provisional application Ser. No.<br>
60/704,035, filed July 29, 2005, which is incorporated herein by reference in its<br>
entirety.<br>
Technical Field<br>
[001] The present invention relates to polyphenol-like compounds that<br>
are useful for inhibiting VCAM-1 expression, MCP-1 expression and/or SMC<br>
proliferation in a mammal. The disclosed compounds are useful for regulating<br>
markers of inflammatory conditions, including vascular inflammation, and for<br>
treatment and prevention of inflammatory and cardiovascular diseases.<br>
BACKGROUND<br>
[002] Atherosclerosis, restenosis and immune disorders, such as<br>
arthritis, are viewed as inflammatory conditions mediated in large part by an<br>
inflammatory cascade. For instance, the pathogenesis of atherosclerosis or<br>
restenosis occurs in three phases; an inflammatory phase, a cellular proliferative<br>
phase, and a phase of remodeling involving extracellular matrix protein synthesis.<br>
The inflammatory phase is initiated by expression and exhibition of inflammatory<br>
molecules (such as VCAM-1, ICAM-1, or E-selectin) on endothelial cells, resulting<br>
in the recruitment of monocytes from the bloodstream into the sub-endothelial<br>
space. When in the endothelium, monocytes transform into macrophages and<br>
become foam cells as they take up cholesterol. These cholesterol-loaded foam<br>
cells release cytokines such as monocyte-colony stimulating factor and monocyte<br>
chemoattractant protein-1 (MCP-1), instigating the cellular proliferative phase.<br>
Cytokine secretion results in localized monocyte and smooth muscle cell (SMC)<br>
proliferation and recruitment and production of extracellular matrix (the final<br>
phase). During this phase macrophages continue their uptake of cholesterol in<br>
the form of oxidized low-density lipoprotein resulting in swelling of the artery wall.<br>
Continuance of this inflammatory cascade eventually results in the formation of a<br>
plaque consisting of lipid-engorged macrophage-foam cells, smooth muscle cells,<br>
and extracellular matrix (Crowther M (2005) Hematology 1, 436).<br>
-1-<br><br>
[003] Expression of vascular adhesion moiecule-1 (VCAM-1) on the<br>
surface of endothelial cells for the adhesion and transmigration of monocytes is a<br>
fundamental early event in a wide variety of inflammatory conditions: such as<br>
autoimmune disorders, bacterial and viral infections, asthma, rheumatoid arthritis,<br>
and autoimmune diabetes, in addition to atherosclerosis (Pilewski JM etal. (1995)<br>
Am J Respir Cell Mol Biol 12,1; Ohkawara Y et al. (1995) Am J Respir Cell Mol<br>
Biol 12, 4; Rabb A et al. (1994) Am J Respir Care Med 11,149). Thus, drugs that<br>
inhibit VCAM-1 expression are desirable therapeutics for the treatment of these<br>
conditions.<br>
[004] Chemoattractant factors, such as MCP-1, have been shown to play<br>
a role in monocyte recruitment, proliferation, and migration in a number of<br>
inflammatory conditions and are correlated with a risk for restenosis (Welt FGP et<br>
al. (2002) Arterioscler Thromb Vase Biol. 22,1769). As such, inhibition of MCP-1<br>
expression represents a desirable property of anti-inflammatory therapeutics.<br>
Finally, smooth muscle cell hyperplasia, resulting in tissue remodeling and<br>
decreased organ function is another characteristic of many inflammatory<br>
conditions including atherosclerosis, restenosis, chronic transplant rejection, and<br>
asthma. Therefore, inhibition of the hyperproliferation of SMC is another desirable<br>
property for therapeutic compounds.<br>
[005] To date the most effective means of preventing and treating<br>
atherosclerosis has been via cholesterol-dependant approaches. These include<br>
seeking to lower low-density lipoprotein or raise high density lipoprotein<br>
cholesterol. For example, one method provides compounds useful for regulating<br>
the expression of ApolipoproteinA-l (ApoA-l) (PCT/US2005/038048) a lipoprotein<br>
important for transporting cholesterol.<br>
[006] However, the identification of new inflammatory mediators in the<br>
early pathogenesis of atherosclerosis and restenosis has led to a new focus on a<br>
variety of inflammatory or cholesterol~/ndepencfenf approaches; including the<br>
inhibition of VCAM-1 and MCP-1 expression, or prevention of smooth muscle cell<br>
(SMC) proliferation. Increasing evidence from epidemiological, clinical, and basic<br>
mechanistic studies supports the importance of these inflammatory targets in the<br>
treatment and prevention of inflammatory conditions. Finding drugs that inhibit<br>
-2-<br><br>
VCAM-1 and/or MCP-1 expression, or inhibit smooth muscle cell proliferation is<br>
desirable.<br>
[007] One class of such compounds thought to play a role in the<br>
prevention of inflammatory conditions are polyphenols. These are common<br>
constituents in of the human diet; they are present in many foods and beverages<br>
of plant origin. Numerous patents and applications describe uses, compositions,<br>
and methods for the prevention, treatment or mitigation of inflammatory and<br>
cardiovascular diseases by the administration of naturally occurring polyphenols<br>
to a patient in need of a pharmaceutical intervention (see, e.g., US/03033578,<br>
US/10696752 ,US 2004 0105817, US 6,900,241, US 6,649,193, US 2002 029088,<br>
US 2003 065505, PCT/09901997/IB, PCT/00000392/AU, PCT/00235153/US,<br>
PCT/US1996/04,028, US 2005 0171163 A1).<br>
[008] It is believed that polyphenols are effective, at least in part, as a<br>
result of their activity on the inhibition of VCAM-1, MCP-1, LDL oxidation, and<br>
smooth muscle cell proliferation (Takahahi R etal. (2005) J Agric Food Chem 53,<br>
1; Fuhrman B et al. (2005) J Nutr 135, 722; Cald UP ef al. (1996) Am J Clin Nutr<br>
63, 403; Tijburg LB et al. (1997) Crit Rev Food Sci Nutr 37, 771; Leiro J et al.<br>
(2004) Int Immunopharmacol 4, 991; Carluccio MA ef al. (2003) Arterioscler<br>
Thromb Vase 23, 622; Ouyang P ef al. (2004) Di Yi Jun Yi Da Xue Xue Bao 24,<br>
975; Hofmann CS et al. (2003) FASEB J17, 702; Araim O et al. (2002) J Vase<br>
Surg 35,1226; El Bedout J et al. (2005) Cardiovasc Res 67, 317). The inverse<br>
relationship between dietary polyphenol consumption and incidence of<br>
cardiovascular diseases is likely associated with their ability to attenuate<br>
biomarkers of oxidative stress, lipidemia and inflammation. Consequently,<br>
naturally occurring polyphenols have the potential to be therapeutically employed.<br>
[009] However, the protective properties of naturally occurring<br>
polyphenols have been difficult to realize for several reasons, including poor<br>
bioavailability and deleterious effects at high concentrations. For instance, the<br>
most abundant and available source of resveratrol for consumers, red wine,<br>
cannot be consumed in therapeutically efficacious quantities on a daily basis<br>
because of the deleterious effects of excessive alcohol consumption.<br>
Furthermore, the use of naturally occurring polyphenols as potential therapies has<br>
also been impeded by an inability to achieve efficacious levels because of poor<br>
-3-<br><br>
bioavailability. Bioavailability of polyphenols in humans ranges from 1% to 26%<br>
with variability between individuals, and between different polyphenols. In<br>
addition to this, polyphenols differ in how they are absorbed, metabolized, and<br>
excreted. For example, polyphenol flavonoids, such as quercetin, have been<br>
reported to have less than 1% intestinal absorption following oral administration<br>
(Gugler et al. (1975) Eur J Clin Pharm 9, 223). Another complicating factor is the<br>
effect of metabolites of polyphenols. These have been shown to have a negative<br>
influence on the biological activity of the parent compounds. Such metabolites<br>
often differ from the parent compound in terms of toxicity, efficacy, and length of<br>
residence in the plasma. These and other limiting factors, such as poor water<br>
solubility limiting the route of administration, have made it difficult to determine<br>
appropriate dosages for use in humans.<br>
[010] Additionally, several human studies on foods or beverages<br>
containing polyphenols have failed to demonstrate any significant benefit on<br>
primary clinical endpoints, such as oxidative stress, lipidemia, and inflammation.<br>
Of twelve recent studies examining differing sources of polyphenols, six showed<br>
no effect on lipid parameters while the other six showed some improvement<br>
(Manach (2005) Curr Opin Lipidol 16, 77-84). Such contradictory data has limited<br>
the use of polyphenols, despite their many potentially beneficial properties.<br>
[011] Thus, there continues to be a need for novel compounds with<br>
properties like those of polyphenols for the prevention and treatment of<br>
inflammatory conditions. Embodiments of the present invention include<br>
compounds that inhibit VCAM-1 and/or MCP-1 expression and/or inhibit smooth<br>
muscle cell proliferation. The compounds of the present invention also possess<br>
other properties, which enable their use in the treatment or prophylaxis of other<br>
diseases and conditions.<br>
SUMMARY<br>
[012] The methods of invention include administering to a mammal (e.g.,<br>
a human) in need thereof a therapeutically effective amount of a compound of<br>
Formula 1:<br>
-4-<br><br><br>
wherein:<br>
X is selected from CRu, CRnR13) CO, CS, O, S, SO, S02) N and NRn,<br>
wherein Rn may be the same or different than R13;<br>
Y is selected from CR12, CR12Ri4, CO, CS, O, S, SO, S02, N and NR12,<br>
wherein R12 may be the same or different than R14;<br>
R-i&gt; R2. R3, R4. R51 R6, R7! R8, R9. R10, R11. R121 R13, Ruand Rare each<br>
independently selected from alkoxy, aryloxy, alkyl, alkenyl, alkynyl, amide, amino,<br>
aryl, arylalkyl, carbamate, carboxy, cyano, cycloalkyl, ester, ether, formyl,<br>
halogen, haloalkyl, heteroaryl, heterocyclyl, hydrogen, hydroxyl, ketone, nitro,<br>
phosphate, sulfide, sulfinyl, sulfonyl, sulfonic acid, sulfonamide and thioketone, or<br>
two adjacent substituents selected from R-i, R2, R3, R4, R5, Re, R7, Rs&gt; R9&gt;<br>
R10, R11, Ri2, R13, and R14 are connected in a 5 or 6-membered ring to form a<br>
bicyclic aryl, bicyclic heteroaryl or bicyclic heterocyclyl;<br>
each W is independently selected from C and N, wherein if W is N, then p<br>
is 0 and if W is C, then p is 1;<br>
Z1, Z2 and Z3 are each independently selected from a single bond and a<br>
double bond;<br>
wherein if Y is O, then X is not CO;<br>
wherein if at least one W is not N, then<br>
a)	X and Y are each CO,<br>
b)	X is NR11 and Z2 is a double bond, or<br>
c)	two adjacent substituents selected from R5, R6, R7, Rs&gt; and R9 are<br>
connected in a 5 or 6-membered ring to form a bicyclic aryl, bicyclic heteroaryl or<br>
bicyclic heterocyclyl;<br>
and pharmaceutically acceptable salts and hydrates thereof.<br>
-5-<br><br>
[013] One embodiment provides methods and compositions useful for<br>
inhibiting VCAM-1 expression, MCP-1 expression and/or SMC proliferation in a<br>
mammal.<br>
[014] In certain embodiments, the methods and compositions of the<br>
invention are useful for treating, preventing or mitigating inflammatory conditions<br>
and related disease states, characterized by altered expression of markers of<br>
inflammation such as VCAM-1, MCP-1 and/or SMC proliferation.<br>
[015] One embodiment provides a compound of Formula I:<br><br>
wherein:<br>
X is selected from CRu, CO, N, NR11 and O;<br>
Y is selected from CR12, CO, and NR-|2;<br>
Ri&gt; R21 R3. R41 R5, R6. R7&gt; Rs&gt; R9, R10, R111 R12, R13. Ri4and Ri7are each<br>
independently selected from alkoxy, alkyl, amino, aminoalkoxy, aminoalkyl,<br>
carboxyalkoxy, halogen, heterocyclyl, heterocyclylalkoxy, heterocyclylalkyl,<br>
hydrogen, hydroxyalkoxy, hydroxyalkyl, and hydroxyl, or<br>
two adjacent substituents selected from R5, R6, R7, Rs and Rg are<br>
connected in a 5 or 6-membered ring to form a bicyclic aryl, bicyclic heteroaryl or<br>
bicyclic heterocyclyl;<br>
each W is independently selected from C and N, wherein if W is N, then p<br>
is 0 and if W is C, then p is 1;<br>
Zi, Z2 and Z3 are each independently selected from a single bond and a<br>
double bond;<br>
wherein if at least one W is not N, then<br>
a)	X and Y are each CO, or<br>
b)	X is NRn and Z2 is a double bond;<br>
and pharmaceutically acceptable salts and hydrates thereof.<br>
-6-<br><br>
DETAILED DESCRIPTION<br>
Definitions<br>
[016] The term "aldehyde" or "formyl" as used herein refers to the radical<br>
-CHO.<br>
[017] The term "alkenyl" as used herein refers to an unsaturated straight<br>
or branched hydrocarbon having at least one carbon-carbon double bond, such as<br>
a straight or branched group of 2-22, 2-8, or 2-6 carbon atoms, referred to herein<br>
as (C2-C22)alkenyl, (C2-C8)alkenyl, and (C2-C6)alkenyl, respectively. Exemplary<br>
alkenyl groups include, but are not limited to, vinyl, allyl, butenyl, pentenyl,<br>
hexenyl, butadienyl, pentadienyl, hexadienyl, 2-ethylhexenyl, 2-propyl-2-butenyl,<br>
4-(2-methyl-3-butene)-pentenyl, etc.<br>
[018] The term "alkoxy" as used herein refers to an alkyl group attached to<br>
an oxygen (-O-alkyl-). "Alkoxy" groups also include an alkenyl group attached to<br>
an oxygen ("alkenoxy") or an alkynyl group attached to an oxygen ("alkynoxy")<br>
groups. Exemplary alkoxy groups include, but are not limited to, groups with an<br>
alkyl, alkenyl or alkynyl group of 1-22, 1-8, or 1-6 carbon atoms, referred to herein<br>
as (C-i_C22)alkoxy, (Ci_C8)alkoxy, and (Ci_C6)alkoxy, respectively. Exemplary<br>
alkoxy groups include, but are not limited to methoxy, ethoxy, etc.<br>
[019] The term "alkyl" as used herein refers to a saturated straight or<br>
branched hydrocarbon, such as a straight or branched group of 1-22,1-8, or 1-6<br>
carbon atoms, referred to herein as (Ci-C22)alkyl, (Ci-C8)alkyl, and (Ci-C6)alkyl,<br>
respectively. Exemplary alkyl groups include, but are not limited to, methyl, ethyl,<br>
propyl, isopropyl, 2-methyl-1-propyl, 2-methyl-2-propyl, 2-methyl-1 -butyl, 3-methyl-<br>
1-butyl, 2-methyl-3-butyl, 2,2-dimethyl-1-propyl, 2-methyl-1-pentyl, 3-methyl-1-<br>
pentyl, 4-methyl-1-pentyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl,<br>
2,2-dimethyl-1-butyl, 3,3-dimethyl-1-butyl, 2-ethyl-1-butyl, butyl, isobutyl, t-butyl,<br>
pentyl, isopentyl, neopentyl, hexyl, heptyl, octyl, etc.<br>
[020] The term "alkynyl" as used herein refers to an unsaturated straight<br>
or branched hydrocarbon having at least one carbon-carbon triple bond, such as a<br>
straight or branched group of 2-22, 2-8, or 2-6 carbon atoms, referred to herein as<br>
(C2-C22)alkynyl, (C2-C8)alkynyl, and (C2-C6)alkynyl, respectively. Exemplary<br>
alkynyl groups include, but are not limited to, ethynyl, propynyl, butynyl, pentynyl,<br>
-7-<br><br>
hexynyl, methylpropynyl, 4-methyl-1-butynyl, 4-propyl-2-pentynyl, and 4-butyl-2-<br>
hexynyl, etc.<br>
[021] The term "amide" as used herein refers to a radical of the form<br>
-RaC(0)N(Rb)-, -RaC(0)N(Rb)Rc_, or -C(0)NRbRG, wherein Rb and Rc are each<br>
independently selected from alkoxy, aryloxy, alkyl, alkenyl, alkynyl, amide, amino,<br>
aryl, arylalkyl, carbamate, carboxy, cyano, cycloalkyl, ester, ether, formyl,<br>
halogen, haloalkyl, heteroaryl, heterocyclyl, hydrogen, hydroxy I, ketone, nitro,<br>
phosphate, sulfide, sulfinyl, sulfonyl, sulfonic acid, sulfonamide and thioketone.<br>
The amide can be attached to another group through the carbon, the nitrogen, Rb,<br>
Rc, or Ra. The amide also may be cyclic, for example Rb and Rc, Ra and Rb, or<br>
Ra and Rc may be joined to form a 3- to 12-membered ring, such as a 3- to 10-<br>
membered ring or a 5- to 6-membered ring. The term "amide" encompasses<br>
groups such as sulfonamide, urea, carbamate, carbamic acid, and cyclic versions<br>
thereof. The term "amide" also encompasses an amide group attached to a<br>
carboxy group, e.g., -amide-COOH or salts such as -amide-COONa, etc, an<br>
amino group attached to a carboxy group, e.g., -amino-COOH or salts such as -<br>
amino-COONa, etc.<br>
[022] The term "amine" or "amino" as used herein refers to a radical of the<br>
form -NRdRe, -N(R<j or where r re> and Rf are<br>
independently selected from alkoxy, aryloxy, alkyl, alkenyl, alkynyl, amide, amino,<br>
aryl, arylalkyl, carbamate, carboxy, cyano, cycloalkyl, ester, ether, formyl,<br>
halogen, haloalkyl, heteroaryl, heterocyclyl, hydrogen, hydroxyl, ketone, nitro,<br>
phosphate, sulfide, sulfinyl, sulfonyl, sulfonic acid, sulfonamide and thioketone.<br>
The amino can be attached to the parent molecular group through the nitrogen,<br>
Rd, Re or Rf. The amino also may be cyclic, for example any two of Ra, Rb, and<br>
Rc may be joined together or with the N to form a 3- to 12-membered ring, e.g.,<br>
morpholino or piperidinyl. The term amino also includes the corresponding<br>
quaternary ammonium salt of any amino group, e.g., -[N(R<j></j>
Exemplary amino groups include aminoalkyl groups, wherein at least one of R,<br>
Re, or Rf is an alkyl group.<br>
-8-<br><br>
[023] The term "aminoalkoxy" as used herein refers to an amino group<br>
attached to an alkoxy group.<br>
[024] The term "aminoalkyl" as used herein refers to an amino group<br>
attached to an alkyl group.<br>
[025] The term "aryl" as used herein refers to a mono-, bi-, or other multi-<br>
carbocyclic, aromatic ring system. The aryl group can optionally be fused to one<br>
or more rings selected from aryls, cycloalkyls, and heterocyclyls. The aryl groups<br>
of this invention can be substituted with groups selected from alkoxy, aryloxy,<br>
alkyl, alkenyi, alkynyl, amide, amino, aryl, arylalkyl, carbamate, carboxy, cyano,<br>
cycloalkyl, ester, ether, formyl, halogen, haloalkyl, heteroaryl, heterocyclyl,<br>
hydroxyl, ketone, nitro, phosphate, sulfide, sulfinyl, sulfonyl, sulfonic acid,<br>
sulfonamide and thioketone. Exemplary aryl groups include, but are not limited to,<br>
phenyl, tolyl, anthracenyl, fluorenyl, indenyl, azulenyl, and naphthyl, as well as<br>
benzo-fused carbocyclic moieties such as 5,6,7,8-tetrahydronaphthyl. Exemplary<br>
aryl groups also include, but are not limited to a monocyclic aromatic ring system,<br>
wherein the ring comprises 6 carbon atoms, referred to herein as "(C6)aryl."<br>
[026] The term "arylalkyl" as used herein refers to an aryl group having at<br>
least one alkyl substituent, e.g. -aryl-alkyk Exemplary arylalkyl groups include,<br>
but are not limited to, arylalkyls having a monocyclic aromatic ring system,<br>
wherein the ring comprises 6 carbon atoms, referred to herein as "(C6)arylalkyl."<br>
[027] The term "aryloxy" as used herein refers to an aryl group attached to<br>
an oxygen atom. Exemplary aryloxy groups include, but are not limited to,<br>
aryloxys having a monocyclic aromatic ring system, wherein the ring comprises 6<br>
carbon atoms, referred to herein as "(C6)aryloxy."<br>
[028] The term "arylthio" as used herein refers to an aryl group attached to<br>
an sulfur atom. Exemplary arylthio groups include, but are not limited to, arylthios<br>
having a monocyclic aromatic ring system, wherein the ring comprises 6 carbon<br>
atoms, referred to herein as "(C6)arylthio."<br>
[029] The term "arylsulfonyl" as used herein refers to an aryl group<br>
attached to a sulfonyl group, e.g., -S(O)2-aryl-. Exemplary arylsulfonyl groups<br>
include, but are not limited to, arylsulfonyls having a monocyclic aromatic ring<br>
system, wherein the ring comprises 6 carbon atoms, referred to herein as<br>
"(C6)arylsulfonyl."<br>
-9-<br><br>
[030] The term "benzyl" as used herein refers to the group -CH2-phenyl.<br>
[031] The term "bicyclic aryl" as used herein refers to an aryl group fused<br>
to another aromatic or non-aromatic carbocylic or heterocyclic ring. Exemplary<br>
bicyclic aryl groups include, but are not limited to, naphthyl or partly reduced forms<br>
thereof, such as di-, tetra-, or hexahydronaphthyl.<br>
[032] The term "bicyclic heteroaryl" as used herein refers to a heteroaryl<br>
group fused to another aromatic or non-aromatic carbocylic or heterocyclic ring.<br>
Exemplary bicyclic heteroaryls include, but are not limited to, 5,6 or 6,6-fused<br>
systems wherein one or both rings contain heteroatoms. The term "bicyclic<br>
heteroaryl" also encompasses reduced or partly reduced forms of fused aromatic<br>
system wherein one or both rings contain ring heteroatoms. The ring system may<br>
contain up to three heteroatoms, independently selected from oxygen, nitrogen, or<br>
sulfur. The bicyclic system may be optionally substituted with one or more groups<br>
selected from alkoxy, aryloxy, alkyl, alkenyl, alkynyl, amide, amino, aryl, arylalkyl,<br>
carbamate, carbbxy, cyano, cycloalkyl, ester, ether, formyl, halogen, haloalkyl,<br>
heteroaryl, heterocyclyl, hydroxyl, ketone, nitro, phosphate, sulfide, sulfinyl,<br>
sulfonyl, sulfonic acid, sulfonamide and thioketone. Exemplary bicyclic<br>
heteroaryls include, but are not limited to, quinazolinyl, benzothiophenyl,<br>
benzoxazolyl, benzimidazolyl, benzothiazolyl, benzofuranyl, indolyl, quinolinyl,<br>
isoquinolinyl, phthalazinyl, benzotriazolyl, benzopyridinyl, and benzofuranyl.<br>
[033] The term "carbamate" as used herein refers to a radical of the form<br>
-RgOC(0)N(Rh)-, -RgOC(0)N(Rh)Rj-, or -OC(0)NRhRj, wherein Rg&gt; Rf, and Rj<br>
are each independently selected from alkoxy, aryloxy, alkyl, alkenyl, alkynyl,<br>
amide, amino, aryl, arylalkyl, carbamate, carboxy, cyano, cycloalkyl, ester, ether,<br>
formyl, halogen, haloalkyl, heteroaryl, heterocyclyl, hydrogen, hydroxyl, ketone,<br>
nitro, phosphate, sulfide, sulfinyl, sulfonyl, sulfonic acid, sulfonamide and<br>
thioketone. Exemplary carbamates include, but are not limited to, arylcarbamates<br>
or heteroaryl carbamates, e.g. wherein at least one of Rg Rf, and Rj are<br>
independently selected from aryl or heteroaryl, such as pyridine, pyridazine,<br>
pyrimidine, and pyrazine.<br>
[034] The term "carbonyl" as used herein refers to the radical -C(O)-.<br>
[035] The term "carboxy" as used herein refers to the radical -COOH or its<br>
corresponding salts, e.g. -COONa, etc. The term carboxy also includes<br>
-10-<br><br>
"carboxycarbonyl," e.g. a carboxy group attached to a carbonyl group, e.g., -C(O)-<br>
COOH or salts such as -C(0)-COONa, etc.<br>
[036] The term "carboxyalkoxy" as used herein refers to the radical<br>
-COOH or its corresponding salts, e.g. -COONa, etc., attached to an alkoxy<br>
group.<br>
[037] The term "cyano" as used herein refers to the radical -CN.<br>
[038] The term "cycloalkoxy" as used herein refers to a cycloalkyl group<br>
attached to an oxygen.<br>
[039] The term "cycloalkyl" as used herein refers to a monovalent<br>
saturated or unsaturated cyclic, bicyclic, or bridged bicyclic hydrocarbon group of<br>
3-12 carbons, or 3-8 carbons, referred to herein as "(C3-C8)cycloalkyl," derived<br>
from a cycloalkane. Exemplary cycloalkyl groups include, but are not limited to,<br>
cyclohexanes, cyclohexenes, cyclopentanes, and cyclopentenes. Cycloalkyl<br>
groups may be substituted with alkoxy, aryloxy, alkyl, alkenyl, alkynyl, amide,<br>
amino, aryl, arylalkyl, carbamate, carboxy, cyano, cycloalkyl, ester, ether, formyl,<br>
halogen, haloalkyl, heteroaryl, heterocyclyl, hydroxyl, ketone, nitro, phosphate,<br>
sulfide, sulfinyl, sulfonyl, sulfonic acid, sulfonamide and thioketone. Cycloalkyl<br>
groups can be fused to other cycloalkyl, aryl, or heterocyclyl groups.<br>
[040] The term "dicarboxylic acid" as used herein refers to a group<br>
containing at least two carboxylic acid groups such as saturated and unsaturated<br>
hydrocarbon dicarboxylic acids and salts thereof. Exemplary dicarboxylic acids<br>
include alkyl dicarboxylic acids. Dicarboxylic acids may be substituted with<br>
alkoxy, aryloxy, alkyl, alkenyl, alkynyl, amide, amino, aryl, arylalkyl, carbamate,<br>
carboxy, cyano, cycloalkyl, ester, ether, formyl, halogen, haloalkyl, heteroaryl,<br>
heterocyclyl, hydrogen, hydroxyl, ketone, nitro, phosphate, sulfide, sulfinyl,<br>
sulfonyl, sulfonic acid, sulfonamide and thioketone. Dicarboxylic acids include,<br>
but are not limited to succinic acid, glutaric acid, adipic acid, suberic acid, sebacic<br>
acid, azelaic acid, maleic acid, phthalic acid, aspartic acid, glutamic acid, malonic<br>
acid, fumaric acid, (+)/(-)-malic acid, (+)/(-) tartaric acid, isophthalic acid, and<br>
terephthalic acid. Dicarboxylic acids further include carboxylic acid derivatives<br>
thereof, such as anhydrides, imides, hydrazides, etc., for example, succinic<br>
anhydride, succinimide, etc.<br>
-11-<br><br>
[041] The term "ester" refers to a radical having the structure -C(0)0-,<br>
-C(0)0-Rj_, -R|<c or where is not bound to hydrogen and></c>
Rj and R[
alkynyl, amide, amino, aryl, arylalkyl, cycloalkyl, ether, formyl, haloalkyl, halogen,<br>
heteroaryl, heterocyclyl, ketone, phosphate, sulfide, sulfinyl, sulfonyl, sulfonic acid<br>
and thioketone. R|
may be cyclic, for example the carbon atom and Rj, the oxygen atom and R, or<br>
Rj and R|
include, but are not limited to, alkyl esters wherein at least one of Rj or Rk is alkyl,<br>
such as -alkyl-C(0)-0- -C(0)-0-alkyl-, -alkyl-C(0)-0-alkyl-, etc. Exemplary<br>
esters also include aryl or heteoraryl esters, e.g. wherein at least one of Rj or Rk<br>
is a heteroaryl group such as pyridine, pyridazine, pyrimidine and pyrazine, such<br>
as a nicotinate ester. Exemplary esters also include reverse esters having the<br>
structure -R|<c where the oxygen is bound to parent molecular group.></c>
Exemplary reverse esters include succinate, D-argininate, L-argininate, L-lysinate<br>
and D-lysinate. Esters also include carboxylic acid anhydrides and acid halides.<br>
[042] The term "ether" refers to a radical having the structure -R|0-Rm_,<br>
where R| and Rm can independently be alkyl, alkenyl, alkynyl, aryl, cycloalkyl,<br>
heterocyclyl, or ether. The ether can be attached to the parent molecular group<br>
through R| or Rm. Exemplary ethers include, but are not limited to, alkoxyalkyl<br>
and alkoxyaryl groups. Ethers also includes polyethers, e.g., where one or both of<br>
R| and Rm are ethers.<br>
[043] The terms "halo" or "halogen" or "Hal" as used herein refer to F, CI,<br>
Br, or I.<br>
[044] The term "haloalkyl" as used herein refers to an alkyl group<br>
substituted with one or more halogen atoms. "Haloalkyls" also encompass alkenyl<br>
or alkynyl groups substituted with one or more halogen atoms.<br>
[045] The term "heteroaryl" as used herein refers to a mono-, bi-, or multi-<br>
cyclic, aromatic ring system containing one or more heteroatoms, for example 1 to<br>
3 heteroatoms, such as nitrogen, oxygen, and sulfur. Heteroaryls can be<br>
substituted with one or more substituents including alkoxy, aryloxy, alkyl, alkenyl,<br>
-12-<br><br>
alkynyl, amide, amino, aryl, arylalkyl, carbamate, carboxy, cyano, cycloalkyl, ester,<br>
ether, formyl, halogen, haloalkyl, heteroaryl, heterocyclyl, hydroxyl, ketone, nitro,<br>
phosphate, sulfide, sulfinyl, sulfonyl, sulfonic acid, sulfonamide and thioketone.<br>
Heteroaryls can also be fused to non-aromatic rings. Illustrative examples of<br>
heteroaryl groups include, but are not limited to, pyridinyl, pyridazinyl, pyrimidyl,<br>
pyrazyl, triazinyl, pyrrolyl, pyrazolyl, imidazolyl, (1,2,3,)- and (1,2,4)-triazolyl,<br>
pyrazinyl, pyrimidilyl, tetrazolyl, furyl, thienyl, isoxazolyl, thiazolyl, furyl, phenyl,<br>
isoxazolyl, and oxazolyl. Exemplary heteroaryl groups include, but are not limited<br>
to, a monocyclic aromatic ring, wherein the ring comprises 2 to 5 carbon atoms<br>
and 1 to 3 heteroatoms, referred to herein as "(C2-C5)heteroaryl,"<br>
[046] The terms "heterocycle," "heterocyclyl," or "heterocyclic" as used<br>
herein refer to a saturated or unsaturated 3-, 4-, 5-, 6- or 7-membered ring<br>
containing one, two, or three heteroatoms independently selected from nitrogen,<br>
oxygen, and sulfur. Heterocycles can be aromatic (heteroaryls) or non-aromatic.<br>
Heterocycles can be substituted with one or more substituents including alkoxy,<br>
aryloxy, alkyl, alkenyl, alkynyl, amide, amino, aryl, arylalkyl, carbamate, carboxy,<br>
cyano, cycloalkyl, ester, ether, formyl, halogen, haloalkyl, heteroaryl, heterocyclyl,<br>
hydroxyl, ketone, nitro, phosphate, sulfide, sulfinyl, sulfonyl, sulfonic acid,<br>
sulfonamide and thioketone.<br>
[047] Heterocycles also include bicyclic, tricyclic, and tetracyclic groups in<br>
which any of the above heterocyclic rings is fused to one or two rings<br>
independently selected from aryls, cycloalkyls, and heterocycles. Exemplary<br>
heterocycles include acridinyl, benzimidazolyl, benzofuryl, benzothiazolyl,<br>
benzothienyl, benzoxazolyl, biotinyl, cinnolinyl, dihydrofuryl, dihydroindolyl,<br>
dihydropyranyl, dihydrothienyl, dithiazolyl, furyl, homopiperidinyl, imidazolidinyl,<br>
imidazolinyl, imidazolyl, indolyl, isoquinolyl, isothiazolidinyl, isothiazolyl,<br>
isoxazolidinyl, isoxazolyl, morpholinyl, oxadiazolyl, oxazolidinyl, oxazolyl,<br>
piperazinyl, piperidinyl, pyranyl, pyrazolidinyl, pyrazinyl, pyrazolyl, pyrazolinyl,<br>
pyridazinyl, pyridyl, pyrimidinyl, pyrimidyl, pyrrolidinyl, pyrrolidin-2-onyl, pyrrolinyl,<br>
pyrrolyl, quinolinyl, quinoxaloyl, tetrahydrofuryl, tetrahydroisoquinolyl,<br>
tetrahydropyranyl, tetrahydroquinolyl, tetrazolyl, thiadiazolyl, thiazolidinyl, thiazolyl,<br>
thienyl, thiomorpholinyl, thiopyranyl, and triazolyl.<br>
-13-<br><br>
[048] The term "heterocyclylalkyl" as used herein refers to a heterocyclyl<br>
attached to an alkyl group.<br>
[049] The term "heterocyclylalkoxy" as used herein refers to a heterocyclyl<br>
attached to an alkoxy group.<br>
[050] The terms "hydroxy" and "hydroxyl" as used herein refers to the<br>
radical -OH.<br>
[051] The term "hydroxyalkoxy" as used herein refers to a hydroxy radical<br>
attached to an alkoxy group.<br>
[052] The term "hydroxyalkyl" as used herein refers to a hydroxy radical<br>
attached to an alkyl group.<br>
[053] The term "hydroxyaryl" as used herein refers to a hydroxy radical<br>
attached to an aryl group.<br>
[054] The term "ketone" as used herein refers to a radical having the<br>
structure -C(0)-Rn (such as acetyl, -C(0)CH3) or -Rn_C(0)-R0_. The ketone can<br>
be attached to another group through Rn or R0. Rn or R0 can be alkyl, alkenyl,<br>
alkynyl, cycloalkyl, heterocyclyl or aryl, or Rn or R0 can be joined to form a 3- to<br>
12-membered ring.<br>
[055] The term "monoester" as used herein refers to an analogue of a<br>
dicarboxylic acid wherein one of the carboxylic acids is functionalized as an ester<br>
and the other carboxylic acid is a free carboxylic acid or salt of a carboxylic acid.<br>
Examples of monoesters include, but are not limited to, to monoesters of succinic<br>
acid, glutaric acid, adipic acid, suberic acid, sebacic acid, azelaic acid, oxalic and<br>
maleic acid.<br>
[056] The term "nitro" as used herein refers to the radical -NO2.<br>
[057] The term "perfluoroalkoxy" as used herein refers to an alkoxy group<br>
in which all of the hydrogen atoms have been replaced by fluorine atoms.<br>
[058] The term "perfluoroalkyl" as used herein refers to an alkyl group in<br>
which all of the hydrogen atoms have been replaced by fluorine atoms.<br>
Exemplary perfluoroalkyl groups include, but are not limited to, Ci_5 perfluoroalkyl,<br>
such as trifluoromethyl, etc.<br>
[059] The term "perfluorocycloalkyl" as used herein refers to a cycloalkyl<br>
group in which all of the hydrogen atoms have been replaced by fluorine atoms.<br>
-14-<br><br>
[060] The term "phenyl" as used herein refers to a 6-membered<br>
carbocyclic aromatic ring. The phenyl group can also be fused to a cyclohexane<br>
or cyclopentane ring. Phenyl can be substituted with one or more substituents<br>
including alkoxy, aryloxy, alkyl, alkenyl, alkynyl, amide, amino, aryl, arylalkyl,<br>
carbamate, carboxy, cyano, cycloalkyl, ester, ether, formyl, halogen, haloalkyl,<br>
heteroaryl, heterocyclyl, hydroxyl, ketone, nitro, phosphate, sulfide, sulfinyl,<br>
sulfonyl, sulfonic acid, sulfonamide and thioketone.<br>
[061] The term "phosphate" as used herein refers to a radical having the<br>
structure -OP(0)02-, -RxOP(0)02-, -OP(0)02Ry-, or -RxOP(0)02Ry-, wherein Rx<br>
and Ry can be alkyl, alkenyl, alkynyl, alkoxy, amide, amino, aryl, aryloxy, carboxy,<br>
cyano, cycloalkyl, ester, ether, halogen, heterocyclyl, hydrogen, hydroxy, ketone,<br>
nitro, sulfonate, sulfonyl, and thio. 	<br>
[062] The term "sulfide" as used herein refers to the radical having the<br>
structure RZS-, where Rz can be alkoxy, aryloxy, alkyl, alkenyl, alkynyl, amide,<br>
amino, aryl, arylalkyl, carbamate, carboxy, cycloalkyl, ester, ether, formyl,<br>
haloalkyl, heteroaryl, heterocyclyl, and ketone. The term "alkylsulfide" as used<br>
herein refers to an alkyl group attached to a sulfur atom.<br>
[063] The term "sulfinyl" as used herein refers to a radical having the<br>
structure -S(0)0-, -RpS(0)0-, -RpS(0)ORq-, or -S(0)ORq-, wherein Rp and RS can<br>
be alkoxy, aryloxy, alkyl, alkenyl, alkynyl, amide, amino, aryl, arylalkyl, cycloalkyl,<br>
ester, ether, formyl, halogen, haloalkyl, heteroaryl, heterocyclyl, hydroxyl, ketone,<br>
nitro, phosphate, sulfide, sulfonyl, sulfonic acid, sulfonamide and thioketone.<br>
Exemplary sulfinyl groups include, but are not limited to, alkylsulfinyls wherein at<br>
least one of Rp or Rq is alkyl, alkenyl or alkynyl.<br>
[064] The term "sulfonamide" as used herein refers to a radical having the<br>
structure -(Rr)-N-S(0)2-Rs- or-Rt(Rr)-N-S(0)2-Rs, where Rt, Rr, and Rs can be,<br>
for example, hydrogen, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, and heterocyclyl.<br>
Exemplary sulfonamides include alkylsulfonamides (e.g., where Rs is alkyl),<br>
arylsulfonamides (e.g., where Rsis aryl), cycloalkyl sulfonamides (e.g., where Rs<br>
is cycloalkyl), and heterocyclyl sulfonamides (e.g., where Rs is heterocyclyl), etc.<br>
[065] The term "sulfonate" as used herein refers to the radical -OSO3".<br>
Sulfonate includes salts such as -OS03Na, -OS03K, etc. and the acid -OS03H<br>
-15-<br><br>
[066] The term "sulfonic acid" refers to the radical -S03H~ and its<br>
corresponding salts, e.g. -SO3K-, -SCNa--.<br>
[067] The term "sulfonyl" as used herein refers to a radical having the<br>
structure RUSO2-, where Ru can be alkyl, alkenyl, alkynyl, amino, amide, aryl,<br>
cycloalkyl, and heterocyclyl, e.g., alkylsulfonyl. The term "alkylsulfonyl" as used<br>
herein refers to an alkyl group attached to a sulfonyl group. "Alkylsulfonyl" groups<br>
can optionally contain alkenyl or alkynyl groups.<br>
[068] The term "thioketone" refers to a radical having the structure<br>
-RV_C(S)-RW_. The ketone can be attached to another group through Rv or Rw.<br>
Rv or Rw can be alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl or aryl, or Rv or<br>
Rw can be joined to form a 3- to 12-membered ring.<br>
[069] "Alkyl," "alkenyl," and "alkynyl" groups, collectively referred to as<br>
"saturated and unsaturated hydrocarbons," and "alkoxy" groups can be substituted<br>
with or interrupted by at least one group selected from alkoxy, aryloxy, alkyl,<br>
alkenyl, alkynyl, amide, amino, aryl, arylalkyl, carbamate, carboxy, cyano,<br>
cycloalkyl, ester, ether, formyl, halogen, haloalkyl, heteroaryl, heterocyclyl,<br>
heterocyclyloxy, hydroxyl, ketone, nitro, phosphate, sulfide, sulfinyl, sulfonyl,<br>
sulfonic acid, sulfonamide, thioketone, and N.<br>
[070] As used herein, a "suitable substituent" refers to a group that does<br>
not nullify the synthetic or pharmaceutical utility of the compounds of the invention<br>
or the intermediates useful for preparing them. Examples of suitable substituents<br>
include, but are not limited to: C1-22, C-i_8, and C1-6 alkyl, alkenyl or alkynyl; C-i_6<br>
aryl, C2-5 heteroaryl; C3_7 cycloalkyl; C-i-22, C-i-s, and Ci-6 alkoxy; C6 aryloxy; -CN;<br>
-OH; oxo; halo, carboxy; amino, such as -NH(Ci-22, Ci.8) or d-6 alkyl), -N((C-i-22,<br>
C-i-s, and C1-6 alkyl)2, -NH((C6)aryl), or -N((C6)aryl)2; formyl; ketones, such as<br>
-CO(Ci-22, C-i-s, and Ci_6 alkyl), -CO((C6 aryl) esters, such as -C02(Ci.22, C-i-8, and<br>
C1-6 alkyl) and -C02 (C6 aryl); and heterocyclyl. One of skill in art can readily<br>
choose a suitable substituent based on the stability and pharmacological and<br>
synthetic activity of the compound of the invention.<br>
[071] The term "pharmaceutically acceptable carrier" as used herein refers<br>
to any and all solvents, dispersion media, coatings, isotonic and absorption<br>
delaying agents, and the like, that are compatible with pharmaceutical<br>
-16-<br><br>
administration. The use of such media and agents for pharmaceutical active<br>
substances is well known in the art. The compositions may also contain other<br>
active compounds providing supplemental, additional, or enhanced therapeutic<br>
functions.<br>
[072] The term "pharmaceutically acceptable composition" as used herein<br>
refers to a composition comprising at least one compound as disclosed herein<br>
formulated together with one or more pharmaceutically acceptable carriers.<br>
[073] The term "pharmaceutically acceptable prodrugs" as used herein<br>
represents those prodrugs of the compounds of the present invention that are,<br>
within the scope of sound medical judgment, suitable for use in contact with the<br>
tissues of humans and lower animals without undue toxicity, irritation, allergic<br>
response, commensurate with a reasonable benefit / risk ratio, and effective for<br>
their intended use, as well as the zwitterionic forms, where possible, of the<br>
compounds of the invention. A discussion is provided in Higuchi et al., "Pro-drugs<br>
as Novel Delivery Systems," ACS Symposium Series, Vol. 14, and in Roche, E.B.,<br>
ed. Bioreversible Carriers in Drug Design, American Pharmaceutical Association<br>
and Pergamon Press, 1987, both of which are incorporated herein by reference.<br>
[074] In one embodiment, pharmaceutically acceptable prodrugs refer to<br>
a compound that is metabolized, for example hydrolyzed or oxidized, in the host to<br>
form the compound of the present invention. Typical examples of prodrugs include<br>
compounds that have biologically labile protecting groups on a functional moiety<br>
of the active compound. Prodrugs include compounds that can be oxidized,<br>
reduced, aminated, deaminated, hydroxylated, dehydroxylated, hydrolyzed,<br>
dehydrolyzed, alkylated, dealkylated, acylated, deacylated, phosphorylated,<br>
dephosphorylated to produce the active compound.<br>
[075] Any of the compounds described herein can be administered as a<br>
prodrug to increase the activity, bioavailability, stability or otherwise alter the<br>
properties of the compound. A number of prodrug ligands are known. In general,<br>
alkylation, acylation or other lipophilic modification of the compound will increase<br>
the stability of Formula 1. Examples of substituent groups that can replace one or<br>
more hydrogens on the compound are alkyl, aryl, steroids, carbohydrates,<br>
including sugars, 1,2-diacylglycerol and alcohols. Many are described in R. Jones<br>
-17-<br><br>
and N. Bischofberger, Antiviral Research, 27 (1995) 1-17. Any of these can be<br>
used in combination with the disclosed compounds to achieve a desired effect.<br>
[076] The term "pharmaceutically acceptable salt(s)" or "complexes" refers<br>
to salts of acidic or basic groups that may be present in compounds used in the<br>
present compositions. In one embodiment, these salts retain the desired<br>
biological activity of the compounds of the present invention and exhibit minimal<br>
undesired toxicological effects. Examples of pharmaceutically acceptable salts<br>
are organic acid addition salts formed with acids, which form a physiological<br>
acceptable anion, for example, tosylate, methanesulfonate, acetate, citrate,<br>
malonate, tartarate, succinate, benzoate, ascorbate, .alpha.-ketoglutarate and<br>
.alpha.-glycerophosphate. Suitable inorganic salts may also be formed, including,<br>
sulfate, nitrate, bicarbonate and carbonate salts. Alternatively, the<br>
pharmaceutically acceptable salts may be made with sufficiently basic compounds<br>
such as an amine with a suitable acid affording a physiologically acceptable anion.<br>
Alkali metal (for example, sodium, potassium or lithium) or alkaline earth metal (for<br>
example calcium) salts of carboxylic acids can also be made.<br>
[077] Nonlimiting examples of such salts are (a) acid addition salts<br>
formed with inorganic acids (for example, hydrochloric acid, hydrobromic acid,<br>
sulfuric acid, phosphoric acid, nitric acid, and the like), and salts formed with<br>
organic acids such as acetic acid, oxalic acid, tartaric acid, succinic acid, malic<br>
acid, ascorbic acid, benzoic acid, tannic acid, pamoic acid, alginic acid,<br>
polyglutamic acid, naphthalenesulfonic acid, naphthalenedisulfonic acid, and<br>
polygalcturonic acid; (b) base addition salts formed with metal cations such as<br>
zinc, calcium, bismuth, barium, magnesium, aluminum, copper, cobalt, nickel,<br>
cadmium, sodium, potassium, and the like, or with a cation formed from ammonia,<br>
N,N-dibenzylethylenediamine, D-glucosamine, tetraethylammonium, or<br>
ethylenediamine; or (c) combinations of (a) and (b); e.g., a zinc tannate salt or the<br>
like. Also included in this definition are pharmaceutically acceptable quaternary<br>
salts known by those skilled in the art, which specifically include the quaternary<br>
ammonium salt of the formula -NR.sup.+A.sup.-, wherein R is as defined above<br>
and A is a counterion, including chloride, bromide, iodide, --O-alkyl,<br>
toluenesulfonate, methylsulfonate, sulfonate, phosphate, or carboxylate (such as<br>
-18-<br><br>
benzoate, succinate, acetate, glycolate, maleate, malate, citrate, tartrate,<br>
ascorbate, benzoate, cinnamoate, mandeloate, benzyloate, and diphenylacetate).<br>
[078] Particular FDA-approved salts can be conveniently divided<br>
between anions and cations (Approved Drug Products with Therapeutic<br>
Equivalence Evaluations (1994) U.S. Department of Health and Human Services,<br>
Public Health Service, FDA, Center for Drug Evaluation and Research, Rockville,<br>
Md; L. D. Bighley, S. M. Berge and D. C. Monkhouse, Salt Forms of Drugs and<br>
Absorption, Encyclopedia of Pharmaceutical Technology, Vol. 13, J. Swarbridk<br>
and J. Boylan, eds., Marcel Dekker, NY (1996)). Among the approved anions<br>
include aceglumate, acephyllinate, acetamidobenzoate, acetate,<br>
acetylasparaginate, acetylaspartate, adipate, aminosalicylate,<br>
anhydromethylenecitrate, ascorbate, aspartate, benzoate, besylate, bicarbonate,<br>
bisulfate, bitartrate, borate, bromide, camphorate, camsylate, carbonate, chloride,<br>
chlorophenoxyacetate, citrate.closylate, cromesilate, cyclamate, dehydrocholate,<br>
dihydrochloride, dimalonate, edentate, edisylate, estolate, esylate, ethylbromide,<br>
ethylsulfate, fendizoate, fosfatex, fumarate, gluceptate, gluconate, glucuronate,<br>
glutamate, glycerophosphate, glysinate, glycollylarsinilate, glycyrrhizate,<br>
hippurate, hemisulfate, hexylresorcinate, hybenzate, hydrobromide, hydrochloride,<br>
hydroiodid, hydroxybenzenesulfonate, hydroxybenzoate, hydroxynaphthoate,<br>
hyclate, iodide, isethionate, lactate, lactobionate, lysine, malate, maleate,<br>
mesylate, methylbromide, methyliodide, methylnitrate, methylsulfate,<br>
monophosadenine, mucate, napadisylate, napsylate, nicotinate, nitrate, oleate,<br>
orotate, oxalate, oxoglurate, pamoate, pantothenate, pectinate,<br>
phenylethylbarbiturate, phosphate, pacrate, plicrilix, polistirex, polygalacturonate,<br>
propionate, pyridoxylphosphate, saccharinate, salicylate, stearate, succinate,<br>
stearylsulfate, subacetate, succinate, sulfate, subsalicylate, tannate, tartrate,<br>
teprosilate, terephthalate, teoclate, thiocyante, tidiacicate, timonacicate, tosylate,<br>
triethiodide, triethiodide, undecanoate, and xinafoate. The approved cations<br>
include ammonium, benethamine, benzathine, betaine, calcium, carnitine,<br>
clemizole, chlorcyclizine, choline, dibenylamine, diethanolamine, diethylamine,<br>
diethylammonium diolamine, eglumine, erbumine, ethylenediamine, heptaminol,<br>
hydrabamine, hydroxyethylpyrrolidone, imadazole, meglumine, olamine,<br>
piperazine, 4-phenylcyclohexylamine, procaine, pyridoxine, triethanolamine, and<br>
-19-<br><br>
tromethamine. Metallic cations include, aluminum, bismuth, calcium lithium,<br>
magnesium, neodymium, potassium, rubidium, sodium, strontium and zinc.<br>
[079] A particular class of salts can be classified as organic amine salts.<br>
The organic amines used to form these salts can be primary amines, secondary<br>
amines or tertiary amines, and the substituents on the amine can be straight,<br>
branched or cyclic groups, including ringed structures formed by attachment of<br>
two or more of the amine substituents. Of particular interest are organic amines<br>
that are substituted by one or more hydroxyalkyl groups, including alditol or<br>
carbohydrate moieties. These hydroxy substituted organic amines can be cyclic or<br>
acyclic, both classes of which can be primary amines, secondary amines or<br>
tertiary amines. A common class of cyclic hydroxy substituted amines is the amino<br>
sugars.<br>
[080] The compounds of the disclosure may contain one or more chiral<br>
centers and/or double bonds and, therefore, exist as stereoisomers, such as<br>
geometric isomers, enantiomers or diastereomers. The term "stereoisomers"<br>
when used herein consist of all geometric isomers, enantiomers or diastereomers.<br>
These compounds may be designated by the symbols "R" or "S," depending on<br>
the configuration of substituents around the stereogenic carbon atom. The<br>
present invention encompasses various stereoisomers of these compounds and<br>
mixtures thereof. Stereoisomers include enantiomers and diastereomers.<br>
Mixtures of enantiomers or diastereomers may be designated "()" in<br>
nomenclature, but the skilled artisan will recognize that a structure may denote a<br>
chiral center implicitly.<br>
[081] It is appreciated that compounds of the present invention may have<br>
a chiral center and may exist in and be isolated in optically active and racemic<br>
forms. Some compounds may exhibit polymorphism. It is to be understood that<br>
the present invention encompasses any racemic, optically-active, diastereomeric,<br>
polymorphic, or stereoisomeric form, or mixtures thereof, of a compound of the<br>
invention, which possess the useful properties described herein, it being well<br>
known in the art how to prepare optically active forms (for example, by resolution<br>
of the racemic form by recrystallization techniques, by synthesis from optically-<br>
active starting materials, by chiral synthesis, or by chromatographic separation<br>
using a chiral stationary phase).<br>
-20-<br><br>
[082] Geometric isomers can also exist in the compounds of the present<br>
invention. The present invention encompasses the various geometric isomers<br>
and mixtures thereof resulting from the arrangement of substituents around a<br>
carbon-carbon double bond or arrangement of substituents around a carbocyciic<br>
ring. Substituents around a carbon-carbon double bond are designated as being<br>
in the "Z' or "" configuration wherein the terms "Z' and "E" are used in<br>
accordance with IUPAC standards. Unless otherwise specified, structures<br>
depicting double bonds encompass both the E and Z isomers.<br>
[083] Substituents around a carbon-carbon double bond alternatively can<br>
be referred to as "cis" or "trans," where "cis" represents substituents on the same<br>
side of the double bond and "trans" represents substituents on opposite sides of<br>
the double bond. The arrangement of substituents around a carbocyciic ring is<br>
designated as "cis" or "trans." The term "cis" represents substituents on the same<br>
side of the plane of the ring and the term "trans" represents substituents on<br>
opposite sides of the plane of the ring. Mixtures of compounds wherein the<br>
substituents are disposed on both the same and opposite sides of plane of the<br>
ring are designated "cis/trans."<br>
Embodiments of the Invention<br>
[084] One embodiment provides methods for inhibiting VCAM-1<br>
expression, MCP-1 expression and/or SMC proliferation in a mammal, comprising<br>
administering a therapeutically effective amount of a compound of Formula 1:<br><br>
wherein:<br>
X is selected from CR-H, CR11R13, CO, CS, O, S, SO, S02, N and NRn,<br>
wherein Rn may be the same or different than R13;<br>
Y is selected from CR12, CR12Ri4, CO, CS, O, S, SO, S02, N and NR12,<br>
wherein Ri2 may be the same or different than R14;<br>
-21 -<br><br>
Ri, R2, R3, R4, R5, Re, R7, Ra, R9, R10, R11, R12, R13, Rand Ri7are each<br>
independently selected from alkoxy, aryloxy, alkyl, alkenyl, alkynyl, amide, amino,<br>
aryl, arylalkyl, carbamate, carboxy, cyano, cycloalkyl, ester, ether, formyl,<br>
halogen, haloalkyl, heteroaryl, heterocyclyl, hydrogen, hydroxyl, ketone, nitro,<br>
phosphate, sulfide, sulfinyl, sulfonyl, sulfonic acid, sulfonamide and thioketone, or<br>
two adjacent substituents selected from R1, R2, R3, R4, R5, R6, R7, Ra, R9,<br>
R10, R11, Ri2&gt; R13, and R14 are connected in a 5 or 6-membered ring to form a<br>
bicyclic aryl, bicyclic heteroaryl or bicyclic heterocyclyl;<br>
each W is independently selected from C and N, wherein if W is N, then p<br>
is 0 and if W is C, then p is 1;<br>
Z-], Z2 and Z3 are each independently selected from a single bond and a<br>
double bond;<br>
wherein if Y is O, then X is not CO;<br>
wherein if at least one W is not N, then<br>
a)	X and Y are each CO,<br>
b)	X is NRn and Z2 is a double bond, or<br>
c)	two adjacent substituents selected from R5, R6, R7, Rs, and Rg are<br>
connected in a 5 or 6-membered ring to form a bicyclic aryl, bicyclic heteroaryl or<br>
bicyclic heterocyclyl;<br>
and pharmaceutically acceptable salts and hydrates thereof.<br>
[085] In one embodiment, R7 is hydroxyl. In another embodiment, at<br>
least one of R1f R2, R3, R4, R5, Re, R7, Ra, R9, R10, R11, R12, R13, Rand R17 is<br>
selected from alkoxy, alkyl, amino, aminoalkoxy, aminoalkyl, carboxyalkoxy,<br>
halogen, heterocyclyl, heterocyclylalkoxy, heterocyclylalkyl, hydroxyalkoxy,<br>
hydroxyalkyl, and hydroxyl.<br>
[086] In one embodiment, X is selected from CR-n, CO, N, NRn and O;<br>
and Y is selected from CR-|2, CO, and NR-12. In another embodiment, X is O and Y<br>
is CO.<br>
[087] In one embodiment, Z1 and Z3 are single bonds, and Z2 is a double<br>
bond. In another embodiment, Z1 is a double bond and Y is CO. In another<br>
embodiment, Z1 and Z3 are double bonds.<br>
[088] In one embodiment, at least one W in the A ring of Formula 1 is N.<br>
In another embodiment, the W bonded to (Rp is N. In another embodiment, the<br>
-22-<br><br>
W bonded to (Rio)P is N. Another embodiment provides that at least one W in the<br>
C ring of Formula 1 is N. In another embodiment, the W bonded to (R7)p is N.<br>
[089] One embodiment provides a compound of Formula I:<br><br>
wherein:<br>
X is selected from CRu, CO, N, NR-H and.O;<br>
Y is selected from CR12, CO, and NR12;<br>
R-ii R2&gt; R3&gt; R4, R5. R6, R7, R8 R9, R10, R11. Ri2&gt; Ri3. Ri4and Rare each<br>
independently selected from alkoxy, alkyl, amino, aminoalkoxy, aminoalkyl,<br>
carboxyalkoxy, halogen, heterocyclyl, heterocyclylalkoxy, heterocyclylalkyl,<br>
hydrogen, hydroxyalkoxy, hydroxyalkyl, and hydroxyl, or<br>
two adjacent substituents selected from R5, R6, R7, Rs and R9 are<br>
connected in a 5 or 6-membered ring to form a bicyclic aryl, bicyclic heteroaryl or<br>
bicyclic heterocyclyl;<br>
each W is independently selected from C and N, wherein if W is N, then p<br>
is 0 and if W is C, then p is 1;<br>
Z-i, Z2 and Z3 are each independently selected from a single bond and a<br>
double bond;<br>
wherein if at least one W is not N, then<br>
a)	X and Y are each CO, or<br>
b)	X is NR11 and Z2 is a double bond;<br>
and pharmaceutically acceptable salts and hydrates thereof.<br>
[090] An alternative embodiment provides compounds of Formula 1:<br>
-23-<br><br><br>
or a pharmaceutical acceptable salt thereof,<br>
wherein<br>
R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, and R17<br>
are independently selected from the group consisting of (Ci-C22)alkyl, (C2-<br>
C22)alkenyl, (C2.C22)alkynyl, aryl, heteroaryl, alkoxy, aryloxy, benzyl, phenyl,<br>
carbonyl, thioketone, hydrogen, hydroxyl (OH), acetyl, hydroxyalkyl, aminoalkyl,<br>
amides, carbamates, halogen, bromide (Br), iodide (I), fluoride (F), chloride (CI),<br>
CF3, CCI3, sulfonic acid (-SO3H), phosphate, O-sulfate (sulfate conjugate), O-<br>
glucoronidate [glucoronic (glucuronic) acid conjugates], monoesters, dicarboxylic<br>
acid, #STR55#, #STR66#, #STR77#, #STR88#, #STR99#, #STR100#,<br>
wherein W can be C or N;<br>
wherein when W is a nitrogen atom, the nitrogen atom will only bind to<br>
three covalent bonds due to available valence electrons.<br>
-24-<br>
The structures below demonstrate a nitrogen arrangement of one<br>
embodiment of the compounds of Formula 1:<br><br><br><br>
wherein the same applies to any W:<br>
wherein<br>
Xcan be CH, CH2, CR11, CR13, CHR11, CHR13, CR11R13, CS, 0, S,<br>
SO, S02) NH, NR11 with the proviso that X and Y do not exceed the number of<br>
valence electrons available as per definitions of X and Y above<br>
Yean beCH, CH2, CR12, CR14, CHR12, CHR14, CR11R14, CO, CS, O,<br>
S, SO, SO2, NH, NR11 with the proviso that X and Y do not exceed the number of<br>
valence electrons available as per definitions of X and Y above<br>
-25-<br>
Z can be a single, double bond or triple bond, with the proviso that X and Y<br>
do not exceed the number of valence electrons available as per definitions of X<br>
and Y above<br><br><br><br>
R15 and R16 are substituents independently selected from the group<br>
consisting of (C-i.Calkyl, (C2-C22)alkenyl, (C2-C22)alkynyl, aryl, heteroaryl, alkoxy,<br>
aryloxy, benzyl, phenyl, carbonyl, hydrogen, hydroxyl (OH), acetyl, hydroxyalkyl,<br>
aminoalkyl, amides, carbamates, halogen, bromide (Br), iodide (I), fluoride (F),<br>
chloride (CI), CF3, CCI3, sulfonic acid (-SO3H), phosphate, or a derivative thereof,<br>
wherein said derivative is optionally substituted and optionally branched, and may<br>
have one or more of the C atoms replaced by S, N or O;<br>
wherein Formula 1 compounds have at least one proviso selected from the<br>
following<br>
R7 is a hydroxyl;<br>
at least one W is a N;<br>
at least one of R1-R10 is #STR77#, #STR88# or #STR99#;<br>
at least one of R1-R10 is #STR66#;<br>
one of R1-R10 is a monoester;<br>
one of R1-R10 is a dicarboxylic acid;<br>
one of R1-R10 is succinic acid;<br>
R7 is #STR55#;<br>
R7 and R2 are #STR55#;<br>
R7 and R2 are hydroxyls; and<br>
R7 is #STR66#.<br>
[091] Non-limiting embodiments of Formula 1 include:<br>
R7 is a hydroxyl and at least one W is a N;<br>
R7 is a hydroxyl and at least one of R1-R6 and R8-R10 is #STR66#;<br>
R7 is a hydroxyl and at least one of R1-R6 and R8-R10 is #STR77#,<br>
#STR88# or#STR99#; and<br>
- 26 -<br><br>
R7 is #STR66# and at least one W is a N.<br>
-27-<br>
[092] Other alternative embodiments of Formula 1 include<br><br><br><br>
-28-<br><br><br>
-29-<br><br><br>
-30-<br><br><br>
or a pharmaceutically acceptable salt thereof,<br>
wherein<br>
R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, and R17<br>
are independently selected from the group consisting of (Ci_C22)alkyl, (C2-<br>
C22)alkenyl, (d-C22)alkynyl, aryl, heteroaryl, alkoxy, aryloxy, benzyl, phenyl,<br>
carbonyl, thioketone, hydrogen, hydroxyl [OH], acetyl, hydroxyalkyl, aminoalkyl,<br>
amides, carbamates, halogen, bromide [Br], iodide [I], fluoride [F], chloride [CI],<br>
CF3, CCI3) sulfonic acid [-SO3H], phosphate, O-sulfate [the sulfate conjugate], O-<br>
glucoronidate [the glucoronic (AKA glucuronic) acid conjugates], monoesters,<br>
dicarboxylic acid, #STR55#, #STR66#, #STR77#, #STR88#, #STR99#,<br>
#STR100#,<br>
wherein W can be C or N;<br>
wherein when W is a nitrogen atom, the nitrogen atom will only bind to<br>
three covalent bonds due to available valence electrons.<br>
The structures below demonstrate a nitrogen arrangement of one<br>
embodiment of the compounds of Formula 1:<br>
-31-<br><br><br>
wherein<br>
Xcan be CH, CH2l CR11, CR13, CHR11, CHR13, CR11R13, CS, O, S,<br>
SO, SO2, NH, NR11 with the proviso that X and Y do not exceed the number of<br>
valence electrons available as per definitions of X and Y above<br>
Yean be CH, CH2, CR12, CR14, CHR12, CHR14, CR11R14, CO, CS, O,<br>
S, SO, S02, NH, NR11 with the proviso that X and Y do not exceed the number of<br>
valence electrons available as per definitions of X and Y above<br>
Z can be a single, double bond or triple bond, with the proviso that X and Y<br>
do not exceed the number of valence electrons available as per definitions of X<br>
and Y above<br>
wherein<br><br>
-32-<br><br><br>
R15 and R16 are substituents independently selected from the group<br>
consisting of (C-i_C22)alkyl, (C2-C22)alkenyl, (Ci.C22)alkynyl, aryl, heteroaryl, alkoxy,<br>
aryloxy, benzyl, phenyl, carbonyl, hydrogen, hydroxyl (OH), acetyl, hydroxyalkyl,<br>
aminoalkyl, amides, carbamates, halogen, bromide (Br), iodide (I), fluoride (F),<br>
chloride (CI), CF3, CCI3, sulfonic acid (-SO3H), phosphate, or a derivative thereof,<br>
wherein said derivative is optionally substituted and optionally branched, and may<br>
have one or more of the C atoms replaced by S, N or O;<br>
wherein non limiting examples of Formula 1 have at least one proviso<br>
selected from the following:<br>
R7 is a hydroxyl;<br>
at least one W is a N;<br>
at least one of R1-R10 is #STR77#, #STR88# or #STR99#;<br>
at least one of R1-R10 is #STR66#;<br>
one of R1-R10 is a monoester;<br>
one of R1-R10 is a dicarboxylic acid;<br>
one of R1-R10 is succinic acid;<br>
R7 is #STR55#;<br>
R7 and R2 are #STR55#;<br>
R7 and R2 are hydroxyls; and<br>
R7 is #STR66#.<br>
-33-<br><br>
[093] Non-limiting examples include compounds of Formula 1 where<br>
R7 is a hydroxyl and at least one W is a N;<br>
R7 is a hydroxyl and at least one of R1-R6 and R8-R10 is #STR66#;<br>
R7 is a hydroxyl and at least one of R1-R6 and R8-R10 is #STR77#,<br>
#STR88# or #STR99#; and<br>
R7 is #STR66# and at least one W is a N.<br>
Pharmaceutical Formulations and Methods of Treatment<br>
[094] Embodiments of the present invention also provide pharmaceutical<br>
compositions comprising compounds disclosed herein formulated together with<br>
one or more pharmaceutically acceptable carriers. These formulations include<br>
those suitable for oral, rectal, topical, buccal and parenteral (e.g., subcutaneous,<br>
intramuscular, intradermal, intravenous) administration, although the most suitable<br>
form of administration in any given case will depend on the degree and severity of<br>
the condition being treated and on the nature of the particular compound being<br>
used.<br>
[095] Formulations suitable for oral administration may be presented in<br>
discrete units, such as capsules, cachets, lozenges, or tablets, each containing a<br>
predetermined amount of the compound as powder or granules; as a solution or a<br>
suspension in an aqueous or non-aqueous liquid; or as an oil-in-water or water-in-<br>
oil emulsion. As indicated, such formulations may be prepared by any suitable<br>
method of pharmacy which includes the step of bringing into association the active<br>
compound and the carrier or excipient (which may constitute one or more<br>
accessory ingredients). The carrier must be acceptable in the sense of being<br>
compatible with the other ingredients of the formulation and must not be<br>
deleterious to the recipient. The carrier may be a solid or a liquid, or both, and<br>
may be formulated with the compound as a unit-dose formulation, for example, a<br>
tablet, which may contain from 0.05% to 95% by weight of the active compound.<br>
Other pharmacologically active substances may also be present including other<br>
compounds. The formulations of the invention may be prepared by any of the well<br>
known techniques of pharmacy consisting essentially of admixing the<br>
components.<br>
-34-<br><br>
[096] For solid compositions, conventional nontoxic solid carriers include,<br>
for example, pharmaceutical grades of mannitol, lactose, starch, magnesium<br>
stearate, sodium saccharin, talc, cellulose, glucose, sucrose, magnesium<br>
carbonate, and the like. Liquid pharmacologically administrable compositions can,<br>
for example, be prepared by dissolving or dispersing, an active compound as<br>
described herein and optional pharmaceutical adjuvants in an excipient, such as,<br>
for example, water, saline, aqueous dextrose, glycerol, ethanol, and the like, to<br>
thereby form a solution or suspension. In general, suitable formulations may be<br>
prepared by uniformly and intimately admixing the active compound with a liquid<br>
or finely divided solid carrier, or both, and then, if necessary, shaping the product.<br>
For example, a tablet may be prepared by compressing or molding a powder or<br>
granules of the compound, optionally with one or more accessory ingredients.<br>
Compressed tablets may be prepared by compressing, in a suitable machine, the<br>
compound in a free-flowing form, such as a powder or granules optionally mixed<br>
with a binder, lubricant, inert diluent and/or surface active/dispersing agent(s).<br>
Molded tablets may be made by molding, in a suitable machine, the powdered<br>
compound moistened with an inert liquid diluent.<br>
[097] Formulations suitable for buccal (sub-lingual) administration<br>
include lozenges comprising a compound in a flavored base, usually sucrose and<br>
acacia ortragacanth, and pastilles comprising the compound in an inert base such<br>
as gelatin and glycerin or sucrose and acacia.<br>
[098] Formulations of the present invention suitable for parenteral<br>
administration comprise sterile aqueous preparations of the compounds, which<br>
are approximately isotonic with the blood of the intended recipient. These<br>
preparations are administered intravenously, although administration may also be<br>
effected by means of subcutaneous, intramuscular, or intradermal injection. Such<br>
preparations may conveniently be prepared by admixing the compound with water<br>
and rendering the resulting solution sterile and isotonic with the blood. Injectable<br>
compositions according to the invention may contain from 0.1 to 5% w/w of the<br>
active compound.<br>
[099] Formulations suitable for rectal administration are presented as<br>
unit-dose suppositories. These may be prepared by admixing the compound with<br>
-35-<br><br>
one or more conventional solid carriers, for example, cocoa butter, and then<br>
shaping the resulting mixture.<br>
[0100] Formulations suitable for topical application to the skin may take<br>
the form of an ointment, cream, lotion, paste, gel, spray, aerosol, or oil. Carriers<br>
and excipients which may be used include Vaseline, lanoline, polyethylene<br>
glycols, alcohols, and combinations of two or more thereof. The active compound<br>
is generally present at a concentration of from about 0.1% to about 15% w/w of<br>
the composition, for example, from about 0.5 to about 2%.<br>
[0101] The amount of active compound administered may be dependent<br>
on the subject being treated, the subject's weight, the manner of administration<br>
and the judgment of the prescribing physician.<br>
[0102] In another embodiment, intermittent administration, such as on a<br>
monthly or yearly basis, of a dose of the encapsulated compound may be<br>
employed. Encapsulation facilitates access to the site of action and allows the<br>
administration of the active ingredients simultaneously, in theory producing a<br>
synergistic effect. In accordance with standard dosing regimens, physicians will<br>
readily determine optimum dosages and will be able to readily modify<br>
administration to achieve such dosages.<br>
[0103] A therapeutically effective amount of a compound or composition<br>
disclosed herein can be measured by assessing the therapeutic effectiveness of<br>
the compound. Toxicity and therapeutic efficacy can be determined by standard<br>
pharmaceutical procedures in cell cultures or experimental animals, e.g., for<br>
determining the LD50 (the dose lethal to 50% of the population) and the ED50 (the<br>
dose therapeutically effective in 50% of the population). The dose ratio between<br>
toxic and therapeutic effects is the therapeutic index and it can be expressed as<br>
the ratio LD50/ED5o. Compositions that exhibit large therapeutic indices are<br>
preferable.<br>
[0104] The therapeutically effective dose can be estimated initially from<br>
cell culture assays. A dose may be formulated in animal models to achieve a<br>
circulating plasma concentration range that includes the IC50 (i.e., the<br>
concentration of the therapeutic which achieves a half-maximal inhibition of<br>
symptoms) as determined in cell culture assays or animal models. Levels in<br>
plasma may be measured, for example, by high performance liquid<br>
-36-<br><br>
chromatography. The effects of any particular dosage can be monitored by a<br>
suitable bioassay. Examples of dosages are: about 0.1 x|C50, about 0.5xlC50,<br>
about 1 xlC5o, about 5x|C5o, 10x|C5o, about 50x|C5o, and about 100x|C5o.<br>
[0105] Data obtained from the cell culture assays or animal studies can be<br>
used in formulating a range of dosage for use in humans. Therapeutically<br>
effective dosages achieved in one animal model may be converted for use in<br>
another animal, including humans, using conversion factors known in the art (e.g.,<br>
Freireich et al. (1966) Cancer Chemother Reports 50, 219-244) and Table 1 for<br>
Equivalent Surface Area Dosage Factors).<br>
Table 1<br><br>
\. To:	Mouse<br>
(20 g)	Rat<br>
(150 g)	Monkey<br>
(3.5 kg)	Dog<br>
(8 kg)	Human<br>
(60 kg)<br>
From: \	<br><br><br><br><br><br>
Mouse	1	1/2	YA	1/6	1/12<br>
Rat	2	1	y2	1/4	1/7<br>
Monkey	4	2	1	3/5	1/3<br>
Dog	6	4	3/5	1	1/2<br>
Human	12	7	3	2	1<br>
[0106] The dosage of such compounds lies preferably within a range of<br>
circulating concentrations that include the ED50 with little or no toxicity. The<br>
dosage may vary within this range depending upon the dosage form employed<br>
and the route of administration utilized. Generally, a therapeutically effective<br>
amount may vary with the subject's age, condition, and sex, as well as the<br>
severity of the medical condition in the subject. The dosage may be determined<br>
by a physician and adjusted, as necessary, to suit observed effects of the<br>
treatment.<br>
[0107] In one embodiment, a compound as disclosed herein, or a<br>
pharmaceutically acceptable salt or hydrate thereof, is administered in<br>
combination with another therapeutic agent. The other therapeutic agent can<br>
provide additive or synergistic value relative to the administration of a flavonoid<br>
compound alone. The therapeutic agent can be, for example, a statin, a PPAR<br>
-37-<br><br>
agonist (e.g., a thiazolidinedione orfibrate), a bile-acid-binding-resin, niacin, a<br>
RXR agonist, an anti-obesity drug, a hormone, a tyrophostine, a sulfonylurea-<br>
based drug, a biguanide, an alpha-glucosidase inhibitor, apolipoprotein E, a<br>
cardiovascular drug, an HDL-raising drug, an HDL enhancer, or a regulator of the<br>
apolipoprotein A-1V and/or apolipoprotein genes.<br>
[0108] One embodiment provides methods for treating, preventing or<br>
mitigating inflammatory conditions and related disease states, characterized by<br>
altered expression of markers of inflammation such as VCAM-1, MCP-1 and/or<br>
SMC proliferation, in a mammal. In one embodiment, the inflammatory conditions<br>
and related disease states are those where inhibition of VCAM-1, MCP-1 and/or<br>
SMC proliferation is desirable.<br>
[0109] Another embodiment provides methods for regulating markers of<br>
inflammation, including vascular inflammation, and their use in the treatment and<br>
prevention of inflammatory and cardiovascular diseases and related disease<br>
states in a mammal.<br>
[0110] In one embodiment, a method of treating, preventing or mitigating<br>
inflammatory conditions, such as cardiovascular or inflammatory disorders,<br>
comprises administering a therapeutically effective amount of a disclosed<br>
compound. The disclosed compound may be administered as a pharmaceutically<br>
acceptable composition, comprising a disclosed compound and a<br>
pharmaceutically acceptable carrier. In another embodiment, a compound of the<br>
present invention is administered as a pharmaceutically acceptable composition,<br>
pharmaceutically acceptable salt, or pharmaceutically acceptable formulation;<br>
optionally in a combination or alternation therapy with a therapeutic agent or at<br>
least one other compound of the present invention. In combination therapy,<br>
effective dosages of two or more agents are administered together, whereas<br>
during alternation therapy an effective dosage of each agent is administered<br>
serially.<br>
[0111] In another embodiment, a compound of the present invention is<br>
administered as a pharmaceutical formulation, or prodrug; optionally in a<br>
combination or alternation therapy with a therapeutic agent or at least one other<br>
compound of the present invention.<br>
-38-<br><br>
[0112] Embodiments of the present invention provide methods for treating,<br>
preventing or mitigating cardiovascular disorders mediated by VCAM-1, MCP-1,<br>
and/or SMC proliferation, comprising administering to a patient a therapeutically<br>
effective amount of a compound of the invention, or in another embodiment, a<br>
composition comprising a compound of the invention and a pharmaceutically<br>
acceptable carrier.<br>
[0113] "Cardiovascular disease" refers to diseases of the heart and<br>
circulatory system. Cardiovascular diseases that the compounds of the present<br>
invention are useful for preventing or treating include metabolic syndrome,<br>
arteriosclerosis, atherosclerosis, angina, stroke, ischemia, endothelial dysfunction<br>
(in particular those affecting blood vessel elasticity), peripheral vascular disease,<br>
coronary heart disease, myocardial infarction, cerebral infarction, obesity,<br>
reperfusion injury, angioplasty restenosis, hypertension, vascular complications of<br>
diabetes and thrombosis.<br>
[0114] In a preferred embodiment, a compound of the present invention is<br>
administered to a patient in a therapeutically effective amount for treating,<br>
preventing or mitigating a cardiovascular disease. In another embodiment, the<br>
compound of the present invention is administered as a pharmaceutically<br>
acceptable composition, pharmaceutically acceptable salt, or pharmaceutically<br>
acceptable formulation; optionally in a combination or alternation therapy with a<br>
therapeutic agent or at least one other compound of the present invention.<br>
[0115] In a preferred embodiment, a compound of the present invention is<br>
administered to a patient in a therapeutically effective amount for treating,<br>
preventing, or mitigating restenosis. In one embodiment, the restenosis is<br>
angioplasty restenosis. In another embodiment, the restenosis is post-angioplasty<br>
restenosis. In another embodiment, the compound of the present invention is<br>
administered as a pharmaceuticaliy acceptable formulation, or prodrug; optionally<br>
in a combination or alternation therapy with a therapeutic agent or at least one<br>
other compound of the present invention.<br>
[0116] Embodiments of the present invention provide methods for treating,<br>
preventing or mitigating inflammatory disorders mediated by VCAM-1 and/or<br>
MCP-1, comprising administering to a patient a therapeutically effective amount of<br>
-39-<br><br>
a compound of the invention, or in another embodiment, a composition comprising<br>
a compound of the invention and a pharmaceutically acceptable carrier.<br>
[0117] "Inflammatory disorders" includes diseases that are mediated by<br>
VCAM-1 and/or MCP-1. Inflammatory disorders that the compounds of the<br>
present invention are useful for preventing or treating include arthritis, asthma,<br>
dermatitis, psoriasis, cystic fibrosis, post transplantation late and chronic solid<br>
organ rejection, multiple sclerosis, systemic lupus erythematosus, inflammatory<br>
bowel diseases, autoimmune diabetes, diabetic retinopathy, diabetic nephropathy,<br>
diabetic vasculopathy, ocular inflammation, uveitis, rhinitis, ischemia-reperfusion<br>
injury, post-angioplasty restenosis, chronic obstructive pulmonary disease<br>
(COPD), glomerulonephritis, Graves disease, gastrointestinal allergies,<br>
conjunctivitis, atherosclerosis, coronary artery disease, angina, and small artery<br>
disease.<br>
[0118] In one embodiment, the inflammatory disorders that the<br>
compounds of the present invention are useful for preventing or treating comprise<br>
diseases, conditions and disorders mediated by VCAM-1, MCP-1, and/or SMC<br>
proliferation that are not disclosed in PCT/US2005/038048. For example,<br>
inflammatory disorders may not be ischemia-reperfusion injury, post-angioplasty<br>
restenosis, atherosclerosis, coronary artery disease, angina, and small artery<br>
disease.<br>
[0119] In a preferred embodiment, a compound of the present invention is<br>
administered to a patient in a therapeutically effective amount for inhibition of<br>
VCAM-1 expression. In another embodiment, the compound of the present<br>
invention is administered as a pharmaceutically acceptable composition, a<br>
pharmaceutically acceptable salt, or a pharmaceutically acceptable formulation;<br>
optionally in a combination or alternation therapy with a therapeutic agent or at<br>
least one compound of the present invention.<br>
[0120] In a preferred embodiment, a compound of the present invention is<br>
administered to a patient in a therapeutically effective amount for inhibition of<br>
MCP-1 expression. In another embodiment, the compound of the present<br>
invention is administered as a pharmaceutically acceptable composition, a<br>
pharmaceutically acceptable salt, or a pharmaceutically acceptable formulation;<br>
-40-<br><br>
optionally in a combination or alternation therapy with a therapeutic agent or at<br>
least one compound of the present invention.<br>
[0121] In a preferred embodiment, a compound of the present invention is<br>
administered to a patient in a therapeutically effective amount for inhibition of<br>
SMC proliferation. In another embodiment, the compound of the present invention<br>
is administered as a pharmaceutical acceptable composition, a pharmaceutically<br>
acceptable salt, or a pharmaceutically acceptable formulation; optionally in a<br>
combination or alternation therapy with a therapeutic agent or at least one<br>
compound of the present invention.<br>
[0122] In a preferred embodiment, a compound of the present invention is<br>
administered to a patient in a therapeutically effective amount for inhibition of<br>
MCP-1 and VCAM-1 expression. In another embodiment, the compound of the<br>
present invention is administered as a pharmaceutically acceptable composition, a<br>
pharmaceutically acceptable salt, or a pharmaceutically acceptable formulation;<br>
optionally in a combination or alternation therapy with a therapeutic agent or at<br>
least one compound of the present invention.<br>
[0123] In another aspect, the present invention provides for the use of the<br>
compounds of the present invention for the manufacture of a medicament for<br>
treating, preventing or mitigating diseases or disorders mediated by SMC<br>
proliferation wherein such compositions comprise an effective SMC proliferation-<br>
inhibiting amount of a compound of the present invention or a pharmaceutically<br>
acceptable salt thereof and/or a pharmaceutically acceptable composition.<br>
[0124] In another aspect, the present invention provides a method for<br>
treating, preventing or mitigating a disease or disorder mediated by SMC<br>
proliferation comprising administering to a patient an effective SMC proliferation-<br>
inhibiting amount of a compound of the present invention or a pharmaceutically<br>
acceptable salt thereof and/or a pharmaceutically acceptable composition.<br>
[0125] Embodiments of the present invention include the use of the<br>
disclosed compounds for the manufacture of a medicament for treating,<br>
preventing or mitigating inflammatory conditions.<br>
[0126] Embodiments of the present invention include the use of the<br>
disclosed compounds for the manufacture of a medicament for treating,<br>
preventing or mitigating diseases or disorders mediated by VCAM-1 expression.<br>
-41 -<br><br>
[0127] Embodiments of the present invention include the use of the<br>
disclosed compounds for the manufacture of a medicament for treating,<br>
preventing or mitigating diseases or disorders mediated by MCP-1 expression.<br>
[0128] Embodiments of the present invention include the use of the<br>
disclosed compounds for the manufacture of a medicament for treating,<br>
preventing or mitigating diseases or disorders mediated by smooth muscle cell<br>
proliferation.<br>
Stents<br>
[0129] Given the correlation between physical injury to the vasculature<br>
and restenosis, for example that arising after angioplasty, it is explicitly<br>
contemplated that the compounds of the present invention are capable of being<br>
used before, contemporaneously with, or subsequent to angioplasty or other<br>
medical treatment expected to give rise to a vascular injury, localized vascular<br>
inflammatory response or vascular injury response.<br>
[0130] In a preferred embodiment, a compound of the present invention<br>
is administered through the use of an intraluminal stent. In another embodiment,<br>
the compound of the present invention is administered as a pharmaceutically<br>
acceptable formulation, prodrug, as a pharmaceutically acceptable salt or in a<br>
combination or alternation therapy with a therapeutic agent or at least one<br>
compound of the present invention.<br>
[0131] Compounds of the present invention may be eluted through a stent<br>
or alternatively may be coated on the stent allowing for controlled release to the<br>
local environment, as taught by US Pat. Nos. 5,837,008, 5,824,048, 5,679,400,<br>
5,464,650, 6,908,624, 6,890,583, and 6,790,228.<br>
[0132] In another aspect, compounds of the present invention may be<br>
administered in a therapeutically effective amount for treatment of small vessel<br>
disease not otherwise treatable by surgery or angioplasty or other vascular<br>
disease in which surgery is not a preferred option. In a preferred embodiment a<br>
compound of the present invention is administered in a therapeutically effective<br>
amount systemically or local to the locus of the small vessel disease. In another<br>
embodiment, the compound of the present invention is administered as a<br>
pharmaceutically acceptable formulation, prodrug, pharmaceutically acceptable<br>
- 42 -<br><br>
salt or in a combination or alternation therapy with a therapeutic agent or at least<br>
one compound of the present invention.<br>
[0133] In a further aspect, compounds of the present invention can be<br>
administered in a therapeutically effective amount prior to revascularization<br>
therapy. In a preferred embodiment, a compound of the present invention is<br>
administered in a therapeutically effective amount systemically or local to the site<br>
of revascularization. In another embodiment, a compound of the present<br>
invention is administered as a pharmaceutically acceptable formulation, prodrug,<br>
pharmaceutical acceptable salt or in a combination or alternation therapy with a<br>
therapeutic agent or at least one compound of the present invention.<br>
Treatment or Prevention of Other Related Diseases<br>
[0134] In a preferred embodiment,-a compound of the present invention is<br>
administered as a preventative measure to a patient having a non-genetic<br>
predisposition to a disease including a cardiovascular disease or an inflammatory<br>
disorder. Examples of such non-genetic predispositions include cardiac bypass<br>
surgery and PTCA (which can lead to restenosis), an accelerated form of<br>
atherosclerosis, diabetes in women, (which can lead to polycystic ovarian<br>
disease), and cardiovascular disease (which can lead to impotence). Accordingly,<br>
compositions of the invention may be used for the prevention of one disease or<br>
disorder and concurrently treating another (e.g., prevention of polycystic ovarian<br>
disease while treating diabetes; prevention of impotence while treating a<br>
cardiovascular disease).<br>
PREPARATION OF COMPOUNDS<br>
[0135] The following examples demonstrate methods to synthesize<br>
compounds of the invention wherein each W is independently a nitrogen or<br>
carbon, and an R-group may be independently selected,from the aforementioned<br>
group of substituents. The chosen synthetic method may involve use of protecting<br>
groups, which can be selected from those known in the art (e.g., Protective<br>
Groups in Organic Synthesis, By TW Greene &amp; PGM Wuts John Wiley &amp; Sons,<br>
New York, 1991, 2nd ed). Compounds synthesized in the manner described<br>
below may additionally be modified by functional group manipulations (e.g.,<br>
Organic Synthesis by MB Smith, McGraw-Hill, New York, 1994, Int. Ed. Chapter<br>
2), including reduction, oxidation, alkylation, and acylation.<br>
-43-<br><br>
[0136] Flavonoid compounds may be represented by the general structure<br>
of Formula A.<br><br>
[0137] Ra may be selected from groups including alkoxy, aryloxy, alkyl,<br>
alkenyl, alkynyl, amide, amino, aryl, arylalkyl, carbamate, carboxy, cyano,<br>
cycloalkyl, ester, ether, formyl, halogen, haloalkyl, heteroaryl, heterocyclyl,<br>
hydrogen, hydroxyl, ketone, nitro, phosphate, sulfide, sulfinyl, sulfonyl, sulfonic<br>
acid, sulfonamide and thioketone. Rbmay be selected from groups including alkyl,<br>
amino, cyano, halogen and hydrogen. Rc represents substituents such as alkyl,<br>
alkoxy, halogen, hydroxyl and hydrogen.<br>
[0138] One of ordinary skill will appreciate that flavonoid compounds as<br>
disclosed herein may be synthesized from readily available starting materials as<br>
outlined below.<br>
[0139] Formula B represents a general formula for flavonoid compounds<br>
comprising a phenyl-chromene:<br><br>
[0140] Flavonoids of Formula B can be synthesized by the procedure of<br>
Scheme 1:<br>
-44-<br><br><br>
[0141] Acid chloride 2 (Rd = CI) may be used directly in a reaction with<br>
acetophenone 1 to provide ester 3. The acid chloride may also be generated in<br>
situ by exposing the carboxylic acid 2 (Rd = OH) to a chlorinating agent such as<br>
POCI3. Ester 3 can be converted into diketone 4 via intramolecular<br>
rearrangement. Rearrangement may be achieved using a catalytic amount of<br>
base, such as potassium t-butoxide, KOH, NaH and the like. Cyclization of phenol<br>
4 to flavonoid 5 can be achieved by heating phenol 4 in the presence of a strong<br>
protic (HCI, AcOH, HI, AcOH, HBr, and mixtures thereof) or Lewis (BBr3) acid.<br>
[0142] Flavonoid compounds can be synthesized following the procedure<br>
of Scheme 2:<br>
-45-<br><br><br>
Scheme 2<br>
[0143] Diketone 10 may be prepared by first exposing methyl ketones 6 or<br>
9 to basic conditions, such as potassium t-butoxide, KOH, NaH and the like, to<br>
form the corresponding enolate. Then, reaction with acyl halide 8 or 7 (X = Hal),<br>
respectively, affords diketone 10. Cyclization of diketone 10 to flavonoid 5 may<br>
likewise be accomplished by a number of methods. When Re= F, exposure of 10<br>
to heat and a polar solvent results in ring closure via nucleophilic aromatic<br>
substitution. Alternatively, strong protic or Lewis acids may be used when Re =<br>
alkoxy, SH, or NH2. Suitable acids include HCI, AcOH, HI, AcOH, HBr, BBr3, and<br>
mixtures thereof.<br>
-46-<br>
[0144] Formula C represents flavonoid compounds comprising a naphthyl;<br><br><br>
[0145] Flavonoids of Formula C can be prepared via the procedure of<br>
Scheme 3.<br><br>
[0146] Arylation of naphthalene analog 11 with boronic acid (or boronic<br>
ester) 12 occurs by a Pd-catalyzed Suzuki coupling. Suitable Pd catalysts include<br>
Pd(Ph3)4 along with non-phosphine Pd catalysts, such palladium acetate. Other<br>
coupling procedures that may be used in the synthesis of flavonoid 13 include<br>
Stille coupling.<br>
[0147] Prodrugs of flavonoid compounds can be prepared according to<br>
Scheme 4:<br><br>
[0148] Prodrug esters 19 can be synthesized by treating phenol 16 with<br>
acid halide 17. Suitable acid halides include acid chlorides and bromides.<br>
Alternatively, esterification of phenol 16 with acid 18 in the presence of a<br>
carbodiimide, such as EDCI, affords ester 19.<br>
[0149] The following compounds were obtained from commercially<br>
available sources: probucol (Sigma catalogue number P9672), resveratrol (Sigma,<br>
catalogue number R5010); taxol (USB catalogue number 10119; and rapamycin<br>
-47-<br><br>
(Calbiochem catalogue number 553210). AGI1067 was prepared according to<br>
known methods (Meng. et al., J. Med. Chem. 2004, 47, 6420-6432).<br>
[0150] Abbreviations used herein denote the following compounds,<br>
reagents and substituents: acetic acid (AcOH); 2,2'-azobisisobutyronitrile (AIBN);<br>
A/-bromosuccinimide (NBS); N-tert-butoxycarbonyl (Boc); t-butyldimethylsilyl<br>
(TBDMS); m-chloroperoxybenzoic acid (mCPBA); dimethylaminopyridine (DMAP);<br>
dichloromethane (DCM); dimethylformamide (DMF); dimethylsulfoxide (DMSO);<br>
ethanol (EtOH); ethyl acetate (EtOAc); 1-ethyl-3-(3-<br>
dimethylaminopropyl)carbodiimide (EDCI); 1-hydroxybenzotriazole (HOBt);<br>
iodomethane (Mel); lithium hexamethyldisilazide (LHMDS); methanol (MeOH);<br>
methoxymethyl (MOM); tetrahydrofuran (THF).<br>
EXAMPLES<br>
Example 1: 2-(4-Hydroxy-pheny!)-pyrano[2,3-b]pyridin-4-one<br><br>
[0151] In a 500 ml_ dry round bottom flask with reflux condenser and<br>
magnetic stirrer was placed with 2-chloro-3-ethyl nicotinate (40.0 g, 215.5 mmol)<br>
in methanol (200 mL). CH3ONa in methanol (25%, 65 ml_, 301.7 mmol) was<br>
added slowly and the reaction mixture was refluxed for 16 hours. The reaction<br>
was cooled to room temperature, quenched by addition of a saturated aqueous<br>
NH4CI solution. The aqueous mixture was extracted with ethyl acetate. The<br>
combined organic layers were washed well with water, brine, dried over Na2S04<br>
and concentrated to give 35 g of 2-methoxy-3-methyl nicotinate with 97% yield.<br>
Sodium hydride (60% in oil, 9.21 g, 230.3 mmol) was added to a dry 500 mL<br>
round bottom flask followed by 100 mL DMF. 4-Methoxyacetophenone (31.45 g,<br>
209.44 mmol) in 50 mL dry DMF was added drop-wise at 0C over 30 min. The<br>
reaction mixture was stirred for 1 h at room temperature. 2-Methoxynicotinic acid<br>
methyl ester (35 g, 209.44 mmol) was dissolved in 50 mL dry DMF and added<br>
-48-<br><br>
slowly, keeping the temperature at 0C. The mixture was stirred for 16 h at room<br>
temperature, then quenched by addition of a saturated aqueous NH4CI solution<br>
and diluted with water. The solid was filtered off, washed with water and dried to<br>
give 56.7 g diketo product in 95% yield.<br>
[0152] The diketo compound (56.7 g, 198.9 mmol) was added to a 1 L<br>
round bottom flask together with pyridinium hydrochloride (345 g). The mixture<br>
was heated at 190C for 5 hours. The reaction mixture was cooled to room<br>
temperature and diluted with water. The solid was isolated by filtration and purified<br>
by column chromatography using 5% methanol in CH2CI2 to give 2-(4-hydroxy-<br>
phenyl)-pyrano[2,3-b]pyridin-4-one (23.25 g, 48.8% yield). MS (ES) m/z: 240.07<br>
(M+1); 13C-NMR (DMSO-de): 5 178.2,164.2,161.8,160.8,153.9,136.3,129.2,<br>
123.2, 121.8,116.8,116.75, 116.74,105.7.<br>
Example 2: 2-(4-Hydroxy~phenyl)-pyrano[3,2-b]pyridin-4-one<br><br>
[0153] An example compound, (2-(4-hydroxy-phenyl)-pyrano[3,2-<br>
b]pyridin-4-one) was synthesized in the following way.<br>
-49-<br><br><br>
[0154] In a 500 ml_ round-bottomed flask fitted with a condenser-and a<br>
magnetic stirrer were placed MeOH (250 ml_), 3-hydroxypyridine-2-carboxylic acid<br>
1 (10.0 g, 72 mmol) and concentrated H2SO4 (3 ml_). The reaction mix was<br>
heated to 64C for 24 hours. The reaction mix was cooled to room temperature.<br>
The solvent was removed under reduced pressure; the residue was partitioned<br>
between ethyl acetate (150 ml_) and water (20 ml_). Solid sodium carbonate was<br>
added to adjust the pH to 6. The organic layer was separated, dried over Na2S04,<br>
and concentrated to give crude 3.5 g of intermediate 2 (32% yield).<br>
[0155] In a 50 ml_ round-bottomed flask fitted with a magnetic stirrer were<br>
placed intermediate 2 (3.5 g, 22.8 mmol), potassium carbonate (3.46 g,<br>
25.0 mmol), methyl iodide (4.87 g, 34.3 mmol) and DMF (20 ml_). The reaction<br>
mix was stirred for 18 h at room temperature under nitrogen. The reaction mix was<br>
diluted with ethyl acetate (30 mL) and water (10 ml_). The organic layer was<br>
separated and aqueous layer was extracted with ethyl acetate. The combined<br>
organic extracts were dried over Na2S04 and concentrated to give crude product,<br>
which was then purified by column chromatography using 30% ethyl acetate in<br>
hexane, to give 2.1 g of intermediate 3 (54% yield).<br>
[0156] In 100 mL round-bottomed flask fitted with a magnetic stirrer were<br>
placed NaH (1.62 g of 60% suspension in mineral oil, 40 mmol) and a solution of<br>
intermediate 3 (3.5 g, 20 mmol) in anhydrous DMF (20 mL). The mixture was<br>
stirred for 15 min at room temperature under nitrogen. Then, a solution of<br>
4-methoxyacetophenone (3.3 g, 22 mmol) was added via syringe. The reaction<br>
-50-<br><br>
mix was stirred for overnight at room temperature. Then, a 10% aqueous solution<br>
of NaH2S04 was used to adjust the pH to 7. The organic layer was separated and<br>
the aqueous layer was extracted with ethyl acetate. The combined organic<br>
extracts were dried over Na2S04 and concentrated to give crude product, which<br>
was purified by column chromatography using 30% ethyl acetate in hexane, to<br>
give 4.68 g of intermediate 4 (80% yield).<br>
[0157] In a 50 ml_ round-bottomed flask fitted with a magnetic stirrer were<br>
placed intermediate 4 (4.68 g, 16 mmol) and 45% HBr (25 mL). The reaction mix<br>
was refluxed for 3 h, then cooled to room temperature. Solid NaHC03 was used to<br>
adjust the pH to 7. Ethyl acetate (30 mL) was then added. The organic layer was<br>
separated and aqueous layer was extracted with ethyl acetate (2x30 mL). The<br>
combined organic extracts were dried over Na2S04 and concentrated to give<br>
crude product, which was purified by column chromatography using 30%<br>
methanol in ethyl acetate to give 125 mg of 2-(4-hydroxy-phenyl)-pyrano[3,2-<br>
b]pyridin-4-one (3.2% yield); MS (ES) m/z: 240.09 (M+1), and 149.06.<br>
Example 3: 2-(4-Hydroxyphenyl)-pyrano[2,3-c]pyridin-4-one<br><br>
[0158] A 50 mL flask was charged with 5.0 g (0.0354 mol) 3-<br>
fluoroisonicotinic acid and thionyl chloride (3.88 mL, 0.053 mol). The mixture was<br>
heated to reflux for 1 h, then the excess thionyl chloride was evaporated under<br>
vacuum. "Anhydrous methanol was added to the residue and the mixture was<br>
heated to reflux for one hour. The reaction mixture was poured into sodium<br>
bicarbonate solution and pH was adjusted to 7.0. The mixture was extracted with<br>
EtOAc and the organic layer was dry over sodium sulfate. The organic solvent<br>
was evaporated yielding the product (4.80 g, 88%). A 50 mL dry flask was<br>
charged with methyl 3-fluoroisonicotinitate (3.50 g, 0.0227 mol), 4-<br>
-51-<br><br>
methoxyacetophenone (3.60 g, 0.024 mol) and 10 mL dry DMF under nitrogen.<br>
Sodium hydride (1.82 g, 60% in oil) was added and the reaction was stirred for 30<br>
min, then poured into ammonium chloride solution and extracted with EtOAc and<br>
dried over sodium sulfate. The solution was concentrated and the residue was<br>
pass through a column (EtOAc:hexane 1:3) to give the product (3.50 g, 54.0%). A<br>
50 mL flask was charged with this product (0.5 g, 1.75 mmol) and pyridine<br>
hydrogen chloride (2.02 g, 17.5 mmol) and heat to 190C for 4 hours. The mixture<br>
was poured into a sodium bicarbonate solution and the solid was collected by<br>
filtration, washed with EtOAc and methanol to give 2-(4-hydroxyphenyl)-<br>
pyrano[2,3-c]pyridin-4-one as a yellow product (0.36 g, 86%). MS (ES) m/z:<br>
240.90 (M+1), 239.89 (M); MP 294-296C.<br>
Example 4: 2-(3-Fluoro-4-hydroxyphenyl)pyrano[2,3-b]pyridine-4-one<br><br>
[0159] Methyl 2-methoxynicotinate was synthesized from ethyl 2-<br>
chloronicotinate with sodium methoxide as in Example 1. A 50 mL flask was<br>
charged with methyl 2-methoxynicotinate (2.50 g, 0.015 mol), 10 mL dry DMF and<br>
60% NaH (0.745 g, 0.0186 mol) with magnetic stirring. 3'-FIuoro-4'-<br>
methoxyacetophenone (2.60 g, 0.0155 mol) in 6 mL anhydrous DMF was added<br>
over 5-10 min. After addition, the reaction mixture was stirred for 30 min. The<br>
mixture was poured into 50 mL NH4CI solution, the yellow solid was filtered and<br>
further washed with water and purified by column chromatography (hexane:EtOAc<br>
4:1) to get (3.0 g, 66.4%) of product. A 50 mL flask was charged with this product<br>
(0.8 g, 2.64 mmol) and pyridine hydrogen chloride (3.04 g, 26.4 mmol) and heated<br>
to 190C for 4 hours. The mixture was poured into sodium bicarbonate solution<br>
and the solid was collected by filtration, washed with EtOAc and MeOH and<br>
passed through a column (methanohdichloromethane 1:4) to afford 400 mg of 2-<br>
-52-<br><br>
(3~fluoro-4-hydroxyphenyl)pyrano[2,3-b]pyridine-4-one (59%). MS (ES) m/z:<br>
257.85 (M); MP 267-268C.<br>
Example 5: 2-(4-Hydroxy-3-methylphenyl)-4H-pyrano[2,3-b]pyridine-4-one<br><br>
[0160] Methyl 2-methoxynicotinate was synthesized from ethyl 2-<br>
chloronicotinate with sodium methoxide as'described in Example 1. A 100 mL dry<br>
flask was charged with 2-methylanisole (7.92 g, 65 mmol), acetyl chloride (5.1 mL,<br>
71 mmol), aluminum chloride (9.45 g, 71 mmol) and 40 mL of anhydrous<br>
dichloromethane. The reaction mixture was kept at reflux for 2 h, then poured into<br>
15 mL of HCI (3 N) and extracted with 100 mL ether. The organic layer was<br>
further washed with sodium bicarbonate to pH 6-7, then further washed with brine<br>
and dried over sodium sulfate. The solvent was evaporated and the residue was<br>
dried under high vacuum to yield the intermediate (10.0 g, 93.85%). A 100 mL dry<br>
flask was charged with methyl 2-methoxynicotinate (2.50 g, 15 mmol), 10 mL<br>
anhydrous DMF and NaH (0.9 g, 22.5 mmol, 60% in oil). The intermediate (2.58 g,<br>
15.7 mmol) in 3 mL anhydrous DMF was added and the reaction was stirred for 2<br>
hours. The mixture was poured into 120 mL of water with 3 mL AcOH. The yellow<br>
solid was further wash with water and passed through a column (hexane:EtOAc<br>
3:1) to give the methoxy intermediate (3.4 g, 75.7%). A 50 mL flask was charged<br>
with the methoxy intermediate (1.0 g, 3.3 mmol) and pyridine hydrogen chloride<br>
(4.0 g, 33 mmol) and heated to 190C for 3 hours. The mixture was poured into a<br>
sodium bicarbonate solution and the solid was collected by filtration, washed with<br>
EtOAc and MeOH (20 mL each) to give 2-(4-hydroxy-3-methylphenyl)-4H-<br>
pyrano[2,3-b]pyridine-4-one (0.58 g, 69.4%). MS (ES) m/z: 254.0 (M+1); MP 300-<br>
302C.<br>
-53-<br><br>
Example 6: 2-(4-Hydroxyphenyl)-4H-pyrano[3,2-c]pyridin-4-one<br><br>
[0161] A solution of 4-chloropicolinic acid (3.0 g, 19.04 mmol) in EtOH<br>
(100 ml_) was mixed with H2S04 (cone, 5 mL) and was stirred at reflux for 48<br>
hours. The reaction mixture was cooled to room temperature and neutralized with<br>
NaOH (1 N) to adjust pH = 8-9. The mixture was extract with dichloromethane<br>
(3&gt;
[0162] To a solution of ethyl 4-ethoxypicolinate (3.44 g, 17.43 mmol) and<br>
4-methoxy acetophenone (2.62 g, 17.43 mmol) in THF (100 mL) and DMSO (50<br>
mL) was added NaH (1.4 g, 34.80 mmol). The resulting mixture was stirred at<br>
95C for 6 hours. The reaction mixture was cooled to room temperature and<br>
quenched with water (100 mL). The mixture was extract with EtOAc (3x150 mL)<br>
and concentration to a yellow solid. The solid was washed with hexanes to afford<br>
the diketone (3.6 g, 69%).<br>
[0163] The diketone (1 g, 3.34 mmol) was mixed with pyridine<br>
hydrochloride (10 g). This mixture was stirred at 190C under nitrogen for 12<br>
hours. The mixture was then diluted with EtOAc (30 mL) and poured into a beaker<br>
of 200 mL ice water. NaOH (1 N) was used to adjust the pH to 9. The solid was<br>
then filtered off and washed with water, hexanes, dichloromethane, EtOAc<br>
sequentially to afford the brownish solid 2-(4-hydroxyphenyl)-4H-pyrano[3,2-<br>
c]pyridin-4-one (0.39 g, 49%). MS (ES) m/z: 240.92 (M+1), 239.89 (M); MP 306-<br>
308C.<br>
Example 7: 2-(3-Chloro-4-hydroxyphenyl)-4H-pyrano[2,3-b]pyridine-4-one<br>
-54-<br><br><br>
[0164] Sodium methoxide (18 ml_, 25 wt% in methanol) was added slowly<br>
to a solution of ethyl-2-chloronicotinate (11.134 g 60 mmol) in 60 mL anhydrous<br>
methanol. The reaction mixture was stirred under reflux for 15 h, then cooled to<br>
room temperature. Methanol was removed in vacuo. The residue was dissolved in<br>
EtOAc (200 mL) and saturated aqueous ammonium chloride (50 mL) was added.<br>
The organic layer was separated and dried over anhydrous Na2S04. The solvent<br>
was removed to give ethyI-2-methoxynicqtinate (8.58 g, 79%). Sodium hydride<br>
(60% in mineral oil, 0.48 g, 12 mmol) was dissolved in anhydrous DMF (10 mL).<br>
A solution of 3'-chloro-4'-methoxy acetophenone (1.85 g, 10 mmol) in anhydrous<br>
DMF (5 mL) was added drop-wise at 0C under nitrogen. The mixture was stirred<br>
at 0C for 5 min. and then at room temperature for 30 min. The mixture was<br>
cooled to 0C. A solution of ethyl 2-methoxy nicotinate (1.81 g, 10 mmol) in<br>
anhydrous DMF (5 mL) was added slowly. The ice bath was removed and the<br>
mixture was stirring at room temperature under nitrogen for 20 hours. Water (20<br>
mL) was added and the mixture was extracted with EtOAc (2x100 mL). The<br>
combined organic layers were washed with brine and dried over anhydrous<br>
Na2S04. Removal of solvent gave a dark colored solid. Triturating with ether gave<br>
a yellow solid (1.64 g, 51 %). The yellow solid (1.36 g, 4.21 mmol) and pyridinium<br>
hydrochloride (7.3 g, 63.2 mmol) were mixed together and stirred at 190C for 2 h,<br>
then cooled to room temperature. Water (100 mL) was added. The solid was<br>
separated by filtration, washed with water and dried under vacuum. The crude<br>
compound was purified by column chromatography (Silica Gel 230-400 mesh; 5%<br>
methanol in dichloromethane as an eluentto afford 2-(3-chloro-4-hydroxyphenyl)-<br>
4H-pyrano[2,3-b]pyridine-4-one (0.385 g, 33% yield) as yellow solid. MS (ES)<br>
m/z: 275.94 + 273.92 (two isotopes of M); MP 259-262C.<br>
Example 8: 2-(4-Hydroxy-3-methoxyphenyl)-4H-pyrano[2,3-b]pyridine-4-one<br>
-55-<br><br><br>
[0165] A solution of ethyl 2-chloronicotinitate (6.0 g, 0.0323 mol) in<br>
anhydrous methanol (10 mL) at room temperature was added sodium methoxide<br>
(10 mL, 25% in methanol). The reaction mixture was stirred for half hour then<br>
heated to reflux for one hour. The mixture was poured into water and extracted<br>
with ethyl acetate and the organic layer was washed with water until neutral, dried<br>
over sodium sulfate, and concentrated to give methyl 2-methoxynicotinitate (5.2 g,<br>
96.3%).<br>
[0166] A 100 mL dry flask was charged with acetovanillone (4.16 g, 0.025<br>
mol) and anhydrous DMF (10 mL). Sodium hydride (1.05 g, 0.0263 mol, 60% in<br>
mineral oil) was added and the reaction mixture was stirred at room temperature<br>
followed by the dropwise addition of benzyl bromide (3.1 mL, 0.0263 mol). The<br>
reaction was carried out at room temperature for 2 h, then poured into water. Ethyl<br>
acetate (150 mL) was used to extract out the compound and the organic layer was<br>
washed with water (2x100 mL), brine, dried over sodium sulfate, and<br>
concentrated to give the benzyl intermediate (6.21 g, 96%), which was<br>
subsequently used without further purification.<br>
[0167] A 100 mL dry flask was charged with methyl 2-methoxynicotinitate<br>
(2.2 g, 0.0131 mol), the benzyl intermediate (3.37 g, 0.0131 mol) and anhydrous<br>
DMF (10 mL). Sodium hydride (0.524 g, 0.0131 mol, 60% in mineral oil) was<br>
added and the reaction mixture was stirred for 2 hours at room temperature. The<br>
reaction mixture was poured into water and extracted with ethyl acetate (150 mL).<br>
The organic layer was washed with water (2*100 mL), brine (100 mL), dried over<br>
sodium sulfate, and concentrated to give the intermediate (5.0 g, 97.6%). This<br>
intermediate (4.0 g, 0.0102 mol) and pyridine hydrochloride (12.0 g, 0.102 mol)<br>
were mixed and heated to 170-190C for 20 min. The reaction mixture was cooled<br>
and poured into water (100 mL). The mixture was extracted with ethyl acetate<br>
(3x200 mL), and the combined organic layers were washed with brine (x3x100<br>
mL), dried over sodium sulfate, and concentrated. The solid was further purified<br>
-56-<br><br>
by refluxing with methanol (40 mL). The solution was cooled and filtered to yield 2-<br>
(4-hydroxy-3-methoxyphenyl)-4H-pyrano[2,3-b]pyridine-4-one (250 mg, 9.1%).<br>
MS (ES) m/r. 270.92, 269.91; MP 253-255C.<br>
Example 9: 2-(4-Methoxyphenyl)-4H-pyrano[2,3-b]pyridine-4-one<br><br>
[0168] In a 500 mL dry round bottom flask with reflux condenser and<br>
magnetic stirrer was placed with 2-chloro-3-ethyI nicotinate (40.0 g, 215.5 mmol)<br>
in methanol (200 mL), and sodium methoxide (65 mL, 301.7 mmol, 25% in<br>
methanol) was added slowly and the reaction mixture was refluxed for 16 hours.<br>
The reaction mixture was cooled to room temperature and the reaction was<br>
quenched by addition of saturated aqueous NH4CI solution, followed by extraction<br>
with ethyl acetate. The combined organic layers were washed well with water,<br>
brine, dried over Na2SO4 and concentrated to give 2-methoxy-3-methyl nicotinate<br>
(35 g, 97%). To a dry 500 mL round bottom flask was added NaH (9.21 g 230.3<br>
mmol, 60% in mineral oil) in DMF (100 mL). 4-Methoxyacetophenone (31.45 g,<br>
209.44 mmol) in dry DMF (50 mL) was added dropwise at 0C over 30 min. The<br>
reaction mixture was stirred for 1 h at room temperature. Then 2-methoxynicotinic<br>
acid methyl ester (35 g, 209.44 mmol) dissolved in dry DMF (50 mL) was added<br>
slowly on cooling. The mixture was stirred for 16 h at room temperature. The<br>
reaction was quenched by addition of saturated NH4CI solution and diluted with<br>
water. The solid was filtered off, washed with water and dried to give the diketo<br>
product (56.7 g, 95 %). Polyphosphoric acid (8.0 g) was heated at 90C and the<br>
diketo compound (1.0 g, 3.50 mmol) was added slowly and heated at 90C for 1<br>
hour. The reaction mixture was cooled to room temperature and diluted with<br>
water. The solid was isolated by filtration, washed with water and dried to give 2-<br>
(4-methoxyphenyl)-4H-pyrano[2,3-b]pyridine-4-one (570 mg, 64%). MS (ES) m/r.<br>
254.89 (M+1), 253.90 (M); MP 269-270C.<br>
-57-<br><br>
Example 10: 2-(4-(2-Hydroxyethoxy)phenyl)-4H-pyrano[2,3-b]pyridine-4-one<br><br>
[0169] In a 100 mL dry round bottom flask with reflux condenser and<br>
magnetic stirrer was placed 2-(4-hydroxy-phenyl)-pyrano[2,3-b]pyridin-4-one<br>
(1.0 g, 4.18 mmol) in EtOH (10 mL) and acetonitrile (50 mL). 2-Chloroethanol<br>
(2.05 g, 25.0 mmol) was added slowly and trie reaction mixture was refluxed for<br>
48 hours. The reaction mixture was cooled to room temperature and concentrated<br>
under reduced pressure. The crude product was purified by column<br>
chromatography, using 2% MeOH in dichloromethane to afford 2-(4-(2-<br>
hydroxyethoxy)phenyl)-4H-pyrano[2,3-b]pyridine-4-one (380 mg, 32% yield). MS<br>
(ES) m/z: 284.94 (M+1), 283.95 (M); MP 157-159C.<br>
Example 11: 2-(5-Hydroxy-pyridin-2-yl)-chromen-4-one<br><br>
[0170] An example compound, 2-(5-hydroxy-pyridin-2-yl)-chromen-4-one<br>
was synthesized in the following way. In a 100 mL round-bottomed flask fitted<br>
with a condenser and a magnetic stirrer were placed 5-amino-2-cyano pyridine<br>
(1.0 g, 8.4 mmol), concentrated H2SO4 (4.2 mL), water (15 mL) and the mixture<br>
was cooled to 0C. A solution of NaN02 (636 mg, 9.22 mmol) in water (5.7 mL)<br>
was added slowly at 0C. Then, the reaction mix was stirred for 30 min. at 0C.<br>
The reaction mix was poured into a boiling mixture of water (11 mL) and H2SO4<br>
-58-<br><br>
(1 mL) and stirred for 30 min. The mixture was cooled and extracted with ethyl<br>
acetate. The organic layer was washed with water, dried and concentrated to give<br>
2 cyano-5-hydroxy pyridine (900 mg, 89%).<br>
[0171] To a mixture of 2-cyano-5-hydroxy pyridine (200 mg, 1.66 mmol),<br>
DMF (10 mL) and K2C03(253 mg, 1.83 mmol), was added Mel (354 mg,<br>
2.49 mmol) at room temperature and the reaction mix was stirred for 24 h at room<br>
temperature. The reaction mix was poured into water and extracted with ethyl<br>
acetate. The organic layer was separated, washed with water, dried and<br>
concentrated to give 2-cyano-5-methoxy pyridine (175 mg, 78% yield).<br>
[0172] The 2-cyano-5-methoxy pyridine (170 mg, 1.26 mmol) was taken<br>
into 6N HCl (4 mL) and refluxed for 16 hours. The reaction mix was cooled to<br>
room temperature and diluted with water, neutralized, and extracted with ethyl<br>
acetate. The organic layer was washed with water, then brine, and was dried and<br>
concentrated to give crude 5-methoxy-2-nicotinic acid (290 mg).<br>
[0173] In a 100 mL round-bottomed flask fitted with a condenser and a<br>
magnetic stirrer were placed 2'-hydroxy acetophenone (3.56 g, 26.1 mmol),<br>
5-methoxy-2-nicotinic acid (4.0 g, 26.1 mmol) and pyridine (50 mL). POCI3 (4 g,<br>
26.1 mmol) was added slowly with cooling. Then, the reaction mix was stirred for<br>
24 h at room temperature under nitrogen. The reaction mix was poured into ice-<br>
water and was extracted with ethyl acetate. The organic layer was washed with<br>
water, dried, and concentrated to give product (1.76 g, 24% yield). To a solution<br>
of this product (1.76 g, 6.5 mmol) in THF (30 mL), was added potassium<br>
t-butoxide (952 mg, 7.8 mmol) and the reaction mix was stirred for 24 h at room<br>
temperature under nitrogen. The reaction mix was poured into a saturated<br>
solution of NH4CI. The organic layer was separated, washed with water, dried and<br>
concentrated to give crude product, which was purified by using column<br>
chromatography using 50% ethyl acetate in hexane to give the diketone (870 mg,<br>
49% yield). The diketone compound (870 mg, 3.2 mmol) was taken into a mixture<br>
of 48% HCl (1 mL) and acetic acid (10 mL) and heated at 100C for 1 hours. The<br>
reaction mix was cooled to room temperature, diluted with water, and extracted<br>
with ethyl acetate. The organic layer was washed with water, then brine, and was<br>
dried and concentrated to give the cyclized product (794 mg, 98%). A mixture of<br>
the 4'-methoxy flavone (790 mg, 3.12 mmol) in HI (10 mL) and acetic acid (4 mL)<br>
-59-<br><br>
was heated at reflux for 6 hours. The reaction mix was cooled to room<br>
temperature, diluted with water, neutralized, and extracted with ethyl acetate to<br>
give crude product. This was purified by column chromatography using 5%<br>
methanol in dichloromethane to give 2-(5-Hydroxy-pyridin-2-yl)-chromen-4-one<br>
(270 mg, 36%); MS (ES) m/z: 240.09 (M+1).<br>
Example 12: 2-Pyridin-4-yl-chromen-4-one<br><br>
[0174] 2-Hydroxyacetophenone (1.36 g, 10 mmol) and isonicotinyl<br>
chloride hydrochloride (1.78 g, 10 mmol) were dissolved in 20 ml_ anhydrous<br>
pyridine and stirred at room temperature for 15 h under nitrogen. Water (20 ml_)<br>
was added and neutralized to pH 6 with 4N HCI. The formed solid was filtered off,<br>
washed with water and dried to give isonicotinic acid-2-acetyl phenyl ester as a<br>
white powder (2.32 g, 96%). To a solution of isonicotinic acid-2-acetyl phenyl ester<br>
(2.2 g, 9.12 mmol) in 20 mL anhydrous pyridine was added powdered potassium<br>
hydroxide (1.54 g, 27.36 mmol) and stirred at room temperature for 15 h under<br>
nitrogen. Water (50 mL) was added and the pH was adjusted to pH 6 with 4N HCI.<br>
The solid formed was filtered off, washed with water and dried to give a yellow<br>
powder (0.66 g). The aqueous phase was extracted with EtOAc. The organic layer<br>
was washed with brine, dried over anhydrous Na2S04, and concentrated to give a<br>
yellow solid (1.32 g, 60%). The compound (0.64 g, 2.654 mmol) was suspended in<br>
6 mL glacial AcOH. Three drops of cone. HCI was added and the mixture was<br>
stirred at 110C for 3 hours. The mixture was cooled to room temperature. Water<br>
(20 mL) was added and the mixture was neutralized to pH 6-7 with a 2 N NaOH<br>
solution. The white precipitate formed was filtered off, washed with water and<br>
dried under vacuum to give 2-pyridin-4-yl-chromen-4-one (0.56 g, 94.5%). MS<br>
(ES) m/z: 224.89 (M+1), 223.92 (M); MP 144-145C.<br>
-60-<br><br>
Example 13: 2-(6-Hydroxypyridin-3-yl)-chromen-4-one<br><br>
[0175] In a 100 ml_ round-bottomed flask fitted with condenser and<br>
magnetic stirrer were placed 2'-hydroxy acetdphenone (2.0 g, 14.69 mmol), 2-<br>
methoxy-5-pyridine carboxylic acid (2.0 g, 14.69 mmo!) and pyridine (20 ml_).<br>
POCI3 (2.25 g, 14.69 mmol) was added slowly on cooling. The reaction mixture<br>
was stirred for 24 h at room temperature under nitrogen. The reaction mixture was<br>
poured into ice-water and extracted with EtOAc. The organic layer was washed<br>
with water, dried and concentrated to give product (2.82 g, 70%). To a solution of<br>
this product (2.8 g, 10.33 mmol) in THF (50 ml_) was added potassium t-butoxide<br>
(1.51 g, 12.4 mmol) and the reaction mixture was stirred for 3 h at room<br>
temperature under nitrogen. The reaction mixture was poured into a saturated<br>
aqueous solution of NH4CI. The organic layer was separated, washed with water,<br>
dried and concentrated to give crude diketone (2.8 g, 99%). The diketone (2.8 g,<br>
10.33 mmol) was dissolved in a mixture of 36% HCI (2 ml_) and AcOH (25 mL)<br>
and heated at 100C for 1 hours. The reaction mixture was cooled to room<br>
temperature, diluted with water and extracted with EtOAc. The organic layer was<br>
washed with water, brine, dried and concentrated to give the crude cyclized<br>
product (1.96 g, 74%). A mixture of the cyclized product (500 mg, 1.97 mmol) and<br>
pyridinium hydrochloride (5 g) was heated at 190C for 1 hour. The reaction<br>
mixture was cooled to room temperature, diluted with water, neutralized with<br>
NaHC03 and filtered to give 2-(6-hydroxypyridin-3-yl)-chromen-4-one (480 mg,<br>
98%). MS (ES) m/z: 240.92 (M+1), 239.89 (M); MP 296-297C.<br>
Example 14: 2-(4-Hydroxy-phenyl)-1H-quinolin-4-one<br>
-61 -<br><br><br>
[0176] In a 50 mL round-bottomed flask fitted with a condenser and a<br>
magnetic stirrer were placed 2-amino acetophenone (1.0 g, 7.4 mmol), THF<br>
(15 mL) and Et3N (2.39 g, 23.6 mmol). To the solution, p-methoxy benzoyl<br>
chloride (1.32 g, 7.76 mmol) in THF (15 mL) was added slowly at 0C and stirred<br>
for 30 min at OX.Then the reaction mix was stirred for 24 h at room temperature<br>
under nitrogen. The reaction mix was poured into ice-water. The precipitate was<br>
collected and the crude product was purified by column chromatography using<br>
25% ethyl acetate in hexane to give 1.865 g of product (93% yield). To a<br>
suspension of this product (0.865 g, 3.2 mmol) in t-butanol (12 mL), was added<br>
potassium t-butoxide (1.57 g, 12.8 mmol) and the reaction mix was heated to<br>
~70C for -24 h under nitrogen. The mixture was then cooled to room<br>
temperature and poured into 30 mL of a saturated solution of NH4CI. The solids<br>
were collected and purified by column chromatography using 10% methanol in<br>
dichloromethane to give 398 mg of product (49% yield). This methoxy compound<br>
(375 mg, 1.5 mmol) was taken into 48% HBr (15 mL) and refluxed for 16 hours.<br>
The solvent was removed at reduced pressure. The solids were taken into water<br>
and neutralized with NaHCO3. Solids were collected and purified by column<br>
chromatography using 5% methanol in dichloromethane to give 350 mg of product<br>
(98% yield). MS (ES): m/z: 238.1 (M+1).<br>
-62-<br>
Example 15: 4-lsoquinolin-3-vl-phenol<br><br><br>
[0177] To a solution of 2-bromobenzaldehyde (1.85 g, 10 mmol) and 4-<br>
methoxyphenyl acetylene (1.58 g, 12 mmol) in 40 ml_ of triethylamine were added<br>
dichlorobis(triphenylphosphine) palladium(ll) (140 mg, 2 mol%) and copper(l)<br>
iodide (20 mg, 1 mol%). The reaction mixture was heated at 50C under nitrogen<br>
for 3 hours. The reaction mixture was cooled to room temperature and the<br>
ammonium salt was removed by filtration. The filtrate was concentrated under<br>
reduced pressure. Purification of the crude compound by column chromatography<br>
(SilicaGel 230-400 mesh; 10% ethyl acetate in hexanes as eluent) afforded of 2-<br>
(4-methoxy phenylethynyl) benzaldehyde (2.1 g, 89%).<br>
[0178] 2-(4-Methoxy phenylethynyl) benzaldehyde (2.06 g, 8.73 mmol)<br>
and t-butylamine (3.83 g, 52.4 mmol) were stirred under nitrogen for 24 h at room<br>
temperature.TrTe resulting mixture was extracted with ether and the organic layer<br>
was dried over anhydrous Na2S04, concentrated to give the imine (2.4 g, 94%)<br>
which was used in the next step without further purification. To a solution of this<br>
imine (2.39 g, 8.2 mmol) in 100 mL anhydrous DMF was added (0.156 g, 0.82<br>
mmol) copper(l) iodide and flushed with nitrogen. The reaction mixture was<br>
heated at 100C for 4 hours. The mixture was cooled to room temperature, and<br>
diluted with ether (200 mL). The organic layer was washed with saturated<br>
aqueous ammonium chloride (3x100 mL). The organic layer was dried over<br>
anhydrous Na2S04 and concentrated to give the crude compound as a dark<br>
colored solid. Purification by column chromatography (SilicaGel 230-400 mesh;<br>
10% ethylacetate in hexanes as eluent) afforded 3-(4-methoxyphenyl)isoquinoline<br>
(1.064 g, 55%) as a white solid. The 3-(4-methoxyphenyl)isoquinoline (1.05 g,<br>
4.47 mmol) was suspended in 30 mL hydroiodic acid and 12 mL of acetic acid<br>
was added. The reaction mixture was stirred at 110C for 2 h, then cooled to room<br>
temperature. The precipitate formed was filtered off, washed with acetic acid (2x5<br>
mL) and dried under vacuum to give a yellow solid. The crude compound was<br>
purified by triturating with 5% methanol in ether to give 4-isoquinolin-3-yl-phenol<br>
(0.83 g, 84%) as a white powder. MS (ES) m/z: 222.89 (M+1), 221.86 (M); MP<br>
218-219C.<br>
-63-<br><br>
Example 16: 7-(3-Fluoro-4-hydroxyphenyl)-6-methyl-1,6-naphthyridin-5(6H)-one<br><br>
[0179] A suspension of 2-methyl nicotinic acid (1.5 g, 10.94 mmol) in DCM<br>
(30 ml_), triethylamine (1.16 g, 11.48 mmol) and oxalyl chloride (2.77 g, 21.87<br>
mmol) were stirred at room temperature for 16 hours. The solvent and excess of<br>
oxalyl chloride were removed at reduced pressure. The solid-vvas-dissolved in<br>
DCM (10 ml_) and methylamine hydrochloride (1.02 g, 32.81 mmol) was added on<br>
cooling followed by stirring at room temperature for 4 hours. The solvent was<br>
removed and the crude product was purified by chromatography by using 5%<br>
MeOH in DCM to give 1.4 g of the amide product (95%). To a solution of the<br>
amide (1.35 g, 8.99 mmol) in THF (25 mL), was slowly added n-butyl lithium (8.3<br>
ml_, 20.68 mmol, 2.5 M solution in hexane) under nitrogen with cooling (ice-salt<br>
bath), maintaining the temperature below 20C. After addition, the mixture was<br>
stirred for 1 h at 0C. The mixture was cooled to -50C and a solution of 4-<br>
methoxy-3-fluoro benzonitrile (1.63 g, 10.79 mmol) in THF (10 mL) was added<br>
quickly. The cooling bath was removed and the mixture was allowed to warm to<br>
room temperature. Saturated NH4CI solution was added under cooling, and the<br>
layers were separated. The organic layer was washed with water, brine, and dried<br>
over Na2SO4. After concentration, the crude product was purified by<br>
chromatography using 5% MeOH in DCM to give 918 mg of the enamine (34%).<br>
To a suspension of the enamine (400 mg, 1.33 mmol) in EtOH (15 mL) was added<br>
cone. HCI (2 mL). The mixture was heated at 80C for 2 hours. The reaction<br>
mixture was cooled to room temperature and the solvent was removed to give 400<br>
mg of crude methoxy compound (94%). In a 50 mL flask were placed the<br>
methoxy compound (400 mg, 1.40 mmol) and pyridinium hydrochloride (6 g),<br>
followed by heating of the mixture at 190C for 4 hours. The flask was then<br>
cooled to room temperature, diluted with water, neutralized with NaHC03 and the<br>
-64-<br><br>
solid was filtered to afford 160 mg of 7-(3-fluoro-4-hydroxyphenyl)-6-methyl-1,6-<br>
naphthyridin-5(6H)-one (42%). MS (ES) m/z: 271.97 (M+1), 270.96 (M); MP 182-<br>
184C.<br>
Example 17: 2-Fluoro-4-(5-methoxy-1-(methyIamino)isoquinoIin-3-yl)phenol<br><br>
[0180] To a suspension of 2-methyl-3-methoxy benzoic acid (2.0 g, 12.03<br>
mmol) in CH2CI2 (30 ml_), oxalyl chloride (3.05 g, 24.07 mmol) was added and<br>
stirred at room temperature for 16 hours. The solvent and excess of oxalyl<br>
chloride were removed at reduced pressure. The solid was dissolved in CH2CI2<br>
(10 ml_) and methyl amine (1.12 g, 36.1 mmol) was added on cooling and the<br>
mixture was stirred at room temperature for 4 hours. The solvent was removed<br>
and the crude product was purified by chromatography using 5% methanol in<br>
CH2CI2 to give the amide product (1.67 g, 78%). To a solution of the amide (946<br>
mg, 5.28 mmol) in THF (20 mL) was added n-butyl lithium (4.85 ml_, 12.14 mmol,<br>
2.5 M solution in hexane) was added slowly under nitrogen with cooling (ice-salt<br>
bath) maintaining temperature below -20C. After completion of addition, the<br>
mixture was stirred for 1 h at 0C, then cooled to -50C and a solution of 4-0-<br>
TBDMS-3-fluoro benzonitrile (1.46 g, 5.8 mmol) in THF (10 mL) was added<br>
quickly. The cooling bath was removed and the reaction mixture was allowed to<br>
warm to room temperature. Saturated NH4CI solution was added under cooling.<br>
The organic layer was washed with water, brine, dried over Na2S04and<br>
concentrated to give the crude product, which was purified by chromatography<br>
using 5% methanol in CH2CI2, to give two products: an enamine (260 mg) and a<br>
cyclized product (450 mg). To a suspension of the enamine (400 mg, 1.33 mmol)<br>
in ethanol (15 mL), cone. HCI (2 mL) was added and heated at 80C for 2 hours.<br>
The reaction mixture was cooled to room temperature and the solvent was<br>
removed and neutralized by NaHC03 to give 2-fluoro-4-(5-methoxy-1-<br>
-65-<br><br>
(methylamino)isoquinoIin-3-yl)phenol (150 mg, 83%). MS (ES) m/r. 300.01<br>
(M+1), 299.00 (M); MP 185-187C.<br>
Example 18: 3-(3-Fluoro-4-hydroxyphenyl)-5-methoxyisoquinolin-1 (2H)-one<br><br>
[0181] To a suspension of 2-methyl-3-methoxy benzoic acid (2.0 g, 12.03<br>
mmol) in DCM (30 ml_), oxalyrchloride (3.05 g, 24.07 mmol-) was added and<br>
stirred at room temperature for 16 hours. The solvent and excess of oxalyl<br>
chloride were removed at reduced pressure. The solid was dissolved in DCM (10<br>
mL) and methyl amine (1.12 g, 36.1 mmol) was added on cooling and the mixture<br>
was stirred at room temperature for 4 hours. The solvent was removed and the<br>
crude product was purified by chromatography using 5% MeOH in DCM to give<br>
the amide product (1.67 g, 78%). To a solution of the amide (946 mg, 5.28 mmol)<br>
in THF (20 ml_) was added n-butyl lithium (4.85 mL, 12.14 mmol, 2.5 M solution in<br>
hexane) was added slowly under nitrogen with cooling (ice-salt bath) maintaining<br>
temperature below -20C. After completion of addition, the mixture was stirred for<br>
1 h at 0C, then cooled to -50C and a solution of 4-0-TBDMS-3-fluoro<br>
benzonitrile (1.46 g, 5.8 mmol) in THF (10 mL) was added quickly. The cooling<br>
bath was removed and the reaction mixture was allowed to warm to room<br>
temperature. Saturated NH4CI solution was added under cooling. The organic<br>
layer was washed with water, brine, dried over Na2S04 and concentrated to give<br>
the crude product, which was purified by chromatography using 5% MeOH in<br>
DCM, to give two products: an enamine (260 mg) and a cyclized product (450<br>
mg). To a suspension of the cyclized product (450 mg, 1.1 mmol) in EtOH (15<br>
mL), cone. HCI (2 mL) was added and heated at 60C for 3 hours. The reaction<br>
mixture was cooled to room temperature and the solvent was removed and<br>
purified by chromatography using 5% MeOH in DCM to give 85 mg of product<br>
(26%). MS (ES) m/z: 286.11; MP 289-291C.<br>
-66-<br><br>
Example 19: 3-(4-Hydroxyphenyl)-6,8-dimethoxyisoquinolin-1 (2H)-one<br><br>
[0182] To a suspension of 2-methyl-4,6-dimethoxy benzoic acid (2.8 g,<br>
14.27 mmol) in CH2CI2 (30 ml_), oxalyl chloride(3.62 g, 28.54 mmol) was added<br>
and the mixture was stirred at room temperature for 16 hours. The solvent and<br>
excess of oxalyl chloride were removed at reduced pressure. The solid was<br>
dissolved in CH2CI2 (10 ml_) and methyl amine hydrochloride (1.33 g, 42.81 mmol)<br>
was added on cooling and the mixture was stirred at room temperature for 4<br>
hours. The solvent was removed and the crude product was purified by<br>
chromatography by using 5% methanol in CH2CI2, to give 1.3 g of the amide<br>
intermediate in 43% yield. To a solution of the amide intermediate (1.29 g, 6.16<br>
mmol) in THF (30 ml_), n-butyl lithium (5.6 mL, 14.18 mmol, 2.5 M solution in<br>
hexane) was added slowly under nitrogen with cooling( ice-salt bath) maintaining<br>
the temperature below 20C. The mixture was stirred for 1 h at 0C, then cooled to<br>
-50C and a solution of 4-O-TBDMS-benzonitrile (1.58 g, 6.78 mmol) in THF (10<br>
mL) was added quickly. The cooling bath was removed and allowed to warm to<br>
room temperature and stirred for 16 h at room temperature. Saturated aqueous<br>
NH4CI solution was added with cooling, and the layers were separated. The<br>
organic layer was washed with water, brine, dried over Na2S04and concentrated<br>
to give the crude intermediate, which was purified by chromatography using 5%<br>
methanol in CH2CI2, to give two products (1) 678 mg of isoquinoline in 26% yield<br>
and (2) 780 mg of quinalone product in 27% yield. To a suspension of the above<br>
quinalone product (2) (780 mg, 1.65 mmol) in ethanol (20 mL), cone. HCI (2 mL)<br>
was added and the mixture was heated at 70C for 2 hours. The reaction mixture<br>
was cooled to room temperature and the solvent was removed and purified by<br>
chromatography using 5% methanol in CH2Cl2 to give 3-(4-hydroxyphenyl)-6,8-<br>
-67-<br><br>
dimethoxyisoquinolin-1(2H)-one (215 mg, 44 %). MS (ES) m/z: 297.93 (M); MP<br>
245-247C.<br>
Example 20: 2-(4-Hydroxy-phenyl)-[1,4]naphthoquinone<br><br>
[0183] An example compound, 2-(4-hydroxy-phenyl)-[1,4]naphthoquinone<br>
was synthesized in the following way. To a mixture of 2-bromo-1, 4-<br>
naphthoquinone (1.0 g, 4.22 mmol), 4-hydroxy phenyl boronic acid (640 mg, 4.64<br>
mmol), potassium phosphate (3.135 g, 14.76 mmol), tri cyclo hexyl phosphine<br>
(118 mg, 0.422 mmol), toluene (20 ml_) and water (1 mL) was added palladium<br>
acetate (47 mg, 0.21 mmol) under nitrogen. The reaction mix was heated to<br>
~100C for 3 h and then cooled to room temperature. Water was added and the<br>
mixture was extracted with ethyl acetate. The organic layer was separated,<br>
washed with water, brine, dried and concentrated to give crude product, which<br>
was purified by column chromatography, using 10% ethyl acetate in hexane to<br>
give (480 mg, 45% yield) of 2-(4-Hydroxy-phenyl)-[1,4]naphthoquinone; MS (ES)<br>
m/z: 251.03 (M+1).<br>
Example 21: 3-(4-Hydroxyphenyl)-2H-isoquinolin-1-one<br><br>
[0184] To a solution of n-methyl-o-toluamide (2.0 g, 13.4 mmol) in THF<br>
(30 mL), n-butyl lithium (12.3 mL, 30.8 mmol, 2.5 M solution in hexane) was<br>
-68-<br><br>
added slowly under nitrogen with cooling (ice-salt bath) maintaining the<br>
temperature below 20C. After addition, the mixture was stirred for 1 h at 0C,<br>
then cooled to -50C. A solution of 4-methoxy benzonitrile (2.14 g, 16.08 mmol) in<br>
THF (5 mL) was added quickly. The cooling bath was removed and the reaction<br>
was allowed to warm to room temperature. A saturated aqueous NH4CI solution<br>
was added during cooling, and the solid was isolated by filtration to give the<br>
methoxy compound (2.2 g, 65%). The methoxy compound (750 mg, 2.98 mmol)<br>
was dissolved in a 50 mL flask and pyridinium hydrochloride (10 g) was added.<br>
The mixture was heated at 190C for 2 h, then cooled to room temperature . The<br>
reaction was then diluted with water, neutralized with NaHC03 and the solid was<br>
isolated by filtration to give 600 mg of 3-(4-hydroxyphenyl)-2H-isoquinolin-1-one<br>
(84%). MS (ES) m/z: 238.92 (M+1), 237.89 (M); MP 239-241 C.<br>
Example 22: 2-Phenyl-4H-pyrano[2,3-b]pyridin-4-one<br><br>
[0185] In a 250 mL dry round bottom flask with a reflux condenser and<br>
magnetic stirrer was placed with 2-chloro-3-ethyl nicotinate (12.0 g, 64.7 mmol) in<br>
dry methanol (200 mL), and CH3ONa (21 mL, 97.0 mmol, 25% in methanol) were<br>
added slowly and the reaction mixture was refluxed for 16 hour. The reaction<br>
mixture was cooled to room temperature and quenched by addition of a saturated<br>
aqueous NH4CI solution and extracted with ethyl acetate. The combined organic<br>
layers were washed with water, brine, dried over Na2S04 and concentrated to give<br>
2-methoxy-3-methyl nicotinate (10.0 g, 93%). In a dry 500 mL round bottom flask<br>
NaH (549 mg, 13.7 mmol, 60% in mineral oil) was added in DMF (10 mL).<br>
Acetophenone (1.5 g, 12.5 mmol) in dry DMF (10 mL) was added drop-wise at<br>
0C in 30 min. The reaction mixture was stirred for 1 h at room temperature. 2-<br>
Methoxy-3-methyl nicotinate (2.08 g, 12.5 mmol) dissolved into dry DMF (10 mL)<br>
was added slowly on cooling. After addition the mixture was stirred for 16 h at<br>
-69-<br><br>
room temperature. The reaction mixture was quenched by addition of a saturated<br>
aqueous NH4CI solution and diluted with water. The solid was filtered off, washed<br>
with water and dried to give the diketo product (2.94 g, 92%). Poly phosphoric<br>
acid (15.0 g) was heated at 90C and the diketo compound (1.5 g, 3.50 mmol)<br>
was added slowly and heated at 90C for 1 hours. The reaction mixture was<br>
cooled to room temperature and diluted with water. The solid was separated by<br>
filtration, washed with water and dried to give pure 2-phenyl-4H-pyrano[2,3-<br>
b]pyridin-4-one (655 mg, 50%); MS (ES) m/z: 224.94 (M+1), 223.95 (M); MP 103-<br>
105C<br>
Example 23: 2-(4-(hydroxymethyl)phenyl)-4H-pyrano[2,3-b]pyridin-4-one<br><br>
[0186] In a 250 ml_ dry round bottom flask with reflux condenser and<br>
magnetic stirrer was placed 2-chloro-3-ethyl nicotinate (12.0 g, 64.7 mmol) in dry<br>
methanol (200 ml_), and CH3ONa (21 ml_, 97.0 mmol, 25% in methanol) were<br>
added slowly and the reaction mixture was refluxed for 16 hour. The reaction<br>
mixture was cooled to room temperature and quenched by addition of a saturated<br>
aqueous NH4CI solution and extracted with ethyl acetate. The combined organic<br>
layers were washed with water, brine, dried over Na2SO4 and concentrated to give<br>
2-methoxy-3-methyl nicotinate (10.0 g, 93%). In a dry 250 ml_ round bottom flask<br>
NaH (1.68 g, 41.0 mmol, 60% in mineral oil) was added in DMF (20 mL). 4'-Methyl<br>
acetophenone (5 g, 37.3 mmol) in dry DMF (10 mL) was added dropwise at 0C in<br>
30 min. The reaction mixture was stirred for 1 h at room temperature. 2-Methoxy-<br>
3-methyl nicotinate (6.23 g, 37.3 mmol) dissolved in dry DMF (10 mL) was added<br>
slowly on cooling. After addition the mixture was stirred for 16 h at room<br>
temperature. The reaction mixture was quenched by addition of a saturated<br>
aqueous NH4CI solution and diluted with water. The solid was filtered off, washed<br>
with water and dried to give the diketo product (9.36 g, 92.5%). Poly phosphoric<br>
acid (30.0 g) was heated at 90C and the diketo compound (4.36 g, 16.1 mmol)<br>
-70-<br><br>
was added slowly and heated at 90C for 1 hours. The reaction mixture was<br>
cooled to room temperature and diluted with water. The solids was separated by<br>
filtration, washed with water and dried to give 2-p-tolyl-4H-pyrano[2,3-b]pyridin-4-<br>
one (3.38 g, 89%). To a solution of 2-p-tolyl-4H-pyrano[2,3-b]pyridin-4-one (1.0 g,<br>
4.2 mmol) in CCI4 (50 mL), NBS (788 mg, 4.44 mmol) was added under nitrogen,<br>
and heated under reflux for 4 h in presence of 600 w light. The reaction mixture<br>
was cooled to room temperature and filtered. The solids were dried and washed<br>
with water to give the bromide compound (698 mg, 52%). To a solution of the<br>
bromide compound (698 mg, 2.20 mmol) in DMF (20 mL), potassium acetate (649<br>
mg, 6.62 mmol) was added. The mixture was heated at 100C for 1 hours. The<br>
reaction mixture was diluted with water and extracted with ethyl acetate. The<br>
combined organic layers were washed with water, brine, dried over Na2S04 and<br>
concentrated to give the crude acetyl flavone (597 mg, 92%). To a solution of<br>
acetyl flavone (597 mg, 2.0 mmol) in methanol (15 mL), K2C03 (840 mg, 6.07<br>
mmol) was added and stirred for 2 h at room temperature. The solvent was<br>
removed and the product was taken into water and neutralized by dilute HCI. The<br>
solid was isolated by filtration, washed with water and purified by chromatography<br>
using 5% MeOH in dichloromethane to give 2-(4-(hydroxymethyl)phenyl)-4H-<br>
pyrano[2,3-b]pyridin-4-one (300 mg, 59%); MS (ES) m/z: 254.89 (M+1), 253.88<br>
(M);MP218-219C<br>
Example 24: 2-(4-hydroxy-3,5-dimethylphenyl)-4H-pyrano[2,3-b]pyridin-4-one<br><br>
[0187] Ethyl-2-chloronicotinate (11.14 g, 60 mmol) was dissolved in<br>
anhydrous methanol (60 mL). Sodium methoxide (18 mL, 25 wt-% in methanol)<br>
was added slowly at room temperature under nitrogen. The reaction mixture was<br>
stirred under reflux for 15 hours. Methanol was removed under vacuum. The<br>
residue was dissolved in ethyl acetate (200 mL). The organic layer was washed<br>
-71-<br><br>
with a saturated aqueous NH4CI solution (1x100 ml_) and brine (50 m!_). Dried<br>
over anhydrous Na2SO4. Removal of solvent gave ethyl-2-methoxynicotinate as<br>
yellow oil (9.88 g, 91%). To a solution of 3,5-dimethyl-4-hydroxyacetophenone<br>
(2.46 g, 15 mmol) in anhydrous DMF (75 ml_) was added imidazole (3.27 g, 48<br>
mmol) and terf-butyldimethylsilylchloride (2.71 g, 18 mmol). The reaction mixture<br>
was stirred at room temperature under nitrogen for 15 hours. Water (200 mL) was<br>
added. The mixture was extracted with ethyl acetate (200 mL). The organic layer<br>
was washed with water (2x100 mL) and brine (100 mL), and dried over anhydrous<br>
Na2S04. Removal of solvent gave 3,5-demthyl-4-ferf-butyldimethylsilyloxy<br>
acetophenone as a colorless oil in quantitative yield (4.4 g). To a stirred solution<br>
of 3,5-demthyl-4-ferf-butyldimethylsilyloxy acetophenone (1.58 g, 5.6 mmol) in<br>
anhydrous THF (15 mL) was added lithium bis(trimethylsilyl) amide (6.8 mL, 1.0M<br>
solution in THF) at -40C over a period of 15 min. under nitrogen. Stirring was<br>
continued at -40C for 15 min. A solution of ethyl-2-methoxynicotinate in<br>
anhydrous THF (15 mL) was added slowly. Stirring was continued at -40C for 10<br>
min. The mixture was allowed to warm to room temperature. Stirring was<br>
continued for another 15 h at room temperature. The reaction mixture was diluted<br>
with ethyl acetate (200 mL). A saturated aqueous NH4CI solution (50 mL) was<br>
added. The organic layer was separated and dried over anhydrous Na2S04.<br>
Removal of solvent gave the desired crude compound (2.4g) which was used in<br>
next step without purification. The above compound (2.31 g, 5.6 mmol) and<br>
pyridinium hydrochloride (6.47 g, 56 mmol) was mixed together and stirred at<br>
190C for 3 hours. The mixture was cooled to room temperature. Water (100 mL)<br>
was added. The solid was filtered off, washed with water and dried under<br>
vacuum. The crude product was purified by column chromatography (SilicaGel<br>
230-400 mesh; 2% methanol in CH2CI2 as eluent) to give 2-(4-hydroxy-3,5-<br>
dimethylphenyl)-4H-pyrano[2,3-b]pyridin-4-one (0.598 g, 40% yield over two<br>
steps); MS (ES) m/z: 268.91 (M+1), 267.88 (M); MP 295-297C<br>
-72-<br><br>
Example 25: 2-(pyridin-3-yl)-4H-chromen-4-one<br><br>
[0188] To a solution of nicotinic acid hydrochloride (0.5 g, 3.1 mmol) in<br>
CH2CI2 (200 mL) at room temperature was added oxalyl chloride (0.42 mL, 4.8<br>
mmol) and three drops of DMF. The reaction mixture was stirred at room<br>
temperature for 1 h and then concentrated using a rotary evaporator. The<br>
resulting residue was re-dissolved in toluene (50 mL).and then again concentrated<br>
using a rotary evaporator to afford nicotinic acid chloride hydrochloride (0.5 g,<br>
90%). To a solution of 2'-hydroxyacetophenone (0.38 g, 2.8 mmol) in THF (50 mL)<br>
at room temperature was added nicotinic acid chloride hydrochloride (0.5 g, 2.8<br>
mmol) and triethylamine (1.2 mL, 8.6 mmol). The reaction mixture was stirred at<br>
room temperature for 2 hours. The reaction was quenched with water (50 mL),<br>
extracted with CH2CI2 (3x100 mL), concentrated using a rotary evaporator. The<br>
residue was purified by column chromatography (hexane: ethyl acetate 2:1) to<br>
provide the corresponding ester (0.42 g, 62%). A solution of the above ester<br>
(0.42 g, 1.73 mmol) in THF (50 mL) was mixed with f-BuOK (0.25 g, 2.25 mmol)<br>
and was stirred at room temperature for 16 hours. The reaction was quenched<br>
with water (50 mL) and the aqueous was acidified with HCI (0.5 N) to pH=6. The<br>
reaction mixture was extract with CH2CI2 (3*100 mL), concentrated using a rotary<br>
evaporator, trituration in hexanes to afford a solid. This solid was collected by<br>
filtration and washed with hexanes to provide the diketone (0.3g, 71%). A solution<br>
of the above diketone (0.3 g, 1.25 mmol) in HOAc (50 mL) and HCI (cone, 1 mL)<br>
was stirred at reflux for 2 hours. The solvent was removed using a rotary<br>
evaporator. The residue was purified by column (hexane: ethyl acetate: MeOH<br>
3:3:1) to provide 2-(pyridin-3-yl)-4H-chromen-4-one as a light yellow solid<br>
(0.202 g, 73%); MS (ES) m/z: 224.90 (M+1), 223.92 (M); MP 122.8-124.0C<br>
- 73 -<br><br>
Example 26: 7-((dimethylamino)methyl)-2-(4-hydroxyphenyl)-4H-pyrano[2,3-<br>
b]pyridin-4-onedihydrochloride<br><br>
[0189] In a 250 ml_ dry round bottom flask with reflux condenser and<br>
magnetic stirrer was placed with 2-chloro-6-methyl-3-methyl nicotinate (5.3 g, 28.6<br>
mmol) in dry methanol (30 mL), and 'CH3ONa (9.2 mL, 42.8 mmol, 25% in<br>
methanol) were added slowly and the reaction mixture was refluxed for 16 hour.<br>
The reaction mixture was cooled to room temperature and quenched by addition<br>
of a saturated aqueous NH4CI solution and extracted with ethyl acetate. The<br>
combined organic layers were washed with water, brine, dried over Na2S04 and<br>
concentrated to give 2-methoxy-6-methyl-3-methyl nicotinate (4.37 g, 84%). In a<br>
dry 250 mL round bottom flask NaH (637 mg, 26.5 mmol, 60% in mineral oil) was<br>
added in DMF (20 mL). 4'-Methoxy acetophenone (3.62 g, 24.1 mmol) in dry DMF<br>
(10 mL) was added dropwise at 0C over 30 min. The reaction mixture was stirred<br>
for 1 h at room temperature. 2-Methoxy-6-methyl-3-methyI nicotinate (4.37 g,<br>
24.1 mmol) dissolved in dry DMF (10 mL) was added slowly on cooling. After<br>
addition the mixture was stirred for 16 h at room temperature. The reaction<br>
mixture was quenched by addition of saturated aqueous NH4CI solution and<br>
diluted with water. The solids were filtered off, washed with water and dried to give<br>
the diketo product (6.18 g, 86 %). In a 50 mL flask were placed the diketo<br>
compound (3.0 g, 10.1 mmol) and pyridinium hydrochloride (25 g). The mixture<br>
was heated at 190C for 4 hours. The flask was cooled to room temperature,<br>
diluted with water, neutralized with NaHC03 and the solids were filtered off, dried<br>
and purified by chromatography using 5 % MeOH in CH2CI2 to give the desired<br>
intermediate (1.15 g , 46%). In a 50 mL round-bottomed flask fitted with<br>
condenser and magnetic stirrer were placed the desired intermediate (1.05 g, 4.13<br>
mmol), Ac20 (463 mg, 4.54 mmol), pyridine (10 mL). The reaction mixture was<br>
stirred for 16 h at room temperature. The reaction mixture was poured into water.<br>
The solids were filtered off, washed with water and dried to give the acetylated<br>
-74-<br><br>
product (1.157 g, 96%). To a solution of acetyl product (1.16 g, 3.92 mmol) in<br>
CCl4(50 mL), NBS (732 mg, 4.11 mmol) was added under nitrogen, and the<br>
reaction mixture was heated under reflux for 4 h in presence of 600 w light. The<br>
reaction mixture was cooled to room temperature and filtered. The solids were<br>
dried and washed well with water. The crude product was purified by<br>
chromatography using 25 % ethyl acetate in dichloromethane to give the bromide<br>
compound (375 mg, 25 %). To a solution of the bromide compound (375 mg, 1.00<br>
mmol) in CH3CN (10 mL), was added dimethyl amine (181 mg, 4.02 mmol, 2 M<br>
solution in THF). The mixture was stirred at room temperature for 1 hours. The<br>
solvent was removed and the crude product was purified by chromatography<br>
using 5% MeOH in dichloromethane to give the free base. The free base was<br>
dissolved in dichibromethane (10 mL) and HCl solution in ether (1 N, 5 mL) was<br>
added. The solvent was removed and solids were dried to give 7-<br>
((dimethylamino)methyl)-2-(4-hydroxyphenyl)-4H-pyrano[2,3-b]pyridin-4-one as<br>
the dihydrochloride (275 mg, 74%). MS (ES) m/z: 296.94 (M); MP 205C at<br>
decomposition<br>
Example 27: 2-(4-(2-(dimethylamino)ethoxy)phenyl)-4H-pyrano[2,3-b]pyridin-4-<br>
one dihydrochloride<br><br>
[0190] In a 500 mL dry round bottom flask with reflux condenser and<br>
magnetic stirrer was placed 2-chloro-3-ethyl nicotinate (40.0 g, 215.5 mmol) in<br>
methanol (200 mL), and CH3ONa (65 mL, 301.7 mmol, 25% in methanol) was<br>
added slowly and the reaction mixture was refluxed for 16 hour. The reaction<br>
mixture was cooled to room temperature, quenched by addition of saturated<br>
NH4CI solution and extracted by ethyl acetate. The combined organic layer was<br>
washed well with water, brine, dried over Na2S04 and concentrated to give 2-<br>
methoxy-3-methyl nicotinate (35 g, 97% yield). In a dry 500 mL round bottom<br>
flask sodium hydride (9.21 g, 230.3 mmol, 60%) was added in DMF (100 mL). 4-<br>
-75-<br><br>
Methoxyacetophenone (31.5 g, 209 mmol) in dry DMF (50 mL) was added<br>
dropwise at 0C over 30 min. The reaction mixture was stirred for 1 h at room<br>
temperature. 2-Methoxynicotinic acid methyl ester (35 g, 209 mmol) dissolved in<br>
dry DMF (50 mL) was added slowly on cooling. After addition the mixture was<br>
stirred for 16 h at room temperature. The reaction mixture was quenched by<br>
addition of a saturated aqueous NH4Cl solution and diluted with water. The solids<br>
were filtered off, washed with water and dried to give the diketo product (56.7 g,<br>
95 %). The above diketo compound (56.7 g, 199 mmol) and pyridinium<br>
hydrochloride (345 g) were placed in a 1000 mL round bottom flask and the<br>
mixture was heated at 190C for 5 hours. The reaction mixture was cooled to<br>
room temperature and diluted with water. The solids were separated by filtration<br>
and purified by column chromatography using 5% methanol in CH2GI2 to give 2-<br>
(4-Hydroxy-phenyl)-pyrano[2,3-b]pyridin-4-one (23.25 g, 48.8%). 2-(4-Hydroxy-<br>
phenyl)-pyrano[2,3-b]pyridin-4-one (0.48 g, 2.0 mmol) was suspended in<br>
anhydrous THF (25 mL). Triphenyl phosphene (0.577 g, 2.2 mmol), N,N-<br>
dimethylaminoethanol (0.213 g, 2.4 mmol) and /S/,A/-diisopropylethylamine (0.37 g,<br>
3.0 mmol), were added. To the stirred solution was added diethylazodicarboxylate<br>
(0.383 g, 2.2 mmol). After the addition of DEAD, the reaction mixture became a<br>
clear solution. The reaction mixture was stirred at room temperature overnight.<br>
Additional triphenyl phosphene (0.288 g, 1.1 mmol), A/,A/-dimethylaminoethanol<br>
(0.107 g, 1.2 mmol); A/,A/-diisopropylethylamine (0.185 g, 1.5 mmol), and<br>
diethylazodicarboxylate (0.191 g, 1.1 mmol) were added and stirring was<br>
continued for 15 hours. The solvent was removed under vacuum. The crude<br>
material was purified by column chromatography (Silica Gel 230-400 mesh; 2-5%<br>
methanol in CH2CI2 as eluent) to give 2-[4-(2-dimethylamino ethoxy) phenyl]<br>
pyrano[2,3-b]pyridine-4-one as white solid (0.445 g, 72%). The above compound<br>
(0.2 g, 0.644 mmol) was dissolved in anhydrous Dichloromethane (10 mL). HCI in<br>
ether (3 mL, 1.0 M) was added dropwise. A yellow precipitate was formed. The<br>
reaction mixture was stirred at room temperature for 30 min. under nitrogen. The<br>
solvent was removed and the crude compound was triturated with ether to give 2-<br>
(4-(2-(dimethylamino)ethoxy)phenyl)-4H-pyrano[2,3-b]pyridin-4-one<br>
dihydrochloride (0.24 g, 97%) as a pale yellow solid. MS (ES) m/r. 311.98 (M+1),<br>
310.94 (M); MP 236-238C.<br>
- 76 -<br><br>
Example 28: 2-(4-hydroxy-3-(thiophen-2-yl)phenyl)-4H-pyrano[2,3-b]pyridin-4-one<br><br>
[0191] To a solution of 4-hydroxyacetophenone (4.0 g, 30 mmol) in 50%<br>
(v/v) of ammonium hydroxide (250 ml_) at room temperature was quickly added a<br>
solution of potassium iodide (24.2 g, 146 mmol) and iodine (7.66 g, 30 mmol) in<br>
water (300 ml_). The resulting mixture was stirred at room temperature for i4<br>
hours and then passed through a celite pad. The filtrate was cooled to 10C and<br>
acidified slowly with HCI (12 N) to pH = 1. The yellow precipitate was collected by<br>
filtration, washed with water to get 4-hydroxy-3-iodoacetophenone (6.3 g, 80%). A<br>
solution of 4-hydroxy-3-iodoacetophenone (3 g, 11.5 mmol) and 2-<br>
thiophenylboronic acid (1.46 g, 11.5 mmol) in DMF (50 mL) was mixed with<br>
potassium carbonate (3.16 g, 22.9 mmol) and Pd(dppf)2 (0.25 g, 0.344 mmol).<br>
The mixture was stirred at 90C for 14 hours, cooled to room temperature and<br>
passed through a celite pad. The filtrate was diluted with water and extracted with<br>
EtOAc (3x100 mL). The residue after concentration was purified by column (Si02,<br>
Hexanes / EtOAc = 4:1) to provide 4-hydroxy-3-(2-thiophenyl)acetophenone (1.1<br>
g, 44%) as a light yellow solid. To a solution of 4-hydroxy-3-(2-<br>
thiophenyl)acetophenone (0.5 g, 2.29 mmol) in THF (50 mL) at -78C was added<br>
LDA in heptane-THF (2.6 mL, 4.7 mmol) and the solution was stirred for 1 hours.<br>
2-Chloronicotinyl chloride (0.202 g, 1.15 mmol) was added and the resulting<br>
mixture was stirred at -78C for 1 h and 1 h at room temperature. The reaction<br>
was quenched with aqueous HCI (0.5 N) and extracted with CH2CI2 (x3*100 mL).<br>
The residue after concentration was purified by column (Si02l Hexanes / EtOAc =<br>
2:1) to provide the corresponding diketone (0.31 g, 76%). The above diketone<br>
(0.28 g, 0.78 mmol) was dissolved in HOAc (50 mL) and stirred at 110C for 2<br>
hours. It was poured into icy water. The solid was collected by filtration, washed<br>
with CH2CI2 to afford 2-(4-hydroxy-3-(thiophen-2-yl)phenyl)-4H-pyrano[2,3-<br>
-77-<br><br>
b]pyridin-4-one (0.146 g, 58%) as a grey solid; MS (ES) m/z: 322.93 (M+1),<br>
321.93 (M); MP 273.5-275C.<br>
Example 29: 2-(2,6-dimethyI-4-(4-oxo-4H-pyrano[2,3-b]pyridin-2-<br>
yl)phenoxy)acetic acid<br><br>
[0192] Ethyl 2-chloronicotinate (11.14 g, 60 mmol) was dissolved in<br>
anhydrous methanol (60 ml_). Sodium methoxide (18 ml_, 25 wt% in methanol)<br>
was added slowly at room temperature under nitrogen. The reaction mixture was<br>
stirred under reflux for 15 hours. Methanol was removed under vacuum. The<br>
residue was dissolved in ethyl acetate (200 mL). The organic layer was washed<br>
with a saturated aqueous NH4CI solution (1*100 mL) and brine (50 mL), and dried<br>
over anhydrous Na2S04. Removal of solvent gave ethyl-2-methoxynicotinate (9.88<br>
g, 91 %) as yellow oil. To a solution of 3,5-dimethyl-4-hydroxyacetophenone (2.46<br>
g, 15 mmol) in anhydrous DMF (75 mL) were added imidazole (3.27 g, 48 mmol)<br>
and terf-butyldimethylsilylchloride (2.7 g, 18 mmol). The reaction mixture was<br>
stirred at room temperature under nitrogen for 15 hours. Water (200 mL) was<br>
added. The mixture was extracted with ethyl acetate (200 mL). The organic layer<br>
was washed with water (2*100 mL) and brine (100 mL), and dried over anhydrous<br>
Na2S04. Removal of solvent gave 3,5-demthyl-4-teAf-butyldimethylsilyloxy<br>
acetophenone as a colorless oil in quantitative yield (4.4 g). To a stirred solution<br>
of 3,5-demthyl-4-ferf-butyldimethylsilyloxy acetophenone (1.58 g, 5.6 mmol) in<br>
anhydrous THF (15 mL) was added lithium bis(trimethylsilyl) amide (6.8 mL, 1.0 M<br>
solution in THF) at -40C under nitrogen over a period of 15 min.. Stirring was<br>
continued at -40C for 15 min. A solution of ethyl-2-methoxynicotinate in<br>
anhydrous THF (15 mL) was added slowly. Stirring was continued at -40C for 10<br>
min, then allowed to warm to room temperature. Stirring was continued for<br>
another 15 h at room temperature. The reaction mixture was diluted with ethyl<br>
-78-<br><br>
acetate (200 mL). A saturated aqueous NH4CI solution (50 ml_) was added. The<br>
organic layer was separated and dried over anhydrous Na2S04. Removal of<br>
solvent gave the desired crude compound (2.4 g) which was used in next step<br>
without purification. The above compound (2.31 g, 5.6 mmol) and pyridinium<br>
hydrochloride (6.47 g, 56 mmol) was mixed together and stirred at 190C for 3<br>
hours. The mixture was cooled to room temperature. Water (100 mL) was added.<br>
The solid was isolated, washed with water and dried under vacuum. The crude<br>
product was purified by column chromatography (SilicaGel 230-400 mesh; 2%<br>
methanol in CH2CI2 as eluent) to give the desired intermediate (0.598 g, 40% over<br>
two steps) as an off-white solid. To a solution of the desired intermediate (0.53 g,<br>
2.0 mmol) in anhydrous DMF (10 mL) sodium hydride (0.88 g, 2.2 mmol) was<br>
added in portions. The reaction mixture was stirred at room temperature for 10<br>
min. Ethyl-2-bromo acetate (0.367 g, 2.2 mmol) was added and stirring was<br>
continued at room temperature for 15 h under nitrogen. Water (30 mL) was added,<br>
and the solid was filtered off, washed with water and dried under vacuum to give<br>
[2,6-dimethyl-4-(4-oxo-4H-pyrano[2,3-b]pyridin-2-yl)phenoxy]aceticacid ethyl<br>
ester (0.69 g, 97%). The above compound (0.35 g, 1.0 mmol) was suspended in<br>
THF (10 mL). An aqueous solution of sodium hydroxide (0.08 g, 2.0 mmol) in<br>
water (1 mL) was added and the mixture was stirred at room temperature for 24 h<br>
(progress of the reaction was monitored by TLC). The solvent was evaporated to<br>
dryness. The crude compound was washed with THF. The residue was dissolved<br>
in water (10 mL) and acidified to pH -2. The formed precipitate was filtered off<br>
and dried under vacuum the crude compound was purified by column<br>
chromatography (Silica Gel 230-400 mesh; 5% MeOH in CH2CI2 as eluent) to give<br>
2-(2,6-dimethyl-4-(4-oxo-4H-pyrano[2,3-b]pyridin-2-yl)phenoxy)acetic acid (0.21 g,<br>
64%) as pale yellow solid; MS (ES) m/z: 326.91 (M+1), 325.90 (M); MP 280C at<br>
decomposition.<br>
-79-<br><br>
Example 30: 2-(pyridin-4~yl)-4H-pyrano[2,3-b]pyridin-4-one hydrochloride<br><br>
[0193] In a dry 250 ml_ round bottom flask NaH (519 mg, 12.98 mmol,<br>
60% in mineral oil) was added in DMF (10 ml_). 4-Acetyl pyridine (1.43 g, 11.8<br>
mmol) in dry DMF (5 ml_) was added dropwise at 0C over 30 min. The reaction<br>
mixture was stirred for 1 h at room temperature. Methyl 2-methoxynicotinate (1.98<br>
g, 11.8 mmol) dissolved in dry DMF (5 ml_) was added slowly on cooling. After<br>
addition, the mixture was stirred for 16 h at room temperature. The reaction<br>
mixture was quenched by addition of a saturated aqueous NH4CI solution and<br>
diluted with water. The product was extracted with ethyl acetate and the<br>
combined organic layers were washed with water, brine, dried over Na2S04 and<br>
concentrated to give 350 mg of the crude diketone. The diketone (350 mg, 1.36<br>
mmol) and polyphosphoric acid (5 g) were placed in a 50 ml_ flask and the mixture<br>
was heated at 100C for 1 hours. The reaction flask was cooled to room<br>
temperature, the mixture was diluted with water, neutralized with 1 N NaOH<br>
solution and extracted with ethyl acetate. The combined organic layers were<br>
washed with water, brine, dried over Na2SO4 and concentrated to give the crude<br>
product, which dissolved in CH2CI2 and treated with 2N HCI solution in ether. The<br>
solids were dissolved in CH2CI2 (10 ml_) and 2N HCI solution in ether was added.<br>
The solids were filtered and dried to give 2-(pyridin-4-yl)-4H-pyrano[2,3-b]pyridin-<br>
4-one hydrochloride (134 mg, 38 %); MS (ES) m/z: 224.90 (M); MP 248-250C.<br>
Example 31:2-(3,5-dimethyl-4-(2-morpholinoethoxy)phenyl)-4H-pyrano[2,3-<br>
b]pyridin-4-one hydrochloride<br>
-80-<br><br><br>
[0194] Ethyl-2-chloronicotinate (11.1 g, 60 mmol) was dissolved in<br>
anhydrous methanol (60 ml_). Sodium methoxide (18 mL, 25 wt% in methanol)<br>
was added slowly at room temperature under nitrogen. The reaction mixture was<br>
stirred under reflux for 15h. The methanol was removed under vacuum. The<br>
residue was taken into ethyl acetate (200 mL). The organic layer was washed with<br>
a saturated aqueous NH4CI solution (1x100 mL) and brine (50 mL), and dried over<br>
anhydrous Na2S04. Removal of solvent gave ethyi-2-rfiethoxynicotinate (9.9 g,<br>
91 %) as yellow oil. To a solution of 3,5-dimethyl-4-hydroxyacetophenone (2.5g,<br>
15 mmol) in anhydrous DMF (75 mL) was added imidazole (3.3 g, 48 mmol) and<br>
ferf-butyldimethylsilylchloride (2.7 g, 18 mmol). The reaction mixture was stirred at<br>
room temperature under nitrogen for 15 hours. Water (200 mL) was added. The<br>
mixture was extracted with ethyl acetate (200 mL). The organic layer was washed<br>
with water (2*100 mL), brine (100 mL), and dried over anhydrous Na2S04.<br>
Removal of solvent gave a colorless oil in quantitative yield (4.4 g). To a stirred<br>
solution of the 3,5-dimethyl-4-terf-butyldimethylsilyloxy acetophenone (1.6 g, 5.6<br>
mmol) in anhydrous THF (15 mL) was added lithium bis(trimethylsilyl) amide (6.8<br>
mL, 1.0 M solution in THF) at -40C over a period of 15 min. under nitrogen. The<br>
stirring continued at -40C for 15 min. A solution of ethyl-2-methoxynicotinate in<br>
anhydrous THF (15 mL) was added slowly. The stirring was continued at -40C for<br>
10 min. Then allowed to warm to room temperature and stirred for another 15 h at<br>
room temperature. The reaction mixture was diluted with ethyl acetate (200 mL).<br>
A saturated aqueous NH4CI solution (50 mL) was added. The organic layer was<br>
separated and dried over anhydrous Na2S04. Removal of solvent gave the crude<br>
product (2.4 g), which was used in next step without purification. The above<br>
compound (2.3Tg, 5.6 mmol) and pyridinium hydrochloride (6.5 g, 56 mmol) was<br>
mixed together and stirred at 190C for 3 hours. The mixture was cooled to room<br>
temperature and water (100 mL) was added. The solid was separated by filtration,<br>
washed with water and dried under vacuum. The crude product was purified by<br>
-81-<br><br>
column chromatography (SilicaGel 230-400 mesh; 2% methanol in CH2CI2 as<br>
eluent) to give the desired intermediate in (0.6 g, 40% yield from two steps) as an<br>
off-white solid. To a solution of the desired intermediate (0.86 g, 3.2 mmol) in<br>
anhydrous DMF (20 mL) was added sodium hydride (0.180 g, 4.49 mmol, 60%<br>
suspension in mineral oil) in small portions and stirred for 15 min. under nitrogen.<br>
A solution of 1-chloro-2-iodoethane (0.765g, 4.02 mmol) in anhydrous DMF (5 mL)<br>
was added dropwise. The reaction mixture was stirred for 3 days (progress of the<br>
reaction mixture was monitored by TLC). Water (100 mL) was added. The<br>
mixture was extracted with THF and ethyl acetate (1:2,150 mL). The organic layer<br>
was washed with brine (50 mL) and dried over anhydrous Na2S04. The crude<br>
material was purified by column chromatography (Silica Gel 230-400 mesh; 2-5%<br>
MeOH in CH2CI2 as eluent) to give~2-[-(2-chloroethoxy)-3,5-<br>
dimethylphenyl]pyrano[2,3-b]pyridine-4-one (0.4g, 38%) of as a pale yellow solid.<br>
The above compound (0.19 g, 0.58 mmol) was dissolved in anhydrous DMSO (5<br>
mL). Morpholine (0.25 g, 2.9 mmol) and triethylamine (0.29 g, 2.9 mmol) were<br>
added and the reaction mixture was stirred at 110C for 15h. The reaction mixture<br>
was cooled to room temperature and water (20 mL) was added. A solid<br>
precipitated out and was isolated by filtration. It was washed with water and dried<br>
under vacuum. The crude compound was purified by column chromatography<br>
(Silica Gel 230-400 mesh; 2-5% MeOH in CH2CI2 as eluent) to give 2-[3,5-<br>
dimethyl-4-(2-morpholin-4-yI-ethoxy)phenyl]pyrano[2,3-b]pyridine-4-one (0.11 g ,<br>
50%) as a pale yellow solid. To a solution of above compound (0.098 g, 0.26<br>
mmol) in anhydrous CH2CI2 (5 mL) was added hydrogen chloride (1 mL, 1.0 M<br>
solution in ether) dropwise. The reaction mixture was stirred at room temperature<br>
for 2 hours. The solvent was removed and the solid was triturated with 10%<br>
methanol in ether to give 2-(3,5-dimethyl-4-(2-morpholinoethoxy)phenyl)-4H-<br>
pyrano[2,3-b]pyridin-4-one (0.09 g , 77%) as the hydrochloride; MS (ES) m/z:<br>
381.03 (M+1); MP 276-278C.<br>
-82-<br><br><br>
Example 32: 2-(3-Bromo-4-hydroxyphenyl)-4H-pyrano[2,3-b]pyridin-4-one<br>
[0195] Sodium methoxide (18 ml_, 25 wt% in methanol) was added slowly<br>
to a solution of ethyl-2-chloronicotinate (11.14 g 60 mmol) in anhydrous methanol<br>
(60 ml_). The reaction mixture was stirred under reflux for 15 h, then cooled to<br>
room temperature. The methanol was removed in vacuo. The residue was<br>
dissolved in EtOAc (200 mL) and sat. ammonium chloride solution (50 ml_) was<br>
added. The organic layer was separated and dried over anhydrous Na2S04.<br>
Removal of solvent gave ethyl-2-methoxynicotinate (8.58 g, 79%) as yellow oil.<br>
Sodium hydride (0.21 g, 60% in mineral oil, 5.16 mmol) was mixed with anhydrous<br>
DMF (5 mL). A solution of 3'-bromo-4'-methoxyacetophenone (0.99 g, 4.3 mmol)<br>
in anhydrous DMF (3 mL) was added drop-wise at 0C under nitrogen. The<br>
mixture was stirred at 0C for 5 min. and then at room temperature for 30 min. The<br>
mixture was cooled to 0C. A solution of ethyl 2-methoxy nicotinate (1.81 g, 10<br>
mmol) in anhydrous DMF (3 mL) was added slowly. The ice bath was removed<br>
and the stirring continued at room temperature under nitrogen for 20 hours. Water<br>
(20 mL) was added and the mixture was extracted with EtOAc (2x100 mL). The<br>
organic layer was washed with brine and dried over anhydrous Na2S04- Removal<br>
of the solvent gave a dark solid. Triturating with ether gave a yellow solid (1.32 g,<br>
84%). The solid (1.31g, 3.6 mmol) and pyridinium hydrochloride (6.24g, 54 mmol)<br>
were mixed together and stirred at 190C for 3 h, The reaction mixture was then<br>
cooled to room temperature, followed by the addition of water (200 mL). The solid<br>
was isolated by filtration, washed with water and dried under vacuum. The crude<br>
compound was purified by column chromatography (Silica Gel 230-400 mesh;<br>
5:4:1 hexanes, EtOAc and methanol as an eluent) to give 2-(3-bromo-4-<br>
hydroxyphenyl)-4H-pyrano[2,3-/)]pyridin-4-one (0.453 g, 40%) of as yellow solid.<br>
MS (ES) m/z: 317.84, 239.9; Mp. 267-272C.<br>
-83-<br><br><br>
Example 33: 2-(4-hydroxy-3,5-dimethylphenyl)-6-(pyrrolidin-1-ylmethyl)-4H-<br>
pyrano[2,3-b]pyridin-4-onedihydrochloride<br>
[0196] A solution of oxalyl chloride (32.8 g, 0.258 mol) in 1,2-<br>
dichloroethane (50 ml_) was added dropwise to a stirred, cooled (0C) solution of<br>
dimethylformamide (43.2 g, 0.591 mol) in 1,2-dichloroethane (70 ml_) so that the<br>
temperature of the reaction mixture did not exceed 10C. The resulting mixture<br>
was stirred at 0-5C for a furtherl .75 hours then allowed to reach room<br>
temperature. 2-Methylmalonic acid (14.0 g, 0.118 mol) was added to the stirred<br>
mixture. The mixture was stirred at reflux temperature for 6 hours then at room<br>
temperature overnight. The solvent was evaporated (keeping bath temperature at<br>
25C or less) and replaced with dry methanol. Methylcyanoacetate (12.9 g, 0.130<br>
mol) was added and the mixture was stirred. Sodium methoxide (86.6 ml_, 25% in<br>
methanol) was added ensuring that the reaction mixture temperature did not<br>
exceed 30C. The cooled mixture was stirred for 30 min. then at room<br>
temperature for 3.5 hours. T solvent was removed by evaporation and replaced<br>
with dichloroethane. The mixture was washed with water, dried and evaporated.<br>
The crude product was triturated with cold methanol (30 ml_) to yield the desired<br>
methyl 5-(N, A/-dimethylamino)-2-cyano-4-methylpent-2,4-dienoate (17.0 g,<br>
66.0%) as a yellow solid. MP 163-164C. Hydrogen chloride gas was bubbled<br>
through a suspension of methyl 5-(N, A/-dimethylamino)-2-cyano-4-methylpent-<br>
2,4-dienoate (17.0 g, 0.078 mol) in 1,2-dichloroethane for 6- hours. Further<br>
saturation of the suspension with HCI gas was followed by stirring at room<br>
temperature overnight. Excess HCI was blown out of the reaction mixture with<br>
nitrogen gas. The mixture was washed with water, dried and evaporated. The<br>
resulting oil crystallized on standing to yield an orange solid (14.4 g, 99%). The<br>
orange solid (14.0 g, 0.0754 mol) in anhydrous methanol (40 ml_) was added to a<br>
250 mL dry flask with reflux condenser. Sodium methoxide (31 ml_, 0.14 mol, 25%<br>
-84-<br><br>
in methanol) was added to the solution and the reaction was carried out at reflux<br>
overnight. Acetic acid was added to the mixture until pH 7.0 and the methanol was<br>
removed. The residue was poured into water and extracted with dichloromethane.<br>
The organic layer was further washed with water, brine and dried over sodium<br>
sulfate. Dichloromethane was removed to yield the desired intermediate (13.5 g,<br>
98.0%). The intermediate (8.65g, 0.048 mol) was dissolved in dry carbon<br>
tetrachloride (80 mL) and NBS (8.95 g, 0.050 mol) was added. The reaction<br>
mixture was heated to reflux under a lamp for 3 hour. After cooling, the solvent<br>
was removed and the residue was further washed with hot water to get ride of the<br>
succinimide. The solid was purified by column (DCM: ethyl acetate 30:1) to yield<br>
the desired intermediate (7.77 g, 62.2%). The intermediate (0.85 g, 0.00327 mol),<br>
pyrrolidine (0.93-g, 0.0131 mol) and anhydrous THF (10 mL) was heated to reflux<br>
for 2 hours. The solvent was evaporated. The residue was purified by column<br>
(ethyl acetate to ethyl acetate : MeOH 9:1) to give the desired advanced<br>
intermediate (0.60 g, 73.4%). 3,5-Dimethyl-4-hydroxyacetophenone (5.3 g, 0.032<br>
mol) and dry DMF (12 mL) was charged in a 100 mL flask. Sodium hydride (1.28<br>
g, 0.032 mol, 60% in mineral oil) was added followed by benzyl bromide (4.0 mL,<br>
0.032 mol) and the reaction mixture was kept stirring for overnight. The reaction<br>
mixture was poured into water (150 mL) and dichloromethane (150 mL) was<br>
added. The organic phase was separated and further washed with water (3x120<br>
mL), brine and dried over sodium sulfate. The DCM was removed and the desired<br>
compound was solidified and further washed with hexane to yield the desired<br>
building block (7.30 g, 89.7%). The advanced intermediate from above (0.60 g,<br>
0.0024 mol) and the building block described above (0.61 g, 0.0024 mol) were<br>
added to a 50 mL flask with anhydrous DMF (5 mL). Sodium hydride (0.2 g, 60%<br>
in mineral oil) was added and the reaction mixture was kept overnight at room<br>
temperature. The mixture was poured into water (80 mL) and extracted with DCM<br>
(3 x 80 mL) after pH was adjusted to 7.0. The organic phase was further washed<br>
with water, brine and dried over sodium sulfate. Evaporation of the solvent left 1.0<br>
g (88.2%) of the crude product. The crude product (1.0 g, 0.0021 mol) and<br>
pyridine hydrogen chloride (2.0 g, 0.0169 mol) were mixed in a 50 mL flask and<br>
heat to 190C for 4 h. The mixture was cooled and poured into methanol (8 mL),<br>
then filtered. The collected solid was further washed with ethyl acetate and dry to<br>
-85-<br><br>
get the hydrochloride 2-(4-hydroxy-3,5-dimethylphenyl)-6-(pyrrolidin-1-ylmethyl)-<br>
4H-pyrano[2,3-b]pyridin-4-one dihydrochloride (0.50 g, 58.7%); MS (ES) m/z:<br>
351.03(M);MP337-338C.<br>
Example 34: 5,7-dimethoxy-2-(pyridin-4-yl)-4H-chromen-4-one hydrochloride<br><br>
[0197] To a mixture of 2-hydroxy-4,6-dimethoxy acetophenone (2.00 g,<br>
10.2 mmol), isonicotinic acid (1.25 g, 10.2 mmol) in pyridine (30 ml_) was added<br>
POCI3 (1.72 g, 11.2 mmol) slowly at 0 C. The reaction was stirred at room<br>
temperature for 16 hours. Water (50 ml_) was added, and the solid was separated<br>
by filtration and dried to give isonicotinic acid-2-acetyl-3,5-dimethoxyphenyl ester<br>
(2.72 g, 86%).<br>
[0198] To a solution of isonicotinic acid-2-acetyl-3,5-dimethoxyphenyl<br>
ester (2.72 g, 9.03 mmol) in anhydrous THF (50 mL) was added potassium tert-<br>
butoxide (1.21 g, 10.8 mmol) in small portions. The reaction mixture was stirred at<br>
room temperature for 24 hours. A sat. NH4CI solution (20 mL) was added. The<br>
organic layer was separated and aqueous phase was extracted with ethyl acetate<br>
(100 mL). The combined organic phase were washed with water, brine and dried<br>
over anhydrous Na2S04. Removal of solvent gave 1-(2-hydroxy-4,6-<br>
dimethoxyphenyl)-3-pyridin-4-yl-propane-1,3-dione (2.4 g, 88%). To a mixture of<br>
1-(2-hydroxy-4,6-dimethoxyphenyl)-3-pyridin-4-yl-propane-1,3-dione (2.4 g, 7.96<br>
mmol) acetic acid (10 mL) and cone. HCI (1 mL) was heated at 100 C for 1 hours.<br>
The reaction mixture was cooled to room temperature, diluted with water,<br>
neutralized with a sat. aqueous NaHC03 solution. The solid was filtered off and<br>
dissolved in CH2CI2 (120 mL) and hydrogen chloride in ether (5 mL, 2.0M solution)<br>
was added. The formed solid was isolated by filtration, washed with 10%<br>
methanol in ether and ether to give 5,7-dimethoxy-2-(pyridin-4-yl)-4H-chromen-4-<br>
-86-<br><br>
one hydrochloride (0.335 g, 13%) as a yellow solid; MS (ES) m/z: 283.94 (M); MP<br>
234-235C<br>
Example 35: 2-phenyl-6-(pyrro!idin-1 -ylmethyl)-4H-pyrano[2,3-b]pyridin-4-one<br>
hydrochloride<br><br>
[019.9L..A solution of oxalyl chloride (32.8 g, 0.258 mol) in 1,2-<br>
dichloroethane (50 ml_) was added dropwise to a stirred, cooled (0C) solution of<br>
dimethylformamide (43.2 g, 0.59 mol) in 1,2-dichloroethane (70 ml_) so that the<br>
temperature of the reaction mixture did not exceed 10C. The resulting mixture<br>
was stirred at 0-5C for 1.75 hours then allowed to reach room temperature. 2-<br>
Methylmalonic acid (14.0 g, 0.12 mol) was added to the stirred mixture. When gas<br>
evolution ceased, the mixture was stirred at reflux temperature for 6 hours then at<br>
room temperature overnight. The solvent was evaporated (keeping bath<br>
temperature at 25C or less) and replaced with dry methanol. Methylcyanoacetate<br>
(12.86 g, 0.130 mol) was added and the mixture was stirred. Sodium methoxide<br>
(86.6 mL 25% in methanol) was added ensuring that the reaction mixture<br>
temperature did not exceed 30C. The cooled mixture was stirred for 30 min. then<br>
at room temperature for 3.5 hours. The solvent was removed by evaporation and<br>
replaced with dichloroethane. The mixture was then washed with water, dried and<br>
concentrated. The crude product was triturated with cold methanol (30 mL) to<br>
yield methyl 5-(N, A/-dimethylamino)-2-cyano-4-methylpent-2,4-dienoate as a<br>
yellow solid (17.0 g 66%). M. p. 163-164C. Hydrogen chloride gas was bubbled<br>
through a suspension of methyl 5-(N, A/-dimethylamino)-2-cyano-4-methylpent-<br>
2,4-dienoate (17.0 g, 0.078 mol) in 1,2-dichloroethane for 6 hours. Further<br>
saturation of the suspension with HCI gas was followed by stirring at room<br>
temperature overnight. Excess HCI was blown out of the reaction mixture with<br>
nitrogen gas. The mixture was washed with water, dried and concentrated. The<br>
-87-<br><br>
resulting oil crystallized on standing to yield an orange solid (14.4 g, 99%). The<br>
orange solid (14.0 g, 0.075 mol) was dissolved in anhydrous methanol (40 mL) in<br>
a 250 mL dry flask with reflux condenser. Sodium methoxide (31 mL, 0.143 mol,<br>
25% in methanol) was added to the solution and the reaction was carried out at<br>
reflux overnight. Acetic acid was added to the mixture to pH 7.0 and methanol was<br>
removed. The residue was poured into water and extracted with dichloromethane.<br>
The organic layer was further washed with water, brine and dried over sodium<br>
sulfate. Dichloromethane was removed to yield the desired intermediate (13.5 g,<br>
98.0%). The intermediate (8.65g, 0.048 mol) was dissolved in dry carbon<br>
tetrachloride (80 mL) followed by addition of NBS (8.95 g, 0.050 mol). The<br>
reaction mixture was heated to reflux under a lamp for 3 hour. After cooling the<br>
solvent was removed and the residue was further washed with hot water to get<br>
ride of succinimide. The solid was then purified by column (DCM: ethyl acetate<br>
30:1) to yield the desired intermediate (7.77 g, 62.2%). A mixture of the<br>
intermediate (4.4 g, 0.017 mol), pyrrolidine (4.81 g, 0.068 mol) and anhydrous<br>
THF (20 mL) was heated to reflux for 2 hours. The solvent was evaporated. The<br>
residue was purified by column (ethyl acetate to ethyl acetate : MeOH 9:1) to give<br>
the desired intermediate (3.50 g, 82.8%). The intermediate (0.50 g, 0.002 mol)<br>
and acetophenone (0.24 g, 0.002 mol) were added to a 50 mL flask with<br>
anhydrous DMF (4 mL). Sodium hydride (0.16 g, 60% in mineral oil) was added<br>
and the reaction mixture was kept overnight at room temperature. The mixture<br>
was poured into water (80 mL) and extracted with DCM (3 * 80 mL) after pH was<br>
adjusted to 7.0. The organic layer was further washed with water and brine. The<br>
organic layer was dried over sodium sulfate and concentrated to yield the desired<br>
intermediate (0.45 g, 66.5%). A 50 mL flask was charged with the intermediate<br>
(0.45 g, 0.00133 mol) and pyridine hydrogen chloride (1.54 g, 0.0133 mol) and<br>
heat to 190C for 1 h. The mixture was cooled and poured into methanol (4 mL)<br>
then filtered, the collected solid was further washed with ethyl acetate and dried to<br>
give 2-phenyl-6-(pyrrolidin-1-ylmethyl)-4H-pyrano[2,3-b]pyridin-4-one (0.190 g,<br>
41.7%) as the hydrochloride salt. MS (ES) m/z: 306 (M); MP 294-296C<br>
-88-<br><br>
Example 36: 6-(4-oxo-4H-chromen-2-yl)benzo[d]oxazol-2(3H)-one<br><br>
[0200] Step 1: To a round bottomed flask was added methyl 4-amino-3-<br>
hydroxybenzoate (4.0 g, 23.9 mmol) under nitrogen. Dry dichloromethane (100<br>
mL) was added with stirring. Triethyl amine (7.3 ml_, 52.6 mmol) was added,<br>
followed-by slow addition of triphosgene (2.84 g, 9.56 mmol). The reaction mixture<br>
was stirred at room temperature overnight. The solvent was evaporated and the<br>
reaction mixture was diluted with ethyl acetate. The organic layer was washed<br>
successively with water, diluted sodium bicarbonate, water, 1N HCI, water, brine<br>
and dried over sodium sulfate. The solvent was evaporated in vacuo to leave a<br>
residue, which was recrystallized from ethyl acetate and hexane afforded 3.4 g<br>
(81%) of desired intermediate.<br>
[0201] Step 2: The product (1.64 g, 8.47 mmol) from step 1 was dissolved<br>
in a mixture of methanol (5 mL) and tetrahydrofuran 5 mL. Potassium hydroxide<br>
(1.25 g, 22.28 mmol) in water (6 mL) was added. The reaction mixture was<br>
refluxed at 70C for 3 days and 80C for 2 days. The solvent was evaporated in<br>
vacuo. Water was added and the reaction mixture was acidified with 1N HCI (pH<br>
4-5) and extracted with ethyl acetate. The solvent was evaporated in vacuo to<br>
leave 1.43 g (94%) of pure compound. The compound was used for the following<br>
reaction without further purification.<br>
[0202] Step 3: The product from step 2 (0.108 g, 0.6 mmol) and 2-<br>
hydroxyacetophenone (0.09 g, 0.66 mmol) were added to a round bottomed flask<br>
under nitrogen. Anhydrous pyridine (5 mL was added to it with stirring. The<br>
reaction mixture was cooled down using an ice bath. Phosphorus oxychloride<br>
(0.15 g, 0.99 mmol) was added and the reaction mixture was stirred at room<br>
temperature overnight. Pyridine was removed under vacuum and the residue was<br>
acidified with 1N HCI (pH 4-5) and extracted with ethyl acetate. The solvent was<br>
-89-<br><br>
evaporated in vacuo to leave a residue which was purified by silica gel column<br>
chromatography (15 g). The eluent was a mixture of ethyl acetate and hexane in<br>
1:1. Fraction 1 was evaporated affording pure compound (0.0192 g, 11%).<br>
[0203] Step 4: The product from step 3 (0.25 g, 0.84 mmol) was taken in a<br>
three-necked round bottomed flask under nitrogen. Anhydrous tetrahydrofuran (15<br>
mL) was added, followed by potassium ferf-butoxide (0.142 g, 1.26 mmol). The<br>
reaction mixture was stirred at room temperature for 24 hours. Water (20 mL) was<br>
added and the reaction mixture was quenched with 1N HCI and extracted with<br>
ethyl acetate. The solvent was evaporated in vacuo to leave a residue, which was<br>
purified by silica gel column chromatography (25 g) using gradient elution<br>
technique (20%-50% ethyl acetate in hexane), giving the desired compound<br>
(0.183 g, 73%).<br>
[0204] Step 5: The compound from step 4 (0.18 g, 0.61 mmol) was<br>
dissolved in acetic acid (30 mL), followed by addition of cone. HCI (2 mL). The<br>
reaction mixture was refluxed for 2 hours (bath temp. 130C). Acetic acid was<br>
evaporated in vacuo and water was added. The solid was filtered off and dried<br>
under vacuum to give 6-(4-oxo-4H-chromen-2-yl)benzo[d]oxazol-2(3H)-one (0.119<br>
g, 70%); MS (ES) m/z: 279.84 (M); MP 347.6-348.2C<br>
Example 37: 2-(4-fluorophenyl)-6-(pyrrolidin-1 -ylmethyl)-4H-pyrano[2,3-b]pyridin-<br>
4-one hydrochloride<br><br>
[0205] To a stirred solution of 2-methoxy-5-pyrrolidin-1-ylmethyl nicotinic<br>
acid methyl ester (0.5 g, 2.0 mmol) and 1-(4-fluorophenyl) ethanone (0.276 g, 2.0<br>
mmol) in anhydrous DMF (3 mL), sodium hydride (0.160 g, 2.0 mmol, 60%<br>
suspension in mineral oil) was added in small portions under nitrogen. The<br>
reaction mixture was stirred overnight at room temperature. A saturated aqueous<br>
NH4CI solution (30 mL) was added. The mixture was extracted with ethyl acetate<br>
-90-<br><br>
(100 ml_). The organic layer was washed with water (30 ml_) and brine (30 mL),<br>
and dried over anhydrous Na2S04. Removal of solvent gave a brown solid (0.45<br>
g) which was used in next step without further purification. The above compound<br>
(0.45 g, 1.26 mmol) and pyridine hydrochloride (1.6 g, 12.6 mmol) were mixed<br>
together and stirred at 190C for 4 hours. Cooled to room temperature. Water (10<br>
mL) was added, neutralized to pH ~9 with sat. aqueous NaHCC
solid was separated by filtration. The solid was dissolved in 1:1 CH2CI2 -<br>
methanol (5 mL). Hydrogen chloride in ether (1 mL, 1.0M solution) was added and<br>
the reaction mixture was stirred at room temperature for 1 hours. The solvent was<br>
removed under reduced pressure. The residue was triturated with 10% methanol<br>
in ether to give 2-(4-fiuorophenyl)-6-(pyrrolidin-1-ylmethyl)-4H-pyrano[2,3-<br>
b]pyridin-4-one hydrochloride (205 mg, 51%) as yellow solid. -MS (ES) m/z:<br>
324.89 (M); MP 265-268C<br>
Example 38: 2-(4-aminophenyl)-4H-pyrano[2,3-b]pyridin-4-one hydrochloride<br><br>
[0206] To a solution of 2-(4-amino phenyl) pyrano[2,3-b]pyridine-4-one<br>
(0.115 g, 0.483 mmol) in dichloromethane (10 mL) and methanol (1 mL) was<br>
added of hydrogen chloride in ether (1.0 mL, 1.0M solution) dropwise. A orange<br>
precipitate was formed. Stirred under nitrogen for 1 hours. The solvent was<br>
removed and the solid was triturated with 10% methanol in ether to give 2-(4-<br>
aminophenyl)-4H-pyrano[2,3-b]pyridin-4-one (0.13 g, 98%) as the orange<br>
hydrochloride; MS (ES) m/z: 238 (M); MP 254-255C<br>
-91 -<br><br>
Example 39: 2-(4-isopropoxyphenyl)-6-(pyrroHdin-1-ylmethyl)-4H-pyrano[2,3-<br>
b]pyridin-4-one hydrochloride<br><br>
[0207] Sodium hydride (1.32 g, 33 mmol, 60% suspension in mineral oil)<br>
was suspended in anhydrous DMF (20 ml_). A solution of 4-hydroxy<br>
acetophenone (4.08 g, 30 mmol) in anhydrous DMF (20 ml_) was added dropwise<br>
at room temperature. The reaction mixture was stirred at room temperature for 30<br>
min. A solution of 2-bromopropane (4.61 g, 37.5 mmol) in anhydrous DMF (10<br>
ml_) was added slowly. The reaction mixture was stirred at room temperature<br>
overnight. Water (100 mL) was added. The mixture was extracted with ethyl<br>
acetate (2&gt;
brine (50 mL). Dried over anhydrous Na2SO4. Removal of solvent gave 1-(4-<br>
isopropoxy phenyl) ethanone as a pale yellow solid (3.52 g, 66%). To a stirred<br>
solution of 2-methoxy-5-pyrrolidin-1-ylmethyI nicotinic acid methyl ester (0.5 g, 2.0<br>
mmol) and 1-(4-isopropoxy phenyl) ethanone in anhydrous DMF (10 mL), sodium<br>
hydride (96 mg, 2.4 mmol, 60% suspension in mineral oil) was added in small<br>
portions under nitrogen. The reaction mixture was stirred overnight at room<br>
temperature. Reaction mixture was stirred at 80C for 1 hours. Water (30 mL) was<br>
added. The mixture was extracted with chloroform (150 mL). The organic layer<br>
was washed with water (30 mL) and brine (30 mL). Dried over anhydrous Na2SO4.<br>
Removal of solvent gave brown solid (0.66 g) which was used in next step without<br>
further purification. The above solid (0.626 g, 1.58 mmol) and pyridine<br>
hydrochloride (1.18 g, 15.8 mmol) were mixed together and stirred at 190C for 20<br>
min. Cooled to room temperature. Water (10 mL) was added, neutralized to pH<br>
~9. The mixture was extracted with chloroform (2x100 mL). The organic layer was<br>
washed with brine (50 mL) and dried (Na2S04). Removal of the solvent gave 2-(4-<br>
isopropoxy phenyl)-6-pyrrolidin-1-ylmethyl pyrano[2,3-b]pyridine-4-one (0.237 g,<br>
41%) as yellow solid. To a soiution of the above compound in anhydrous CH2CI2<br>
-92-<br><br>
(10 mL) was added 1.0 M solution of hydrogen chloride in ether dropwise. The<br>
reaction mixture was stirred for 10 min. The solvent was removed under reduced<br>
pressure. The residue was washed with hexane and ether. Purified by triturating<br>
with 10% methanol in ether to give 2-(4-isopropoxyphenyl)-6-(pyrrolidin-1-<br>
ylmethyl)-4H-pyrano[2,3-b]pyridin-4-one hydrochloride (0.20 g, 83%) as yellow<br>
solid. MS (ES) m/z: 264 (M); MP 261-263C<br>
Example 40: 7-(4-hydroxy-3,5-dimethylphenyl)-1,6-naphthyridin-5(6H)-one<br>
hydrochloride<br><br>
[0208] Oxalyl chloride (1.90 mL, 21.8 mmol) was added to 2-methyl<br>
nicotinic acid (1.50 g, 10.9 mmol) in anhydrous dichloromethane (20 mL) with<br>
triethylamine (1.6 mL, 11.5 mmol) and the reaction mixture was kept at room<br>
temperature overnight and the solvent was removed. THF was added to the<br>
residue and ammonia gas was bubbled into for 2 hours. THF was removed and<br>
the residue was dissolved into methanol and water and adjusted pH to 10.0 by<br>
potassium carbonate and concentrated. After column chromatography the desired<br>
amide was isolated (1.10 g, 73.8%). NaH (0.428 g, 10.7 mmol, 60% in mineral oil)<br>
was added to 4-hydroxy-3,5-dimethylbenzonitrile (1.50 g, 10 mmol) in anhydrous<br>
DMF (8 mL) and then benzyl bromide (1.83 g, 10.7 mmol) was added and the<br>
reaction was kept at room temperature overnight. The reaction mixture was<br>
poured into water and filter the solid was further washed with hexane to yield the<br>
desired ether (2.0 g, 84.3%). It was used for next step reaction without further<br>
purification. The above amide (0.65 g, 4.77 mmol) in anhydrous THF (15 mL) was<br>
added dropwise to BuLi (7.5 mL, 1.60 M) at -20C. The reaction mixture was kept<br>
at this temperature for one hour and then the above described ether (1.13 g, 4.77<br>
mmol) in THF (20 mL) was added drop-wise at -20C and the reaction was further<br>
kept for 1.5 hours. The reaction temperature was increased to room temperature<br>
-93-<br><br>
and kept for another hour. Water (20 mL) was added and the mixture was stirred<br>
for a while and the solvent was removed and the residue was purified by column<br>
to yield the desired intermediate (0.50 g, 29.4%). In a 50 mL flask was charged<br>
with the above described intermediate (0.50 g, 0.0014 mol) and pyridine hydrogen<br>
chloride (2.4 g, 0.014 mol) and the mixture was heated to 180C for 1.5 hour. The<br>
mixture was cooled and poured into methanol (4 mL) then filtered. The collected<br>
solid was further washed with ethyl acetate and dried to give 7-(4-hydroxy-3,5-<br>
dimethylphenyl)-1,6-naphthyridin-5(6H)-one (350 mg, 82.7%) as the hydrochloride<br>
salt; MS (ES) m/z: 266 (M); MP &gt;350C<br>
Example 41: 2-hydroxy-7-(4-hydroxy-3,5-dimethylphenyl)-4-methoxy-1,6-<br>
naphthyridin-5(6H)-one dihydrochioride<br><br>
[0209] A mixture of malonic acid (20 g, 192 mmol), 2,4,6-trichlorophenol<br>
(72 g, 365 mmol), and phosphorus oxychloride (38 mL, 403.2 mmol) was stirred at<br>
reflux for 12 hours. The reaction mixture was cooled to 70C and poured into ice<br>
water. The solid was collected by filtration, washed with water, and air dried to<br>
give malonic acid bis-(2,4,6-trichloro-phenyl) ester (85 g, 95%). A solution of<br>
malonic acid bis-(2,4,6-trich!oro-phenyl) ester (85 g, 183.6 mmol) and ethyl 3-<br>
aminocrotonate (26.1 g, 202 mmol) in bromobenzene (100 mL) was stirred at<br>
reflux for 50 min. The reaction mixture was cooled to 50C and diluted with EtOAc<br>
(260 mL). The solid was collected by filtration, washed with water, and air dried to<br>
give 4,6-dihydroxy-2-methyl nicotinic acid ethyl ester (31 g, 86%).<br>
[0210] A solution of 4,6-dihydroxy-2-methyl nicotinic acid ethyl ester (31 g,<br>
157 mmol) in phosphorus oxychloride (60 mL, 629 mmol) was stirred at reflux for<br>
1.5 hours. The extra phosphorus oxychloride was removed using a rotary<br>
evaporator and the reaction mixture was purred into icy water. The solid was<br>
-94-<br><br>
removed by filtration. The filtrate was extracted with dichloromethane (3x100 mL),<br>
and concentrated using a rotary evaporator. The residue was further purified by<br>
column (Si02, Hexanes/EtOAc = 5:1) to yield 4,6-dichloro-2-methyl nicotinic acid<br>
ethyl ester (16.9 g, 46%). A solution of 4,6-dichloro-2-methyl nicotinic acid ethyl<br>
ester (16.9 g, 71.3 mmol) in MeOH (60 mL) was mixed with sodium methoxide (58<br>
mL, 257 mmol) and stirred at reflux for 12 hours. The reaction was quenched by<br>
adding AcOH (50 mL), diluted with water (200 mL), extracted with<br>
dichloromethane (3x100 mL), and concentrated using a rotary evaporator. The<br>
residue was further purified by column (Si02, Hexanes/EtOAc = 6:1) to yield 4,6-<br>
dimethoxy-2-methyl nicotinic acid methyl ester (10 g, 67%). A solution of 4,6-<br>
dimethoxy-2-methyl nicotinic acid methyl ester (2.6 g, 12.3 mmol) and lithium<br>
hydroxide (1.06 g, 44.1 mmol) in water (40 mL), MeOH (30 mL) and THF (20 mL)<br>
was stirred at reflux for 4 hours. The reaction mixture was concentrated using a<br>
rotary evaporator to dryness. The residue was mixed with HCI (cone.) (20 mL) and<br>
was concentrated again on high vacuum to dryness to yield crude 4,6-dimethoxy-<br>
2-methyl nicotinic acid (quantitative). To a solution of 4,6-dimethoxy-2-methyl<br>
nicotinic acid (2.5 g, 12.0 mmol) in dichloromethane (50 mL) and THF (50 mL) at<br>
room temperature was added oxalyl chloride (2.57 mL, 29.4 mmol) and DMF (3<br>
drops). The reaction mixture was stirred at room temperature for 30 min,<br>
concentrated to dryness using a rotary evaporator to afford 4,6-dimethoxy-2-<br>
methyl nicotinic acid chloride HCI salt (2.8 g). A solution of 4,6-dimethoxy-2-<br>
methyl nicotinic acid chloride HCI salt (8.5 g, 33.73 mmol) in dichloromethane (20<br>
mL) and THF (20 mL) at room temperature was mixed with methylamine in THF<br>
(50 mL, 98 mmol) and stirred at 20C for 1 hour. The reaction mixture was diluted<br>
with water (100 mL), extracted with dichloromethane (3x100 mL), and<br>
concentrated using a rotary evaporator to yield 4,6-dimethoxy-2,N-dimethyl-<br>
nicotinamide (4.2 g, 66%) as a light yellow solid. A solution of 4-hydroxy-3,5-<br>
dimethylbenzonitrile (2 g, 13.6 mmol) in DMF (20 mL) at room temperature was<br>
mixed with sodium hydride ( 0.706 g, 17.6 mmol) and stirred for 30 min.. Benzyl<br>
bromide (1.62 mL, 13.59 mmol) was then added and the reaction mixture was<br>
stirred at room temperature for 24 hours. The reaction was quenched by adding<br>
water (200 mL), extracted with EtOAc (3x100 mL), and concentrated using a<br>
rotary evaporator. The residue was further purified by column (SiO2,<br>
-95-<br><br>
Hexanes/EtOAc = 6:1) to yield 4-benzyloxy-3,5-dimethylbenzonitrile (3.25 g,<br>
100%) as a white solid. To a solution of 4,6-dimethoxy-2,N-dimethyl-nicotinamide<br>
(0.54 g, 2.57 mmol) in THF (50 ml_) at -20C was added n-BuLi (3.54 mL, 5.67<br>
mmol). The reaction was stirred at -20C ~ 0C for 2 hours and then was cooled to<br>
-78C. At -78C 4-benzyloxy-3,5-dimethylbenzonitrile (0.49 g, 2.057 mmol) was<br>
added, the cooling bath was removed, and the reaction was allowed to warm up<br>
gradually to room temperature. After stirring at room temperature for 14 hours the<br>
reaction was quenched by adding water (100 mL), extracted with dichloromethane<br>
(x3&gt;
further purified by column (SiO2, Hexanes/EtOAc = 1:5) to yield 7-(4-benzyloxy-<br>
3,5-dimethyl-phenyl)-2,4-dimethoxy-6H-[1,6]naphthyridin-5-one (0.32 g, 37%). A<br>
solution of 7-(4-benzyloxy-3,5-dimethy]-phenyl)-2,4-dimethoxy-6H-<br>
[1,6]naphthyridin-5-one (0.25 g, 0.6 mmol) in dichloromethane (100 mL) was<br>
mixed with BBr3 (3 mL, 3 mmol) and stirred at room temperature for 16 hours. The<br>
reaction was quenched by adding water (20 mL). The resulting solid was collected<br>
by filtration, washed with water and DCM to yield a light yellow solid. This solid<br>
was mixed with HCI in ether (10 mL, 10 mmol), stirred for 1 hour, filtered to afford<br>
2-hydroxy-7-(4-hydroxy-3,5-dimethylphenyl)-4-methoxy-1,6-naphthyridin-5(6H)-<br>
one (70 mg, 37%) as a light yellow dihydrochloride. MS (ES) m/z: 312 (M); MP<br>
&gt;330C<br>
Example 42: 3-(4-(2-hydroxy-2-methylpropoxy)-3,5-dimethyIphenyl)-6,8-<br>
dimethoxyisoquinolin-1 (2H)-one<br><br>
[0211 ] To a solution of 4-hydroxy-3,5-dimethylbenzonitrile (2.00 g, 13.5<br>
mmol) and 1-chloro-2-methyl propan-2-ol (8.85 g, 81.5 mmol) in ethanol (50 mL)<br>
was added potassium carbonate (7.5 g, 54 mmol) and water (5 mL). The reaction<br>
-96-<br><br>
mixture was stirred at reflux for 24 hours. Cooled to room temperature. The<br>
precipitated solid was filtered off and washed with water. The solid was dissolved<br>
in ethyl acetate (100 mL), washed with water (50 ml_), brine (50 ml_) and dried<br>
over anhydrous Na2S04. Removal of solvent gave 4-(2-hydroxy-2-<br>
methylpropoxy)-3,5-dimethyl benzonitrile (2.9 g, 97%) as a white solid. To a<br>
solution of 4-(2-hydroxy-2-methylpropoxy)-3,5-dimethyl benzonitrile (2.90 g, 13.2<br>
mmol) in anhydrous DMF (20 mL) was added imidazole (2.7 g, 40 mmol) and tert-<br>
butyldimethylsilylchloride (2.19 g, 14.6 mmol). The reaction mixture was stirred at<br>
room temperature under nitrogen for 3 days. Water (200 mL) was added and the<br>
mixture was extracted with ethyl acetate (200 mL). The organic layer was washed<br>
with water (2x100 mL) and brine (100 mL), and dried over anhydrous Na2SO4.<br>
The solventwas removed under reduced pressure and the crude compound was<br>
purified by column chromatography (Silica Gel 230-400 mesh; 10% ethyl acetate<br>
in hexanes as eluent) to give 4-[2-(ferf-butyldimethylsilanyloxy)-2-methylpropoxy]-<br>
3,5-dimethylbenzonitrile (2.24 g, 54%). n-Butyl lithium (6.2 mL, 6.6 mmol, 1.6 M<br>
solution in hexanes) was added to a solution of 2,4-dimethoxy-6-A/-<br>
dimethylbenzamide (0.9 g, 4.3 mmol) in anhydrous THF (10 mL) dropwise at -<br>
10C over a period of 10 min under nitrogen. The stirring was continued at 0C<br>
for 1 hour. The reaction mixture was cooled to -50C. A solution of 4-[2-(tert-<br>
butyldimethylsilanyloxy)-2-methylpropoxy]-3,5-dimethylbenzonitrile (1.58 g, 4.73<br>
mmol) in anhydrous THF (5 mL) was quickly added. The cooling bath was<br>
removed and the reaction mixture was allowed to warm to room temperature. The<br>
stirring was continued at room temperature for 1 hour. Aqueous ammonium<br>
chloride solution (10 mL) was added. Ethyl acetate (100 mL) was added. The<br>
organic layer was separated, washed with water (10 mL) and dried (Na2S04). The<br>
solvent was removed under reduced pressure and the crude compound was<br>
purified by column chromatography (Silica Gel 230-400 mesh; 0-5% methanol in<br>
CH2CI2 as eluent) to give 3-{4-[2-(terf-butyIdimethylsilanyloxy)-2-methylpropoxy]-<br>
3,5-dimethylphenyl}-6,8-dimethoxy-2H-isoquinolin-1-one (0.82 g, 37%) of as white<br>
solid. The above compound (0.42 g, 0.82 mmol) was dissolved in anhydrous THF<br>
(20 mL). Tetrabutyl ammonium fluoride (4.1 mL, 1.0M solution in THF) was added<br>
at 0C. The reaction mixture was stirred at 0C for 10 min, then at room<br>
temperature for 2 h and then stirred at 70C for 24 hours. The mixture was cooled<br>
-97-<br><br>
to room temperature. Saturated aqueous ammonium chloride (30 mL) was added.<br>
The organic phase was separated, washed with water, brine and dried over<br>
anhydrous Na2S04. The solvent was removed under reduced pressure. The<br>
crude product was purified by column chromatography (Silica Gel 230-400 mesh;<br>
0-4% methanol in CH2CI2 as eluent) to give 3-(4-(2-hydroxy-2-methylpropoxy)-3,5-<br>
dimethylphenyl)-6,8-dimethoxyisoquinolin-1(2H)-one (0.15 g, 46%) as a white<br>
solid. MS (ES) m/z: 398.96 (M+1); MP 252-254C<br>
Example 43: 2,6-dimethyl-4-(1-(methylamino)-7-((4-methylpiperazin-1-<br>
yl)methyl)isoquinolin-3-yl)phenoltrihydrochloride<br><br>
[0212] To a solution of 5-bromomethyl-2,A/-dimethylbenzamide (4.94 g, 24<br>
mmol) in anhydrous THF (75 mL) was added A/-methyipiperazine (5.3 mL, 4.81 g,<br>
48 mmol). A white precipitate was formed. Stirring continued overnight. Water<br>
(100mL) was added, and the mixture was extracted with ethyl acetate (200 mL).<br>
The organic layer was washed with brine and dried over anhydrous Na2S04.<br>
Purification by column chromatography (Silica Gel 230-400 mesh; 0-5% methanol<br>
(containing 7.0 M ammonia) in CH2CI2 as eluent) to give 2,N-dimethyl-5-(4-<br>
methylpiperazin-1-ylmethyl) benzamide (2.4 g, 38%) of as a gummy material, n-<br>
Butyl lithium (9.1 mL, 14.64 mmol, 1.6 M solution in hexanes) was added to a<br>
solution of 2,N-dimethyl-5-(4-methylpiperazin-1-ylmethyl) benzamide (0.87 g, 3.33<br>
mmol) in anhydrous THF (10 mL) dropwise at -10C over a period of 10 min under<br>
nitrogen. Color changed to orange-red. Stirring continued at 0C for 1 hour. The<br>
reaction mixture was cooled to -50C. A solution of 4-(tert-<br>
butyldimethyIsilanyloxy)-3,5-dimethylbenzonitrile (1.09 g, 4.16 mmol) in anhydrous<br>
THF (5 mL) was quickly added. Cooling bath was removed and the reaction<br>
mixture was allowed to warm to room temperature. Stirring was continued at room<br>
-98-<br><br>
temperature for 1 hour. The reaction mixture became dark colored. An aqueous<br>
ammonium chloride solution (20 mL) was added. The color changed to pale<br>
yellow. Ethyl acetate (50 mL) was added. The organic layer was separated,<br>
washed with water (10ml_) and dried (Na2SO4). Removal of the solvent gave a<br>
yellow gummy material, which was used in next step without further purification.<br>
The above compound (1.87 g) was dissolved in anhydrous THF (10 mL).<br>
Tetrabutyl ammonium fluoride (6.8 mL, 1.0M solution in THF) was added at 0C.<br>
The reaction mixture was stirred at 0C for 30 min. and then at room temperature<br>
for 1 hour. Saturated aqueous ammonium chloride (30 mL) was added. The<br>
mixture was extracted with ethyl acetate (100 mL) and the organic layer was<br>
separated and dried over anhydrous NaaSO. The solvent was removed under<br>
reduced pressure, the crude product was purified by column chromatography<br>
(Silica Gel 230-400 mesh; 0-5% methanol (containing 7.0 M ammonia) in CH2CI2<br>
as eluent) to give 2,6-dimethyl-4-[1-methylamino-7-(4-methylpiperazin-1-ylmethyl)<br>
isoquinolin-3-yl] phenol (0.487 g, 33%) as purple solid. To a solution of above<br>
compound (0.17 g, 0.43 mmol) in CH2CI2 (10 mL) was added hydrogen chloride in<br>
ether (2.0 mL, 1.0 M solution) dropwise under nitrogen. A yellow precipitate was<br>
formed. The reaction mixture was stirred at room temperature for 1 hour. Solvent<br>
was removed under reduced pressure and dried under vacuum to give 2,6-<br>
dimethyl-4-(1-(methylamino)-7-((4-methylpiperazin-1-yl)methyl)isoquinolin-3-<br>
yl)phenol (0.178 g, 97%) as the trihydrochloride; MS (ES) m/z: 391.10 (M+1); MP<br>
264-266C<br>
Example 44: 2-(quinoxalin-6-yl)-4H-pyrano[2,3-b]pyridin-4-one<br><br>
[0213] A mixture of quinoxaline-6-carboxylic acid (2 g, 11.49 mmol) and<br>
thionyl chloride (30 mL) was stirred at reflux for 2 hours. The reaction mixture was<br>
concentrated to dryness using a rotary evaporator to afford quinoxaline-6-<br>
- 99 -<br><br>
carboxylic acid chloride (crude quantitative). A solution of the above acid chloride<br>
(11.49 mmol) in DCM (50 mL) and pyridine (20 ml_) was mixed with N,0-dimethyl<br>
hydroxylamine HCI salt (2.24 g, 23 mmol) and stirred at room temperature for 12<br>
hours. The reaction was quenched by adding aqueous HCI (50 mL, 1 N),<br>
extracted with DCM (3*100 mL), concentrated using a rotary evaporator. The<br>
residue was further purified by column (Si02, Hexanes/EtOAc = 1:3) to yield<br>
quinoxaline-6-carboxylic acid methoxy-methyl-amide (2 g, 80%). To a solution of<br>
the above Weinreb amide (2.0 g, 9.2 mmol) in THF (30 mL) at 0C was added<br>
methyl magnesium bromide (3.9 mL, 11.6 mmol). The reaction mixture was stirred<br>
at 0C for 2 hours and then 1 hour at room temperature, quenched by adding<br>
aqueous HCI (20 mL, 1N), extracted with DCM (3x100 mL), concentrated using a<br>
rotary evaporator. The residue was further-purified by column (Si02,<br>
Hexanes/EtOAc = 1:3) to yield 6-acetylquinoxaline (1.17 g, 74%). A solution of 2-<br>
chloronicotinic acid ethyl ester (5.0 g, 27 mmol) in MeOH (25 mL) was mixed with<br>
sodium methoxide (25.6 mL, 112.5 mmol) and stirred at reflux for 12 hours. The<br>
reaction was quenched by adding water (100 mL), extracted with DCM (3x100<br>
mL), concentrated using a rotary evaporator to afford 2-methoxynicotinic acid<br>
methyl ester (3.2 g, 71%). A solution of 6-acetylquinoxaline (0.62 g, 3.6 mmol), 2-<br>
methoxynicotinic acid methyl ester (0.64 g, 3.8 mmol), and sodium hydride (0.46<br>
g, 11.4 mmol) in THF (100 mL) was stirred at room temperature for 16 hours. The<br>
reaction was quenched by adding water (100 mL) and AcOH (20 mL), extracted<br>
with dichloromethane (3x100 mL), and concentrated using a rotary evaporator.<br>
The residue was re-dissolved in DCM (5 mL) and MeOH (3 mL) and was diluted<br>
with Hexanes (50 mL). The solid was removed by filtration and the filtrate was<br>
concentrated to afford the diketo compound (0.7 g, 60%). A solution of the above<br>
diketone (0.4 g, 1.3 mmol) in AcOH (50 mL) and sulfuric acid (cone, 15 drops)<br>
was stirred at reflux for 1 hour. Most of the solvent was removed using a rotary<br>
evaporator. The residue was re-dissolved in MeOH and neutralized with<br>
potassium carbonate to pH = 8. The solid residue was removed by filtration,<br>
washed with MeOH and DCM. The filtrate was extracted with CH2CI2 (3x100 mL)<br>
and concentrated using a rotary evaporator. The solid residue was purified by<br>
 column (Si02, Hexanes/EtOAc/MeOH = 2:2:1) to afford 2-(quinoxalin-6-yl)-4H-<br>
-100-<br><br>
pyrano[2,3-b]pyridin-4-one (90 mg, 24%); MS (ES) m/z: 276 (M+1); MP 272.3-<br>
274.8C<br>
Example 45: 4-(5-amino-2,4-dimethoxy-1,6-naphthyridin-7-yl)-2,6-dimethylphenol<br><br>
[0214] A mixture of malonic acid (20 g, 192 mmol), 2,4,6-trichlorophenol<br>
(72 g, 365 mmol), and phosphorus oxychloride (38 ml_, 403.2 mmol) was stirred at<br>
reflux for 12 hours. The reaction mixture was cooled to 70C and poured into icy<br>
water. The solid was collected by filtration, washed with water, and air dried to<br>
give malonic acid bis-(2,4,6-trichloro-phenyl) ester (85 g, 95%). A solution of<br>
malonic acid bis-(2,4,6-trichloro-phenyl) ester (85 g, 184 mmol) and ethyl 3-<br>
aminocrotonate (26.08 g, 202 mmol) in bromobenzene (100 mL) was stirred at<br>
reflux for 50 min. The reaction mixture was cooled to 50C and diluted with EtOAc<br>
(260 mL). The solid was collected by filtration, washed with water, and air dried to<br>
give 4,6-dihydroxy-2-methyl nicotinic acid ethyl ester (31 g, 86%). A solution of<br>
4,6-dihydroxy-2-methyl nicotinic acid ethyl ester (31.0 g, 157 mmol) in phosphorus<br>
oxychloride (60.0 mL, 629 mmol) was stirred at reflux for 1.5 hours. The extra<br>
phosphorus oxychloride was removed using a rotary evaporator and the reaction<br>
mixture was poured into icy water. The solid was removed by filtration. The filtrate<br>
was extracted with dichloromethane (3x100 mL), and concentrated using a rotary<br>
evaporator. The residue was further purified by column (Si02, Hexanes/EtOAc =<br>
5:1) to yield 4,6-dichloro-2-methyl nicotinic acid ethyl ester (16.9 g, 46%). A<br>
solution of 4,6-dichloro-2-methyl nicotinic acid ethyl ester (16.9 g, 71.3 mmol) in<br>
MeOH (60 mL) was mixed with sodium methoxide (58 mL, 257 mmol) and stirred<br>
at reflux for 12 hours. The reaction was quenched by adding AcOH (50 mL),<br>
diluted with water (200 mL), extracted with dichloromethane (3*100 mL), and<br>
concentrated using a rotary evaporator. The residue was further purified by<br>
-101 -<br><br>
column (Si02, Hexanes/EtOAc = 6:1) to yield 4,6-dimethoxy-2-methyl nicotinic<br>
acid methyl ester (10g , 67%). A solution of 4,6-dimethoxy-2-methyl nicotinic acid<br>
methyl ester (2.6 g, 12.3 mmol) and lithium hydroxide (1.06 g, 44.1 mmol) in water<br>
(40 ml_), MeOH (30 mL) and THF (20 ml_) was stirred at reflux for 4 hours. The<br>
reaction mixture was concentrated using a rotary evaporator to dryness. The<br>
residue was mixed with cone. HCI (20 mL) and was concentrated again on high<br>
vacuum to dryness to yield crude 4,6-dimethoxy-2-methyl nicotinic acid. To a<br>
solution of 4,6-dimethoxy-2-methyl nicotinic acid (2.5 g, 12.0 mmol) in<br>
dichloromethane (50 mL) and THF (50 mL) at room temperature was added oxalyl<br>
chloride (2.57 mL, 29.4 mmol) and DMF (3 drops). The reaction mixture was<br>
stirred at room temperature for 30 min., concentrated to dryness using a rotary<br>
evaporator to afford crude 4,6-dimethoxy-2-methyl nicotinic acid chloride HCI salt<br>
(2.8 g). A solution of 4,6-dimethoxy-2-methyl nicotinic acid chloride HCI salt (4.8<br>
g, 23.5 mmol) in dichloromethane (100 mL) at room temperature was poured in to<br>
a beaker of ammonium hydroxide (200 mL). The reaction mixture was stirred at<br>
room temperature for 1 hour, extracted with dichloromethane (3*100 mL), and<br>
concentrated using a rotary evaporator to yield 4,6-dimethoxy-2-methyl-<br>
nicotinamide (2.4 g, 52%) as a light yellow solid. A solution of 4-hydroxy-3,5-<br>
dimethylbenzonitrile (2 g, 13.6 mmol) in DMF (20 mL) at room temperature was<br>
mixed with sodium hydride (0.706 g, 17.6 mmol) and stirred for 30 min. Benzyl<br>
bromide (1.62 mL, 13.6 mmol) was then added and the reaction mixture was<br>
stirred at room temperature for 24 hours. The reaction was quenched by adding<br>
water (200 mL), extracted with EtOAc (3*100 mL), and concentrated using a<br>
rotary evaporator. The residue was further purified by column (SiC)2,<br>
Hexanes/EtOAc = 6:1) to yield 4-benzyloxy-3,5-dimethylbenzonitrile (3.25 g,<br>
100%) as a white solid. To a solution of 4,6-dimethoxy-2-methyl-nicotinamide (1<br>
g, 5.1 mmol) in THF (120 mL) at -20C was added n-BuLi (9.6 mL, 15.3 mmol).<br>
The reaction was stirred at -20C ~ 0C for 2.5 hours and then was cooled to<br>
-78C. At -78C 4-benzyloxy-3,5-dimethylbenzonitrile (1.21 g, 5.1 mmol) was<br>
added, the cooling bath was removed, and the reaction was allowed to warm up<br>
gradually to room temperature. After stirring at room temperature for 20 hours the<br>
reaction was quenched by adding water (100 mL), extracted with dichloromethane<br>
(3*100 mL), and concentrated using a rotary evaporator. The residue was further<br>
-102-<br><br>
purified by column (Si02) Hexanes/EtOAc/MeOH = 3:2:1) to yield 7-(4-benzyloxy-<br>
3,5-dimethyl-phenyl)-2,4-dimethoxy-[1,6]naphthyridin-5-ylamine (0.4 g, 19%) and<br>
7-(4-benzyloxy-3,5-dimethyl-phenyl)-2,4-dimethoxy-6H-[1,6]naphthyridin-5-one<br>
(0.34 g, 16%). A solution of 7-(4-benzyloxy-3,5-dimethyl-phenyl)-2,4-dimethoxy-<br>
[1,63naphthyridin-5-ylamine (0.4 g, 0.96 mmol) in DMF (100 ml_) and MeOH (50<br>
ml_) was mixed with palladium/carbon (0.1 g) and subjected to hydrogenation (50<br>
psi) for 2 hours. The mixture was filtered through a celite-pad. The filtrate was<br>
concentrated on high vacuum to afford 4-(5-amino-2,4-dimethoxy-1,6-<br>
naphthyridin-7-yl)-2,6-dimethylphenol (0.31 g, 100%); MS (ES) m/z: 326 (M+1);<br>
MP 163.2-165.5C<br>
Exampie 46: 2-(4-fluorophenyl)-6-(rnorpholinomethyl)quinazolin-4(3H)-one<br><br>
[0215] A mixture of 2-amino-5-methylbenzamide (1.0 g, 6.7 mmol), 4-<br>
fluorobenzaldehyde (0.83 g, 6.7 mmol), iodine (2.03 g, 8.0 mmol), and potassium<br>
carbonate (1.38 g, 10 mmol) in DMF (50 mL) was stirred at 80C for 16 hours. The<br>
reaction mixture was cooled to 20C and poured into icy water. The solid was<br>
collected by filtration, washed with water, and air dried to give 2-(4-fluoro-phenyl)-<br>
6-methyl-3H-quinazolin-4-one (1.41 g, 83%). A solution of 2-(4-fluoro-phenyl)-6-<br>
methyl-3H-quinazolin-4-one (1.4 g, 5.5 mmol), NBS (0.98 g, 5.6 mmol), and<br>
benzoyl peroxide (67.0 mg, 0.276 mmol) in AcOH (150 mL) and chloroform (150<br>
mL) was stirred at 80C for 5 hours with light shedding on. The reaction mixture<br>
was cooled to 20C and concentrated using a rotary evaporator to yield the crude<br>
bromide. A solution of the above crude bromide in DMF (20 mL) and 1,4-dioxane<br>
(100 mL) was mixed with morpholine (10 mL) and stirred at 80C for 4 hours. The<br>
reaction was quenched by adding water (200 mL), extracted with dichloromethane<br>
(3x100 mL), and concentrated using a rotary evaporator. The residue was further<br>
purified by column (Si02, Hexanes/EtOAc/MeOH = 4:3:1) to yield 2-(4-fluoro-<br>
-103-<br><br>
phenyl)-6-morpholin-4-ylmethyl-3H-quinazolin-4-one (0.89 g, 48% over two steps).<br>
A solution of 2-(4-fluoro-phenyl)-6-morpho!in-4-ylmethyl-3H-quinazolin-4-one (0.89<br>
g, 2.62 mmol) in dichloromethane (100 mL) and MeOH (50 mL) was mixed with<br>
HCI in ether (8 mL, 16 mmol) and stirred for 1 hour. The reaction was<br>
concentrated using a rotary evaporator. The solid was rinsed with DCM (50 mL)<br>
and MeOH (5 mL), collected by filtration, washed with DCM-MeOH (10:1) to afford<br>
2-(4-fluorophenyl)-6-(morpholinomethyl)quinazolin-4(3H)-one (0.82 g, 76%) as an<br>
off-white solid; MS (ES) m/z: 340 (M+1); MP 321.8-323.3C<br>
Example 47: 2-(1 H-indazol-5-yl)-6-(morpholinomethyl)-4H-pyrano[2,3-b]pyridin-4-<br>
one<br><br>
[0216] Methyl 2-methoxy-5-(morpholinomethyl)nicotinate (0.413 g, 1.55<br>
mmol) and 1-(2-(4-methoxybenzyl)-2H-indazol-5-yl)ethanone (0.436 g, 1.55 mmol)<br>
were dissolved in anhydrous DMF (5 mL) under nitrogen. Sodium hydride (0.093<br>
g, 2.3 mmol) was added with stirring at room temperature. The color of the<br>
reaction mixture changed from colorless to brown to orange. The reaction mixture<br>
was stirred at room temperature overnight before pouring into water (100 mL),<br>
adjusted pH ~7 by adding acetic acid. The mixture was stirred for an hour and the<br>
solid (0.1 g) was filtered off, washed with water and hexane. The mother liquor<br>
was extracted with ethyl acetate, evaporated and dried. The two solids were<br>
combined and purified by silica gel (50 g) column chromatography employing 2-<br>
5% methanol in dichloromethane as eluents to give the desired diketo compound<br>
(0.2704 g). The diketo compound (0.270 g, 0.525 mmol) was taken in a round<br>
bottomed flask. Glacial acetic acid (50 mL) was added, followed by cone. HCI (2<br>
mL). The reaction mixture was refluxed for 2 hours (bath temp. 130C). Acetic<br>
acid was evaporated in vacuo and methanol was added. The solvent was<br>
removed in vacuo, water was added, basified with NaHC03 and extracted with<br>
ethyl acetate. The solvent was evaporated in vacuo to leave a crude product<br>
-104-<br><br>
(0.218 g, 86%) which was used for the next step without further purification. The<br>
compound from above (0.218 g, 0.45 mmol) was taken into trifluoroacetic acid (10<br>
mL) and the reaction mixture was refluxed (bath temperature 80C) for 24 hours.<br>
The solvent was evaporated in vacuo and the residue was dissolved in NaOH (20<br>
mL, 0.25 N), acidified with acetic acid. The formed solid was filtered off and<br>
washed with water and hexane. This impure material was further purified by silica<br>
gel (25 g) column chromatography employing 2-5% methanol in hexane/ethyl<br>
acetate as eluents to give the desired intermediate (0.2359 g). The above<br>
compound was dissolved in 5% methanol in dichloromethane. A solution of<br>
hydrogen chloride in diethyl ether was added dropwise. The flask was kept<br>
standing for 0.5 h and the solid was filtered off and dried to give 2-(1 H-indazol-5-<br>
.yl)-6-(morpholinomethyl)-4H-pyrano[2,3-b]pyridin-4-one (0.1217 g, 34%). MS<br>
(ES) m/z: 363 (M+1); MP 293.1-293.2C<br>
Example 48: 3-(3,5-dimethyl-4-(2-morpholinoethoxy)phenyl)-6,8-<br>
dimethoxyisoquinolin-1 (2H)-one<br><br>
[0217] (3,5-Dimethoxy-phenyl)-acetic acid (10.0 g, 50.96 mmol) was<br>
dissolved in anhydrous methanol (100 mL) and hSCUO mL) was added<br>
dropwise. The reaction mixture was refluxed overnight. Cooled to room<br>
temperature. The solvent was removed and the residue was dissolved in ethyl<br>
acetate and washed with a saturated aqueous NaHC03 solution, water and dried<br>
(Na2S04). The solvent was evaporated in vacuo to obtain (3,5-dimethoxy-phenyl)-<br>
acetic acid methyl ester (10.4 g, 97%). To a solution of (3,5-dimethoxy-phenyl)-<br>
acetic acid methyl ester (10.4 g, 49.5 mmol) in dimethyl formamide (40 mL),<br>
POCI3 (5.4 mL, 59.4 mmol) was added at 55C. After the addition, the reaction<br>
mixture was heated at 100C for 10 min. and then stirred at room temperature<br>
overnight. The reaction mixture was poured into ice-water and extracted with ethyl<br>
-105-<br><br>
acetate, washed with water, brine, dried over anhydrous Na2S04 and evaporated<br>
in vacuo to obtain (2-formyi-3,5-dimethoxy-phenyl)-acetic acid methyl ester (10.0<br>
g, 85%). (2-Formyl-3,5-dimethoxy-phenyl)-acetic acid methyl ester (5.0 g, 21.0<br>
mmol) was dissolved in CH3CN (100 mL), NaH2P04 (0.655 g, 5.46 mmol) in water<br>
(2 mL) and H202 (2.3 mL, 20.99 mmol, 30%) were added. The reaction mixture<br>
was cooled to 0C and a solution of Na02CI (2.65 g, 29.4 mmol) in water (5 mL)<br>
was added slowly. The reaction mixture was stirred at room temperature for 4<br>
hours before being quenched by the addition of Na2S03 solution. The mixture was<br>
acidified with 2 N HCI and extracted with ethyl acetate. The solvent was<br>
evaporated in vacuo to obtain 2,4-dimethoxy-6-methoxycarbonylmethyl-benzoic<br>
acid (5.25 g, 98%). To a solution of 2,4-dimethoxy-6-methoxycarbonylmethyl-<br>
benzoic acid (5.25 g, 20.6 mmol) in methanol (50 mL), a solution of NaOH (4.12 g,<br>
103 mmol) in water (20 mL) was added and the reaction mixture was allowed to<br>
stir at room temperature for 3 hours. The solvent was removed, diluted with water<br>
and acidified with 2 N HCI. The compound was extracted with ethyl acetate,<br>
washed with water, brine, dried over anhydrous Na2S04 and evaporated in vacuo<br>
to obtain 2-carboxymethyl-4,6-dimethoxy-benzoic acid (4.65 g, 94%). To a<br>
suspension of 2-carboxymethyl-4,6-dimethoxy-benzoic acid (4.65 g, 19.36 mmol)<br>
in toluene (50 mL) and acetic anhydride (2.01 mL, 21.3 mmol) were refluxed for 2<br>
hours. After cooling to 0 C, the precipitated solid was filtered off and washed with<br>
heptane and hexane to obtain 6,8-dimethoxy-isochroman-1,3-dione (3.56 g, 83%).<br>
[0218] To a solution of 3,5-dimethyl-4-hydroxy-benzoic acid (3.0 g, 18.05<br>
mmol) in pyridine (7 mL), acetic anhydride (2.05 mL, 21.66 mmol) was added and<br>
the reaction mixture was stirred at room temperature for 16 hours. Water was<br>
added and the compound was extracted with ethyl acetate, washed with water,<br>
brine and dried over anhydrous Na2S04. The solvent was evaporated in vacuo to<br>
obtain 4-acetoxy-3,5-dimethyl-benzoic acid (3.52 g, 94%). To a solution of 4-<br>
acetoxy-3,5-dimethyl-benzoic acid (6.02 g, 28.91 mmol) in CH2CI2 (80 mL), oxalyl<br>
chloride (5.04 mL, 57.83 mmol) was added slowly, followed by a drop of<br>
dimethylformamide. The reaction mixture was stirred at room temperature for 2<br>
hours. The solvent was removed and the solid acid chloride was dried under<br>
vacuum (6.37 g, 97%). To a solution of A/,A/,A/,A/-tetramethyl guanidine (2.77 mL,<br>
22.078 mmol) in CH3CN (50 mL), a solution of 6,8-dimethoxy-isochroman-1,3-<br>
-106-<br><br>
dione (4.46 g, 20.1 mmol) in CH3CN (100 ml_) was added slowly at 
temperature -20C) over 30 min. Et3N (1 eq.) was added in one portion, followed<br>
by a solution of acetic acid 4-chlorocarbonyl-2,6-dimethyl-phenyl ester (6.37 g,<br>
28.1 mmol) in CH3CN (50 mL) and stirred for 30 min. at 
mixture was stirred at room temperature for 16 hour before being refluxed for 3<br>
hour. After cooling to room temperature, the reaction mixture was quenched with 1<br>
N HCI. The precipitated solid was filtered off to give a mixture of acetic acid 4-(6,8-<br>
dimethoxy-1,3-dioxo-isochroman-4-carbonyl)-2,6-dimethyl-phenyl ester and acetic<br>
acid 4-(6,8-dimethoxy-1 -oxo-1 H-isochromen-3-yl)-2,6-dimethyl-phenyl ester<br>
(combined 6.0 g). The above mixture of compounds (6.0 g) was dissolved in 30%<br>
H2SO4 (30 mL) and heated at 100C for 2 hours. The reaction mixture was cooled<br>
to room temperature and the precipitated solid-was filtered off to obtain a mixture<br>
of acetic acid 4-(6,8-dimethoxy-1 -oxo-1 H-isochromen-3-yl)-2,6-dimethyl-phenyl<br>
ester and 3-(4-hydroxy-3,5-dimethyl-phenyl)-6,8-dimethoxy-isochromen-1 -one<br>
(5.5 g). The above mixture (5.5 g) was dissolved in methanol (30 mL) and K2C03<br>
(3.09 g, 22.4 mmol) and water (10 mL) were added. The reaction mixture was<br>
stirred at room temperature for 6 hours. The solvent was removed and the mixture<br>
was acidified with diluted HCI. The compound was extracted with ethyl acetate,<br>
washed with water, brine and dried over anhydrous Na2S04. The solvent was<br>
evaporated in vacuo to leave a residue which was purified by chromatography<br>
(Silica Gel, 230-250 mesh; 2% methanol in dichloromethane) to obtain 3-(4-<br>
hydroxy-3,5-dimethyl-phenyl)-6,8-dimethoxy-isochromen-1-one (1.46 g). To a<br>
solution of compound 3-(4-hydroxy-3,5-dimethyl-phenyl)-6,8-dimethoxy-<br>
isochromen-1-one (0.875 g, 2.68 mmol) in DMF (5 mL), NaH (0.129 g, 3.22 mmol)<br>
was added and the mixture was stirred for 1 hour. To the reaction mixture was<br>
added 1-chloro-2-iodo-ethane (1.23 mL, 13.4 mmol) and the mixture was stirred at<br>
room temperature for 16 hour. The reaction mixture was heated at 80C before<br>
being quenched with 1 N HCI at room temperature. The crude was purified by<br>
column chromatography (Silica Gel, 230-250 mesh; 2% methanol in<br>
dichloromethane) to give 3-[4-(2-hloro-ethoxy)-3,5-dimethyl-phenyl]-6,8-<br>
dimethoxy-isochromen-1-one (0.36 g, 35%). The compound 3-[4-(2-hloro-<br>
ethoxy)-3,5-dimethyl-phenyl]-6,8-dimethoxy-isochromen-1-one (0.36 g, 0.93<br>
mmol) was dissolved in DMSO (5 mL) and morpholine (0.4 mL, 4.63 mmol) and<br>
-107-<br><br>
Et3N (0.64 mL, 4.63 mmol) were added. The reaction mixture was heated at<br>
110C for 16 h before being cooled to room temperature. Water was added and<br>
the compound was extracted with ethyl acetate. The solvent was evaporated in<br>
vacuo to leave a residue which was purified by chromatography (Silica Gel, 230-<br>
250 mesh) to give 3-[3,5-dimethyl-4-(2-morpholin-4-yl-ethoxy)-phenyl]-6,8-<br>
dimethoxy-isochromen-1-one (0.13 g, 31%). The compound 3-[3,5-dimethyl-4-(2-<br>
morpholin-4-yl-ethoxy)-phenyl]-6,8-dimethoxy-isochromen-1-one (0.13 g, 0.29<br>
mmol) and NH3 (2.0 M solution in ethanol, 30 mL) were mixed in a steel bomb and<br>
heated at 130C for 16 hours. The solvent was removed and the crude compound<br>
was purified by chromatography (Silica Gel, 230-250 mesh). The compound was<br>
then converted into a salt by treatment with HCI in ether to give 3-(3,5-dimethyl-4-<br>
(2-morpholinoethoxy)phenyl)a6,8-di?TLethoxyisoquinolin-1(2H)-one (80 mg, 59 %);<br>
MS (ES) m/z: 349 (M+1); MP 196-198C<br>
Example 49: 5-methyl-2-(pyridin-4-yl)-4H-chromen-4-one<br><br>
[0219] In a solution of 2-methoxy-6-methylbenzoic acid ethyl ester (5 g,<br>
25.77 mmol) and NaOH (6.18 g, 154.64 mmol) in EtOH (100 mL) and water (40<br>
mL) was stirred at reflux for 24 hours. EtOH was then removed using a rotary<br>
evaporator and the aqueous was acidified with HCI (1 N) to pH=4. Extract with<br>
CH2CI2 (3X100 mL) followed by concentration using a rotary evaporator afforded<br>
4.25 g of 2-methoxy-6-methylbenzoic acid (100%) as a white solid. To a solution<br>
of 2-methoxy-6-methylbenzoic acid (1.66 g, 10 mmol) in CH2CI2 (80 mL) at room<br>
temperature was added BBr3 in CH2CI2 (20 mL, 20 mmol). The reaction mixture<br>
was stirred at room temperature for 20 hour and then concentrated using a rotary<br>
evaporator. The resulting residue was re-dissolved in CH2CI2 (50 mL), diluted with<br>
HCI (0.5 N), extracted with CH2CI2 (3x100 mL) and concentrated using a rotary<br>
evaporator to afford 1.52 g of 2-hydroxy-6-methyIbenzoic acid (100%). To a<br>
solution of 2-hydroxy-6-methylbenzoic acid (1.52 g, 10 mmol) in THF (50 mL) at<br>
room temperature was slowly added CH3Li in ether (22 mL, 35 mmol) and the<br>
suspension was stirred at 60C for 6 hour. The reaction was quenched with HCI<br>
-108-<br><br>
(0.5 N) aqueous and extracted with CH2Cl2( 3&gt;
rotary evaporator afforded 1 g of 2'-hydroxy-6'-methyiacetophenone (67%) as a<br>
brown oil. A solution of 2'-hydroxy-6'-methylacetophenone (1.0 g, 6.67 mmol) in<br>
CH2CI2 (50 mL) at room temperature was mixed with isonicotinoyl chloride<br>
hydrochloride (2.136 g, 12 mmol) and triethylamine (3.9 mL, 28 mmol)<br>
sequentially. The resulting mixture was stirred at room temperature for 2 hours,<br>
quenched with water, and extracted with CH2CI2 ( 3x100 mL) The volume was<br>
reduced using a rotary evaporator to minimal and triturated with hexanes. The<br>
solid was collected by filtration to afford 1.2 g of the corresponding isonicotinic aryl<br>
ester (70%). A solution of the above isonicotinic aryl ester (1.2 g, 4.70 mmol) in<br>
THF (50 mL) was mixed with potassium tert-butoxide (2.24 g, 20 mmol) and<br>
stirred at 65C foji2 hours. The reaction was quenched with water and acidified<br>
with HCI (0.5 N) to pH = 6. Extract with CH2CI2 (3x100 mL) followed by<br>
concentration using a rotary evaporator afforded a yellow solid residue. It was<br>
purified by column (Si02, hexane / EtOAc = 1:1) to provide 0.72 g of the diketone<br>
(60%). A solution of the above diketone (0.7 g, 2.745 mmol) in HOAc (50 mL)<br>
was stirred at reflux for 2 hours. All the solvent was removed using a rotary<br>
evaporator to afford a solid residue. It was then diluted with water and neutralized<br>
with NaOH (0.5 N) to pH = 8. The solid was collected by filtration and washed with<br>
water and hexanes sequentially to afford 0.32 g of 5-methyl-2-(pyridin-4-y!)-4H-<br>
chromen-4-one as a light yellow solid (49%).<br>
Example 50: 6-((dimethylamino)methyl)-2-(pyridin-4-yl)-4H-chromen-4-one<br><br>
[0220] In a solution of 2'-hydroxyacetophenone (10 g, 73.53 mmol) in 12<br>
N HCI (160 mL) at room temperature was mixed with paraformaldehyde (2.43 g,<br>
80.88 mmol) and stirred at 40C for 8 hours. The reaction was diluted with water,<br>
extracted with CH2CI2 (3x100 mL), and concentrated using a rotary evaporator to<br>
provide 13 g of 5'-chloromethyl-2'-hydroxyacetophenone (98%). To a solution of<br>
5!-chloromethyl-2'-hydroxyacetophenone (4 g, 21.74 mmol) in THF (50 mL) at<br>
-109-<br><br>
room temperature was added dimethylamine in THF (13 ml_, 26 mmol). The<br>
reaction mixture was stirred at 60C for 6 hours. It was quenched with water and<br>
neutralized with potassium carbonate to pH = 8. Extract with CH2CI2 (3x100 ml_)<br>
followed by concentration using a rotary evaporator provided 3.86 g of 5'-(N,N-<br>
dimethylaminomethy)-2'-hydroxyacetophenone (92%). A solution of 5'-(N,N-<br>
dimethylaminomethy)-2'-hydroxyacetophenone (1.4 g, 7.25 mmol) and ethyl<br>
isonicotinate (1.1 g, 7.25 mmol) in THF (100 mL) at room temperature was mixed<br>
with NaH (1.02 g, 25.375 mmol) and was stirred at reflux for 6 hours. The reaction<br>
was quenched with water and extracted with CH2CI2 (3x100 mL). The volume was<br>
reduced using a rotary evaporator to minimal and triturated with hexanes. The<br>
solid was collected by filtration to afford 1.85 g of the corresponding diketone<br>
(86%). A solution of the above diketone (1.85 g,6.19 mmol) in HOAc (100 mL)<br>
was stirred at reflux for 2 hours. All the solvent was removed using a rotary<br>
evaporator to afford a solid residue. It was then re-dissolved in CH2CI2, diluted<br>
with water and neutralized with potassium carbonate to pH = 8, extracted with<br>
CH2CI2 (3x100 mL) and concentrated using a rotary evaporator The solid residue<br>
was purified by column (Si02, hexanes / EtOAc / MeOH = 2:2:1) to afford 1.4 g of<br>
the intermediate (80%). A solution of the above intermediate (0.7 g, 2.34 mmol) in<br>
CH2CI2 (20 mL) was mixed with HCI in ether (10 mL, 20 mmol) and stirred at room<br>
temperature for 30 min. The solid was collected by filtration and washed with<br>
CH2CI2 and MeOH sequentially to obtain 0.48 g of the 6-((dimethylamino)methyl)-<br>
2-(pyridin-4-yl)-4H-chromen-4-one hydrochloride (60%) as an off-white solid.<br>
Example 51: 5-(hydroxymethyl)-2-(pyridin-4-yl)-4H-chromen-4-one<br><br>
[0221] In a solution of 2-methoxy-6-methylbenzoic acid ethyl ester (5 g,<br>
25.77 mmol) and NaOH (6.18 g, 154.64 mmol) in EtOH (100 mL) and water (40<br>
mL) was stirred at reflux for 24 hours. EtOH was then removed using a rotary<br>
evaporator and the aqueous was acidified with HCI (1 N) to pH=4. Extract with<br>
CH2CI2 (3x100 mL) followed by concentration using a rotary evaporator afforded<br>
-110-<br><br>
4.25 g of 2-methoxy-6-methylbenzoic acid (100%) as a white solid. To a solution<br>
of 2-methoxy-6-methylbenzoic acid (3.5 g, 21 mmol) in CH2CI2 (100 mL) at room<br>
temperature was added BBr3 in CH2CI2 (42 mL, 42 mmol). The reaction mixture<br>
was stirred at room temperature for 14 hrs and then concentrated using a rotary<br>
evaporator. The resulting residue was re-dissolved in CH2CI2 (50 mL), diluted with<br>
HCI (0.5 N), extracted with CH2CI2 (3x100 mL) and concentrated using a rotary<br>
evaporator to afford 3.3 g of 2-hydroxy-6-m ethyl benzoic acid (100%). To a<br>
solution of 2-hydroxy-6-methylbenzoic acid (3.3 g, 21.7 mmol) in THF (200 mL) at<br>
room temperature was slowly added CH3Li in ether (47 mL, 76 mmol) and the<br>
suspension was stirred at 60C for 6 hour. The reaction was quenched with HCI<br>
(0.5 N) aqueous and extracted with CH2CI2 (3x100 mL). Concentration using a<br>
rotary evaporator afforded an oily residue. It was purified by column (Si02,<br>
hexane / EtOAc = 4:1) to provide 3 g of 2'-hydroxy-6'-methylacetophenone (92%)<br>
as a light yellow oil. A solution of 2'-hydroxy-6'-methylacetophenone (1.5 g, 10<br>
mmol) in CH2CI2 (50 mL) at room temperature was mixed with isonicotinoyl<br>
chloride hydrochloride (2.0 g, 11 mmol) and triethylamine (4.9 mL, 35 mmol)<br>
sequentially. The resulting mixture was stirred at room temperature for 14 hours,<br>
quenched with water, and extracted with CH2CI2 (3x100 mL). Concentration using<br>
a rotary evaporator afforded a solid residue. It was purified by column (Si02,<br>
hexane / EtOAc = 3:1) to provide 1.5 g of the corresponding isonicotinic aryl ester<br>
(59%) as a light yellow solid. A solution of the above isonicotinic aryl ester (1.5 g,<br>
5.88 mmol) in THF (100 mL) was mixed with potassium tert-butoxide (1.384 g,<br>
12.35 mmol) and stirred at reflux for 2 hours. The reaction was quenched with<br>
water and acidified with HCI (0.5 N) to pH = 6. Extract with CH2CI2 (3x100 mL)<br>
followed by concentration using a rotary evaporator afforded a yellow solid<br>
residue. It was purified by column (Si02, hexane / EtOAc = 1:1) to provide 1.2 g of<br>
the diketone (80%). A solution of the above diketone (1.2 g, 24.71 mmol) in HOAc<br>
(100 mL) was stirred at reflux for 2 hours. All the solvent was removed using a<br>
rotary evaporator to afford a solid residue. It was then diluted with water and<br>
neutralized with NaOH (0.5 N) to pH = 8. The solid was collected by filtration and<br>
washed with water and hexanes sequentially to afford 1 g of 5-methyl-2-(pyridin-4-<br>
yl)-4H-chromen-4-one as a light yellow solid (89%). A solution of 5-methyl-2-<br>
(pyridin-4-yl)-4H-chromen-4-one (0.85 g, 3.59 mmol) in dry carbon tetrachloride<br>
-111-<br><br>
(250 mL) was mixed with NBS (0.67 g, 3.77 mmol) and benzyl peroxide (0.1 g,<br>
0.422 mmol). The reaction mixture was stirred at reflux for 6 hours. After cooling<br>
the solvent was removed and the residue was further washed with hot water to get<br>
rid of succinimide. The solid was then purified by column (Si02, hexanes / EtOAc<br>
= 1:1) to yield 0.61 g of bromide (54%). A solution of the above bromide (0.61 g,<br>
1.93 mmol) and NaOAc (1.82 g, 22.15 mmol) in HOAc (50 mL) was stirred at<br>
reflux for 6 hours.. All the solvent was removed using a rotary evaporator to afford<br>
a solid residue. It was then diluted with water, extracted with CH2CI2 (3x100 mL),<br>
and concentrated using a rotary evaporator. The solid was purified by column<br>
(Si02, hexanes / EtOAc / MeOH = 2:2:1) to yield 0.3 g of the corresponding<br>
acetate (53%). A solution of the above acetate (0.3 g, 1.01 mmol) and potassium<br>
carbonate (0.414 g, 3.0 mmol) in MeOH-(30 mL)-and water (3 mL) was stirred at<br>
room temperature for 48 hours. MeOH was removed using a rotary evaporator<br>
and the resulting mixture was further diluted with water (25 mL) to get a<br>
suspension. The solid was collected by filtration and washed with water and<br>
hexanes to yield 0.16 g of 5-hydroxymethyl intermediate (65%) as a light yellow<br>
solid. A suspension of the above intermediate (0.114 g, 0.45 mmol) in ethyl ether<br>
(10 mL) was mixed with HCI in ether (10 mL, 20 mmol) and the mixture was<br>
stirred at room temperature for 2 hours to get a even finer suspension. The solid<br>
was collected by filtration and washed with hexanes to yield 0.126 g of 5-<br>
(hydroxymethyl)-2-(pyridin-4-yl)-4H-chromen-4-one (96%) as a light yellow solid.<br>
[0222] The ability of a compound of the present invention to inhibit the<br>
expression of VCAM-1, MCP-1, and/or SMC proliferation, or in the treatment of<br>
diseases in a host can be assessed using methods known to those skilled in the<br>
art, including those described below.<br>
Example 52 MCP-1 and VCAM-1 Assays<br>
[0223] Compounds were dissolved in DMSO, aliquoted, and stored at<br>
-20C. Cultured human vascular endothelial cells (HUVECs) were seeded in 96-<br>
well plates in complete EGM-2 media (-100 uL/well); cells were plated at ~2-<br>
3&gt;
the following day cells are stimulated with TNF-a (~1 ng/mL) in the presence or<br>
-112-<br><br>
absence of compounds dissolved in DMSO. Triplicate wells were used for each<br>
test. To establish a dose curve and an IC50, multiple concentrations in 2- to 5-fold<br>
increments were used. Cells were exposed to TNF-a and compounds for<br>
approximately 16 hours. The next day, cells were visually examined via light<br>
microscopy to score for visual signs of toxicity. Cell culture media was analyzed<br>
using an MCP-1 ELISA. Cells were refed (-100 uL/well) with 20% CellTiter 96<br>
Aqueous One Cell Proliferation Solution (Promega), 80% EGM-2 medium. Media<br>
optical density (at 490 nm) was determined after 1 hour. Plates were aspirated<br>
and cell lysates were prepared and these lysates were tested using a VCAM-1<br>
ELISA.<br>
[0224] In Table 2, a positive result (+) was defined as at least 50%<br>
inhibition of the protein levels MCP-1 or VCAM-1, as determined by the ELISA.<br>
For comparison, resveratrol, a naturally occurring polyphenol, demonstrated 47%<br>
inhibition of MCP-1 and 54% inhibition of VCAM-1.<br>
Example 53 Smooth Muscle Cell Proliferation Protocol<br>
[0225] Compounds were dissolved in DMSO, aliquoted, and stored at<br>
-20C. Human coronary artery smooth muscle cells (CASMCs) were plated in 96-<br>
well plates and were grown in SmBM-2 media. After 1-2 hours, media was<br>
aspirated and replaced with serum-free ME/F12 media, except the controls. Cells<br>
were incubated for a further 48 hours. Compounds were diluted in DME/F12<br>
containing 10% FBS. Media was aspirated from the plates and compounds in<br>
DME/F12 containing 10% FBS. Six wells were used per condition and duplicate<br>
plates were used. Cells were incubated for a further 72 hours. Media was<br>
aspirated from one set of plates; those cells were refed (-100 uL/well) with 20%<br>
CellTiter 96 Aqueous One Cell Proliferation Solution (Promega), 80% EGM-2<br>
medium. Media optical density (at 490 nm) was determined after 3-4 hours. In<br>
the second set of plates, serum-free DME/F12 media (20uL) was added to each<br>
well. Part of the supernatant (50uL) was removed and placed in an ELISA plate<br>
and was stored temporarily at 4C. The remaining media and cells in the second<br>
set of plates were freeze-thawed for four cycles. The lysates and supematants<br>
were mixed and centrifuged. Part of the supernatant (50uL) was removed and<br>
-113-<br><br>
placed in an ELISA plate. The Promega Cytotox assay was performed on the<br>
ELISA plates. The ratio of supernatant OD to supernatant+cell lysate OD was<br>
determined.<br>
[0226] In Table 2, a positive result (+) was defined as at least 40%<br>
inhibition of the proliferation of SMC, as determined by the assay. For comparison,<br>
rapamycin, a known inhibitor of SMC proliferation, demonstrated 43% inhibition.<br><br><br><br><br><br><br><br><br><br><br><br>
-119-<br><br><br>
-120-<br><br><br><br><br>
[0227] Modifications and variations of the present invention relating to<br>
compounds and methods of treating diseases will be obvious to those skilled in<br>
the art from the foregoing detailed description of the invention. Such modifications<br>
and variations are intended to come within the scope of the appended claims.<br>
The practice of the present invention employs, unless otherwise indicated,<br>
conventional methods of organic and medicinal chemistry, cell and tissue culture,<br>
and animal husbandry within the ordinary skill of the art. Such techniques are<br>
explained fully in the literature. All publications, patents, and patent applications<br>
cited herein are incorporated by reference in their entirety. To the extent the<br>
present disclosure is contradictory to the disclosure of PCT/US2005/038048<br>
and/or U.S. provisional application No. 60/704,035, the present application<br>
supercedes their disclosure. It is intended that the specification and examples be<br>
considered as exemplary only, with a true scope and spirit of the invention being<br>
indicated by the following claims.<br>
-122-<br><br>
WHAT IS CLAIMED IS:<br>
1. A method for inhibiting VCAM-1 expression, MCP-1 expression<br>
and/or SMC proliferation in a mammal, comprising administering a therapeutically<br>
effective amount of a compound of Formula 1:<br><br>
wherein:<br>
X is selected from CRu, CRnR-13, CO, CS, O, S, SO, S02, N and NRn,<br>
wherein Rn may be the same or different than R13;<br>
Y is selected from CR12, CR12R14, CO, CS, O, S, SO, S02, N and NR12,<br>
wherein Ri2 may be the same or different than Ru,<br>
R-i, R2, R3, R4, R5, Re, R7, Re, R9, R10, R11, R12, R13, Rand Ri7are each<br>
independently selected from alkoxy, aryloxy, alkyl, alkenyl, alkynyl, amide, amino,<br>
aryl, arylalkyl, carbamate, carboxy, cyano, cycloalkyl, ester, ether, formyl,<br>
halogen, haloalkyl, heteroaryl, heterocyclyl, hydrogen, hydroxyl, ketone, nitro,<br>
phosphate, sulfide, sulfinyl, sulfonyl, sulfonic acid, sulfonamide and thioketone, or<br>
two adjacent substituents selected from R1, R2, R3. R4, R5, R6. R7. Rs. R9,<br>
R10, R11, R12, R13. and R14 are connected in a 5 or 6-membered ring to form a<br>
bicyclic aryl, bicyclic heteroaryl or bicyclic heterocyclyl;<br>
each W is independently selected from C and N, wherein if W is N, then p<br>
is 0 and if W is C, then p is 1;<br>
Z-i, Z2 and Z3 are each independently selected from a single bond and a<br>
double bond;<br>
wherein if Y is O, then X is not CO;<br>
wherein if at least one W is not N, then<br>
a)	X and Y are each CO,<br>
b)	X is NR-11 and Z2 is a double bond, or<br>
-123-<br><br>
c) two adjacent substituents selected from R5, R6, R7, Rs, and R9 are<br>
connected in a 5 or 6-membered ring to form a bicyclic aryl, bicyclic heteroaryl or<br>
bicyclic heterocyclyl;<br>
and pharmaceutically acceptable salts and hydrates thereof.<br>
2.	The method of claim 1, wherein R7 is hydroxyl.<br>
3.	The method of claim 1, wherein at least one of R1, R2, R3, R4, R5, Re,<br>
R7, Rs, R9, R10, R11, R12, R13, Ri4and R17 is selected from alkoxy, alkyl, amino,<br>
aminoalkoxy, aminoalkyl, carboxyalkoxy, halogen, heterocyclyl,<br>
heterocyclylalkoxy, heterocyclylalkyl, hydroxyalkoxy, hydroxyalkyl, and hydroxyl.<br>
4.	The method of claim 1, wherein X is selected from CR-n, CO, N,<br>
NR11 and O; and Y is selected from CR-12, CO, and NR12.<br>
5.	The method of claim 4, wherein X is O and Y is CO.<br>
6.	The method of claim 1, wherein Z\ and Z3 are single bonds, and Z2<br>
is a double bond.<br>
7.	The method of claim 1, wherein Z1 is a double bond and Y is CO.<br>
8.	The method of claim 1, wherein Z1 and Z3 are double bonds.<br>
9.	The method of claim 1, wherein at least one W in the A ring of<br>
Formula 1 is N.<br>
10.	The method of claim 9, wherein the W bonded to (R4)p is N.<br>
11.	The method of claim 1, wherein the W bonded to (Rio)P is N.<br>
12.	The method of claim 1, wherein at least one W in the C ring of<br>
Formula 1 is N.<br>
13.	The method of claim 12, wherein the W bonded to (R7V is N.<br>
14.	The method of claim 1, wherein the compound of Formula 1 is<br>
selected from<br>
2-(4-Hydroxy-phenyl)-pyrano[2,3-b]pyridin-4-one,<br>
2-(4-Hydroxy-phenyl)-pyrano[3,2-b]pyridin-4-one,<br>
2-(4-Hydroxypheny()-pyrano[2,3-c3pyridin-4-one,<br>
2-(3-Fluoro-4-hydroxyphenyl)pyrano[2,3-b]pyridine-4-one,<br>
2-(4-Hydroxyphenyl)-4H-pyrano[3,2-c]pyridin-4-one,<br>
2-(3-Chloro-4-hydroxyphenyl)-4H-pyrano[2,3-b]pyridine-4-one,<br>
2-(4-Hydroxy-3-methoxyphenyl)-4H-pyrano[2,3-b]pyridine-4-one,<br>
2-(4-Methoxyphenyl)-4H-pyrano[2,3-b]pyridine-4-one,<br>
-124-<br><br>
2-(4-(2-Hydroxyethoxy)phenyl)-4H-pyrano[2,3-b]pyridine-4-one,<br>
2-Pyridin-4-yl-chromen-4-one,<br>
2-(6-Hydroxypyridin-3-yl)-chromen-4-one,<br>
2-(4-Hydroxy-phenyl)-1 H-quinolin-4-one,<br>
4-lsoquinolin-3-yI-phenol,<br>
2-Fluoro-4-(5-methoxy-1-(methylamino)isoquinolin-3-yl)phenol,<br>
3-(3-Fluoro-4-hydroxyphenyl)-5-methoxyisoquinolin-1(2H)-one,<br>
3-(4-Hydroxyphenyl)-6,8-dimethoxyisoquinolin-1(2H)-one,<br>
2-(4-Hydroxy-phenyl)-[1,4]naphthoquinone,<br>
3-(4-Hydroxyphenyl)-2H-isoquinolin-1-one,<br>
2-Phenyl-4H-pyrano[2,3-b]pyridin-4-one,<br>
2-(4-(hydroxymethyl)pheny!)-4H-pyrano[2,3-b]pyridin-4-one,<br>
2-(4-hydroxy-3,5-dimethylphenyl)-4H-pyrano[2,3-b]pyridin-4-one,<br>
2-(pyridin-3-yl)-4H-chromen-4-one,<br>
7-((dimethylamino)methyl)-2-(4-hydroxyphenyl)-4H-pyrano[2,3-b]pyridin-4-one<br>
dihydrochloride,<br>
2-(4-(2-(dimethylamino)ethoxy)phenyl)-4H-pyrano[2,3-b]pyridin-4-one<br>
dihydrochloride,<br>
2-(4-hydroxy-3-(thiophen-2-yl)phenyl)-4H-pyrano[2,3-b]pyridin-4-one,<br>
2-(2,6-dimethyl-4-(4-oxo-4H-pyrano[2,3-b]pyridin-2-yl)phenoxy)aceticacid,<br>
2-(pyridin-4-yl)-4H-pyrano[2,3-b]pyridin-4-one hydrochloride,<br>
2-(3,5-dimethyl-4-(2-morpholinoethoxy)phenyl)-4H-pyrano[2,3-b]pyridin-4-one<br>
hydrochloride,<br>
2-(3-Bromo-4-hydroxyphenyl)-4H-pyrano[2,3-b]pyridin-4-one,<br>
2-(4-hydroxy-3,5-dimethylphenyl)-6-(pyrrolidin-1-ylmethyl)-4H-pyrano[2,3-<br>
b]pyridin-4-one dihydrochloride,<br>
5(7-dimethoxy-2-(pyridin-4-yl)-4H-chromen-4-one hydrochloride,<br>
2-phenyl-6-(pyrrolidin-1-ylmethyl)-4H-pyrano[2,3-b]pyridin-4-one hydrochloride<br>
6-(4-oxo-4H-chromen-2-yl)benzo[d]oxazol-2(3H)-one,<br>
2-(4-fluorophenyl)-6-(pyrrolidin-1-ylmethyl)-4H-pyrano[2,3-b]pyridin-4-one<br>
hydrochloride,<br>
2-(4-aminophenyl)-4H-pyrano[2,3-b]pyridin-4-one hydrochloride,<br>
-125-<br><br>
2-(4-isopropoxyphenyl)-6-(pyrrolidin-1-ylmethyl)-4H-pyrano[2,3-b]pyridin-4-one<br>
hydrochloride,<br>
7-(4-hydroxy-3,5-dimethylphenyl)-1,6-naphthyridin-5(6H)-one hydrochloride,<br>
2-hydroxy-7-(4-hydroxy-3,5-dimethylphenyl)-4-methoxy-1,6-naphthyridin-5(6H)-<br>
one dihydrochloride,<br>
3-(4-(2-hydroxy-2-methylpropoxy)-3,5-dimethylphenyl)-6,8-dimethoxyisoquinolin-<br>
1(2H)-one,<br>
2,6-dimethyl-4-(1-(methylamino)-7-((4-methylpiperazin-1-yl)methyl)isoquinolin-3-<br>
yl)phenol trihydrochloride,<br>
2-(quinoxalin-6-yl)-4H-pyrano[2,3-b]pyridin-4-one,<br>
4-(5-amino-2,4-dimethoxy-1,6-naphthyridin-7-yl)-2,6-dimethylphenol,<br>
2-(4-fluorophenyl)-6-(morpholinomethyl)quinazolin-4(3H)-one,<br>
2-(1H-indazol-5-yl)-6-(morpholinomethyl)-4H-pyrano[2,3-b]pyridin-4-one,<br>
3-(3,5-dimethyl-4-(2-morpholinoethoxy)phenyl)-6,8-dimethoxyisoquinolin-1(2H)-<br>
one, and<br>
6-((dimethylamino)methyl)-2-(pyridin-4-yl)-4H-chromen-4-one.<br>
15.	The method of claim 1, wherein the therapeutically effective amount<br>
of the compound of Formula 1 is administered with a pharmaceutical acceptable<br>
carrier in a pharmaceutically acceptable composition.<br>
16.	The method of claim 15, wherein the pharmaceutically acceptable<br>
composition comprises a second therapeutic agent selected from a statin, a PPAR<br>
agonist, a bile-acid-binding-resin, niacin, a RXR agonist, an anti-obesity drug, a<br>
hormone, a tyrophostine, a sulfonylurea-based drug, a biguanide, an alpha-<br>
glucosidase inhibitor, apolipoprotein E, a cardiovascular drug, an HDL-raising<br>
drug, an HDL enhancer, or a regulator of the apolipoprotein A-IV and/or<br>
apolipoprotein genes.<br>
17.	The method of claim 1, wherein the therapeutically effective amount<br>
of the compound of Formula 1 is administered as a pharmaceutically acceptable<br>
composition, a pharmaceutically acceptable salt, or a pharmaceutically acceptable<br>
formulation; optionally in a combination or alternation therapy with a therapeutic<br>
agent or at least one compound of Formula 1.<br>
-126-<br><br>
18.	The method of claim 1, wherein the therapeutically effective amount<br>
of the compound of Formula 1 is administered through the use of an intraluminal<br>
stent.<br>
19.	The method of claim 1, wherein VCAM-1 expression is inhibited.<br>
20.	The method of claim 1, wherein MCP-1 expression is inhibited.<br>
21.	The method of claim 1, wherein SMC proliferation expression is<br>
inhibited.<br>
22.	The method of claim 1, further comprising treating, preventing or<br>
mitigating inflammatory conditions and related disease states, characterized by<br>
altered expression of markers of inflammation selected from VCAM-1, MCP-1<br>
and/or SMC proliferation.<br>
23.	The method of claim 22, wherein the inflammatory conditions are<br>
selected from cardiovascular or inflammatory disorders mediated by VCAM-1,<br>
MCP-1, and/or SMC proliferation.<br>
24.	The method of claim 23, wherein the inflammatory conditions are<br>
cardiovascular diseases mediated by VCAM-1, MCP-1, and/or SMC proliferation.<br>
25.	The method of claim 23, wherein the inflammatory conditions are<br>
inflammatory disorders mediated by VCAM-1 and/or MCP-1.<br>
26.	The method of claim 23, wherein the inflammatory condition is<br>
restenosis.<br>
27.	The method of claim 22, wherein the therapeutically effective<br>
amount of the compound of Formula 1 is administered prior to revascularization<br>
therapy.<br><br>
wherein:<br>
X is selected from CRu, CO, N, NRn and O;<br>
-127-<br>
28.	A compound of Formula I:<br><br>
Y is selected from CR12, CO, and NR12;<br>
Ri, R2, R3, R4, R5, R6. R7, Re, R9, R10, R11, R12, R13, Rand Ri7are each<br>
independently selected from alkoxy, alkyl, amino, aminoalkoxy, aminoalkyl,<br>
carboxyalkoxy, halogen, heterocyclyl, heterocyclylalkoxy, heterocyclylalkyl,<br>
hydrogen, hydroxyalkoxy, hydroxyalkyl, and hydroxyl, or<br>
two adjacent substituents selected from R5, R6, R7, Rs and R9 are<br>
connected in a 5 or 6-membered ring to form a bicyclic aryl, bicyclic heteroaryl or<br>
bicyclic heterocyclyl;<br>
each W is independently selected from C and N, wherein if W is N, then p<br>
is 0 and if W is C, then p is 1;<br>
Z-i, Z2 and Z3 are each independently selected from a single bond and a<br>
double bond;<br>
wherein if at least one W is not N, then<br>
a)	X and Y are each CO, or<br>
b)	X is NR11 and Z2 is a double bond;<br>
and pharmaceutical acceptable salts and hydrates thereof.<br>
29.	The compound of claim 28, wherein R7 is hydroxyl.<br>
30.	The compound of claim 28, wherein X is O and Y is CO.<br>
31.	The compound of claim 28, wherein Z1 and Z3 are single bonds, and<br>
Z2 is a double bond.<br>
32.	The compound of claim 28, wherein Z1 is a double bond and Y is<br>
CO.<br>
33.	The compound of claim 28, wherein Zt and Z3 are double bonds.<br>
34.	The compound of claim 28, wherein at least one W in the A ring of<br>
Formula 1 is N.<br>
35.	The compound of claim 28, wherein the W bonded to (R4)p is N.<br>
36.	The compound of claim 28, wherein the W bonded to (Rio)P is N.<br>
37.	The compound of claim 28, wherein at least one W in the C ring of<br>
Formula 1 is N.<br>
38.	The compound of claim 28, wherein the W bonded to (R7)p is N.<br>
39.	A pharmaceutical composition comprising the compound of claim 28<br>
and a pharmaceutically acceptable carrier.<br>
-128-<br><br>
40.	A method for inhibiting VCAM-1 expression, MCP-1 expression<br>
and/or SMC proliferation in a mammal, comprising administering a therapeutically<br>
effective amount of the compound of claim 28.<br>
41.	A method for treating, preventing or mitigating inflammatory<br>
conditions and related disease states, characterized by altered expression of<br>
markers of inflammation selected from VCAM-1, MCP-1 and/or SMC proliferation,<br>
comprising administering a therapeutically effective amount of the compound of<br>
claim 28.<br>
-129-<br><br>
The present invention relates to polyphenol-like compounds that are useful for inhibiting VCAM-1 expression,<br>
MCP-1 expression and/or SMC proliferation in a mammal. The disclosed compounds are useful for regulating markers of inflammatory conditions, including vascular inflammation, and for treatment and prevention of inflammatory and cardiovascular diseases<br>
and related disease states.<br></j></td>
			</tr>
		</table>	
		<br>
		<h3>Documents:</h3>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDA0OTgta29sbnAtMjAwOC1hYnN0cmFjdC5wZGY=" target="_blank" style="word-wrap:break-word;">00498-kolnp-2008-abstract.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDA0OTgta29sbnAtMjAwOC1jbGFpbXMucGRm" target="_blank" style="word-wrap:break-word;">00498-kolnp-2008-claims.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDA0OTgta29sbnAtMjAwOC1jb3JyZXNwb25kZW5jZSBvdGhlcnMucGRm" target="_blank" style="word-wrap:break-word;">00498-kolnp-2008-correspondence others.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDA0OTgta29sbnAtMjAwOC1kZXNjcmlwdGlvbiBjb21wbGV0ZS5wZGY=" target="_blank" style="word-wrap:break-word;">00498-kolnp-2008-description complete.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDA0OTgta29sbnAtMjAwOC1mb3JtIDEucGRm" target="_blank" style="word-wrap:break-word;">00498-kolnp-2008-form 1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDA0OTgta29sbnAtMjAwOC1mb3JtIDMucGRm" target="_blank" style="word-wrap:break-word;">00498-kolnp-2008-form 3.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDA0OTgta29sbnAtMjAwOC1mb3JtIDUucGRm" target="_blank" style="word-wrap:break-word;">00498-kolnp-2008-form 5.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDA0OTgta29sbnAtMjAwOC1pbnRlcm5hdGlvbmFsIHB1YmxpY2F0aW9uLnBkZg==" target="_blank" style="word-wrap:break-word;">00498-kolnp-2008-international publication.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDA0OTgta29sbnAtMjAwOC1pbnRlcm5hdGlvbmFsIHNlYXJjaCByZXBvcnQucGRm" target="_blank" style="word-wrap:break-word;">00498-kolnp-2008-international search report.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDA0OTgta29sbnAtMjAwOC1wY3QgcHJpb3JpdHkgZG9jdW1lbnQgbm90aWZpY2F0aW9uLnBkZg==" target="_blank" style="word-wrap:break-word;">00498-kolnp-2008-pct priority document notification.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDA0OTgta29sbnAtMjAwOC1wY3QgcmVxdWVzdCBmb3JtLnBkZg==" target="_blank" style="word-wrap:break-word;">00498-kolnp-2008-pct request form.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NDk4LUtPTE5QLTIwMDgtKDA1LTA5LTIwMTMpLUFOTkVYVVJFIFRPIEZPUk0gMy5wZGY=" target="_blank" style="word-wrap:break-word;">498-KOLNP-2008-(05-09-2013)-ANNEXURE TO FORM 3.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NDk4LUtPTE5QLTIwMDgtKDA1LTA5LTIwMTMpLUNPUlJFU1BPTkRFTkNFLnBkZg==" target="_blank" style="word-wrap:break-word;">498-KOLNP-2008-(05-09-2013)-CORRESPONDENCE.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NDk4LUtPTE5QLTIwMDgtKDI2LTA4LTIwMTMpLUFOTkVYVVJFIFRPIEZPUk0gMy5wZGY=" target="_blank" style="word-wrap:break-word;">498-KOLNP-2008-(26-08-2013)-ANNEXURE TO FORM 3.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NDk4LUtPTE5QLTIwMDgtKDI2LTA4LTIwMTMpLUNMQUlNUy5wZGY=" target="_blank" style="word-wrap:break-word;">498-KOLNP-2008-(26-08-2013)-CLAIMS.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NDk4LUtPTE5QLTIwMDgtKDI2LTA4LTIwMTMpLUNPUlJFU1BPTkRFTkNFLnBkZg==" target="_blank" style="word-wrap:break-word;">498-KOLNP-2008-(26-08-2013)-CORRESPONDENCE.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NDk4LUtPTE5QLTIwMDgtKDI2LTA4LTIwMTMpLUZPUk0tMS5wZGY=" target="_blank" style="word-wrap:break-word;">498-KOLNP-2008-(26-08-2013)-FORM-1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NDk4LUtPTE5QLTIwMDgtKDI2LTA4LTIwMTMpLUZPUk0tMi5wZGY=" target="_blank" style="word-wrap:break-word;">498-KOLNP-2008-(26-08-2013)-FORM-2.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NDk4LUtPTE5QLTIwMDgtKDI2LTA4LTIwMTMpLUZPUk0tNS5wZGY=" target="_blank" style="word-wrap:break-word;">498-KOLNP-2008-(26-08-2013)-FORM-5.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NDk4LUtPTE5QLTIwMDgtKDI2LTA4LTIwMTMpLU9USEVSUy5wZGY=" target="_blank" style="word-wrap:break-word;">498-KOLNP-2008-(26-08-2013)-OTHERS.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NDk4LUtPTE5QLTIwMDgtKDI2LTA4LTIwMTMpLVBFVElUSU9OIFVOREVSIFJVTEUgMTM3LnBkZg==" target="_blank" style="word-wrap:break-word;">498-KOLNP-2008-(26-08-2013)-PETITION UNDER RULE 137.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NDk4LUtPTE5QLTIwMDgtKDI3LTA3LTIwMDkpLUZPUk0gMTMucGRm" target="_blank" style="word-wrap:break-word;">498-KOLNP-2008-(27-07-2009)-FORM 13.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NDk4LUtPTE5QLTIwMDgtKDI4LTAyLTIwMTMpLUNPUlJFU1BPTkRFTkNFLnBkZg==" target="_blank" style="word-wrap:break-word;">498-KOLNP-2008-(28-02-2013)-CORRESPONDENCE.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NDk4LUtPTE5QLTIwMDgtKDI4LTAyLTIwMTMpLU9USEVSUy5wZGY=" target="_blank" style="word-wrap:break-word;">498-KOLNP-2008-(28-02-2013)-OTHERS.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NDk4LUtPTE5QLTIwMDgtKDI4LTAyLTIwMTMpLVBBLnBkZg==" target="_blank" style="word-wrap:break-word;">498-KOLNP-2008-(28-02-2013)-PA.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NDk4LUtPTE5QLTIwMDgtQVNTSUdOTUVOVC5wZGY=" target="_blank" style="word-wrap:break-word;">498-KOLNP-2008-ASSIGNMENT.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NDk4LUtPTE5QLTIwMDgtQ09SUkVTUE9OREVOQ0UgT1RIRVJTIDEuMS5wZGY=" target="_blank" style="word-wrap:break-word;">498-KOLNP-2008-CORRESPONDENCE OTHERS 1.1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NDk4LUtPTE5QLTIwMDgtQ09SUkVTUE9OREVOQ0UgT1RIRVJTIDEuMi5wZGY=" target="_blank" style="word-wrap:break-word;">498-KOLNP-2008-CORRESPONDENCE OTHERS 1.2.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NDk4LUtPTE5QLTIwMDgtRk9STSAzLTEuMS5wZGY=" target="_blank" style="word-wrap:break-word;">498-KOLNP-2008-FORM 3-1.1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NDk4LUtPTE5QLTIwMDgtR1BBLnBkZg==" target="_blank" style="word-wrap:break-word;">498-KOLNP-2008-GPA.pdf</a></p>
		<br>
		<div class="pull-left">
			<a href="264415-piperazinyl-and-piperidinyl-ureas-as-modulators-of-fatty-acid-amide-hydrolase.html">&laquo; Previous Patent</a>
		</div>
		<div class="pull-right">
			<a href="264417-copolyetherimides.html">Next Patent &raquo;</a>
		</div>			
	</div><!-- /span8 -->
	<div class="span4">
		<div class="well infobox">
			<table class="table table-condensed">
				<tr>
					<th>Patent Number</th>
					<td>264416</td>
				</tr>
				<tr>
					<th>Indian Patent Application Number</th>
					<td>498/KOLNP/2008</td>
				</tr>
				<tr>
					<th>PG Journal Number</th>
					<td>01/2015</td>
				</tr>
				<tr>
					<th>Publication Date</th>
					<td>02-Jan-2015</td>
				</tr>
				<tr>
					<th>Grant Date</th>
					<td>29-Dec-2014</td>
				</tr>
				<tr>
					<th>Date of Filing</th>
					<td>04-Feb-2008</td>
				</tr>
				<tr>
					<th>Name of Patentee</th>
					<td>RESVERLOGIX CORP.</td>
				</tr>
				<tr>
					<th>Applicant Address</th>
					<td>202, 279 MIDPARK WAY SE COLGARY, ALBERTA T2X 1M2</td>
				</tr>
				<tr>
					<td colspan=2>
								<h5>Inventors:</h5>
								<table class="table">
									<tr>
										<th>#</th>
										<th>Inventor's Name</th>
										<th>Inventor's Address</th>
									</tr>

										<tr>
											<td>1</td>
											<td>CHIACCHIA FABRIZIO S</td>
											<td>130, 603 7TH AVENUE NE, CALGARY, ALBERTA T2E 0N4</td>
										</tr>
										<tr>
											<td>2</td>
											<td>WONG NORMAN C.W.</td>
											<td>616 EDGEMONT BAY NW, CALGARY, ALBERTA T3A 2K8</td>
										</tr>
										<tr>
											<td>3</td>
											<td>JOHANSSON JAN O</td>
											<td>165 MERANO STREET, DANVILLE, CA 94526</td>
										</tr>
										<tr>
											<td>4</td>
											<td>HANSEN HENRIK C</td>
											<td>4903 CARNEY ROAD NW, CALGARY, ALBERTA T2L, 1E6</td>
										</tr>
								</table>
					</td>
				</tr>
				<tr>
					<th>PCT International Classification Number</th>
					<td>A61K 31/4353</td>
				</tr>
				<tr>
					<th>PCT International Application Number</th>
					<td>PCT/US2006/029827</td>
				</tr>
				<tr>
					<th>PCT International Filing date</th>
					<td>2006-07-28</td>
				</tr>
				<tr>
					<td colspan=2>
						<h5>PCT Conventions:</h5>
						<table class="table">
							<tr>
								<th>#</th>
								<th>PCT Application Number</th>
								<th>Date of Convention</th>
								<th>Priority Country</th>
							</tr>

								<tr>
									<td>1</td>
									<td>60/704035</td>
									<td>2005-07-29</td>
								    <td>U.S.A.</td>
								</tr>

						</table>
					</td>
				</tr>
			</table>
		</div><!-- /well -->
	</div><!-- /span4 -->
</div><!-- /row-fluid -->

        </div>

      </div><!--/row-->

      <footer class="footer">

        <style>
        .allindianpatents-footer { width: 320px; height: 50px; }
        @media(min-width: 500px) { .allindianpatents-footer { width: 468px; height: 60px; } }
        @media(min-width: 800px) { .allindianpatents-footer { width: 728px; height: 90px; } }
        </style>
        <center>
        </center>

        <p>&copy; All Indian Patents, 2013-2021.</p>
        <p>Patent data available in the public domain from Indian Patents Office, Department of Industrial Policy and Promotions, Ministry of Commerce and Industry, Government of India.</p>
      </footer>

    </div> <!-- /container -->

    <!-- Javascripts
    ================================================== -->
    <!-- Placed at the end of the document so the pages load faster -->
    <script src="../assets/application-95f297ff0d8d2015987f04b30593c800.js" type="text/javascript"></script>

    <!-- Start of StatCounter Code for Default Guide -->
    <script type="text/javascript">
    var sc_project=8902313; 
    var sc_invisible=1; 
    var sc_security="3c1f8147"; 
    var scJsHost = (("https:" == document.location.protocol) ?
    "https://secure." : "http://www.");
    document.write("<sc"+"ript type='text/javascript' src='" +
    scJsHost+
    "statcounter.com/counter/counter.js'></"+"script>");
    </script>
    <noscript><div class="statcounter"><a title="web stats"
    href="http://statcounter.com/free-web-stats/"
    target="_blank"><img class="statcounter"
    src="http://c.statcounter.com/8902313/0/3c1f8147/1/"
    alt="web stats"></a></div></noscript>
    <!-- End of StatCounter Code for Default Guide -->

    <script>
      (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
      (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
      m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
      })(window,document,'script','http://www.google-analytics.com/analytics.js','ga');

      ga('create', 'UA-244143-31', 'allindianpatents.com');
      ga('send', 'pageview');

    </script>

  </body>

<!-- Mirrored from www.allindianpatents.com/patents/264416-pharmaceutical-compositions-for-the-prevention-and-treatment-of-complex-diseases-and-their-delivery-by-insertable-medical-devices by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 01:17:07 GMT -->
</html>
